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Abstract
Globally HIV is increasing rapidly amongst women and an appreciation of the total 
burden of infection amongst this population group is essential for planning purposes. 
In GB women having live births are taken to be representative of all women. 
Monitoring is undertaken using samples from neonates as maternal antibodies to HIV 
cross the placenta prior birth. However, results may be biased as pregnant women 
could differ from all women in terms of HIV prevalence and those with HIV could 
have differential fertility than uninfected women. In this thesis, ways to improve the 
extrapolation of neonatal seroprevalence to all women are investigated.
The application of pregnant women data to all women assumes no differential fertility 
between persons at varying risk o f HTV infection. However, analyses showed African 
women have both higher HIV and fertility rates than other women. In addition, results 
from a literature review suggested that HIV infected women may have reduced live 
birth rates after diagnosis, although it was unclear whether recent advances in the 
therapeutic and mother to child prophylactic management for HIV infected women 
have affected women’s desire for children. A cross-sectional questionnaire study 
carried out to address these questions showed a third of HIV positive women did not 
want children after they received their HTV diagnosis. Of this group, approximately 
half changed their desire for children due to improvements in HIV management. 
Additional analyses confirmed recent changes in childbearing patterns amongst HIV 
positive women were likely to have taken place and that the factor most strongly 
associated with desire for children was reproductive history.
2
A model developed using results described above estimated 16,000 women were 
living with HIV in GB in 2002. This was more than previously estimated using a 
‘direct’ approach, reflecting an improved methodology accounting for differences in 
fertility and HIV risk between pregnant and non-pregnant women.
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Chapter 1: Demography patterns and HIV risk amongst women in Great Britain
1.1: Introduction
Now in its third decade, the human immuno-deficiency virus (HIV) / acquired 
immuno-deficiency syndrome (AIDS) pandemic has been disastrous from a public 
health perspective. The Joint United Nations Programme on HIV/AIDS (UNAIDS) 
and the World Health Organisation (WHO) estimated that globally by the end of 2003 
there were nearly 38 million adults and children living with HIV/AIDS (1). During 
2003 almost 5 million people were newly infected with HIV, the greatest number in 
any given year since the beginning of the epidemic. In the same year almost 3 million 
people died from an AIDS-related death. Heterosexual transmission of HIV is the 
predominant exposure amongst adults, while mother-to-child transmission accounts 
for the majority of infections in children. The region of the world most affected by 
HIV is sub-Saharan Africa1 (SSA) where over two thirds of the estimated numbers of 
infected people live. Globally, HIV infection in women accounts for nearly 50% of 
adult infections (1).
Accurate HTV prevalence estimates are needed to respond to the enormous challenge 
posed by HIV. The levels and associated risks for HIV infection require monitoring, 
both in adults whose risk behaviour makes them more at risk to infection (for example 
homo/bisexual men) and among the less at risk who are more broadly representative 
of the adult population (for example pregnant women) (2). These estimates are needed 
in order to detect changes in transmission patterns where HIV is already present and 
to recognise emerging problems elsewhere (3). In Great Britain (GB), estimates of
1 Sub-Saharan Africa consists of Eastern Africa, Middle Africa, Southern Africa and Western Africa
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HIV in the general adult population have been based on results from neonatal 
seroprevalence surveys (4-5). HIV prevalence amongst neonates reflects level of HIV 
infection amongst pregnant women as maternal antibodies pass over the placenta prior 
to birth (6). However, these results are potentially biased when estimating HIV 
amongst all women as only women who become pregnant and have a live birth will 
be included in neonatal surveys and these women may differ from others in terms of 
HTV prevalence (7).
The aim of this thesis was to investigate ways to improve the extrapolation of 
neonatal seroprevalence data to the general female population in GB, accounting 
among other factors for biases relating to the fertility differential between HIV- 
positive and HTV-negative women. As GB is a culturally diverse country with 
continuing waves of immigration, often from areas of high HTV prevalence rates such 
as Africa, and patterns of fertility and HIV prevalence are associated with the 
demographic characteristics of the population under study, chapter 1 begins with a 
brief description of the British population. Throughout the thesis many different 
sources of health information were used to address the overall aim of improving HIV 
prevalence estimates among the general population. These sources of information 
were collected according to different geographical areas. Therefore to aid 
interpretation of results, a brief description of the current organisation of health 
boundaries is given. Next a detailed description of HIV prevalence amongst women in 
GB is provided and the importance of monitoring HIV prevalence and the underlying 
assumptions when this is achieved through the use of neonatal seroprevalence data is 
discussed. Finally, techniques which have already been developed to adjust HIV 
prevalence estimates from pregnant women to be representative of HIV prevalence
16
among all women of reproductive age are described, and areas for improvement 
identified.
1.2: Population of Great Britain
Great Britain2 is situated in Northern Europe and is part of the European Union. As 
well as having close links with other countries within Europe, close ties exist with the 
Commonwealth3. Within GB is a universal health care system structured into 
geographic health boundaries, which over the last 10 years have changed a number of 
times. Figure 1.1 shows the organisation of the National Health Service for the 3 
countries of GB. In England there have been major re-organisations in 1996, 2002 and 
2003 and the current structure consists of 28 Strategic Health Authorities, which are 
constituted from groupings of the 303 Primary Care Organisations. Scotland has 15 
Health Boards which form a single local health care system and Wales consists of 22 
Local Health Boards (http://www.statistics.gov.uk/geography/health geog.asp 
(accessed August 2004)). Infectious disease surveillance of HIV/AIDS is primarily 
organised on a national level by the Communicable Disease Surveillance Centre 
(CDSC) (England and Wales) and the Scottish Centre for Infection and 
Environmental Health (SCIEH) (Scotland).
2 Great Britain (GB) consists of England, Wales and Scotland and is part of the United Kingdom of 
Great Britain and Northern Ireland (UK).
3 The old Commonwealth comprises Australia, Canada, South Africa and New Zealand; the New 
Commonwealth comprises of the other 49 sovereign states within the Commonwealth, including much 
of Africa, south Asia and the Caribbean
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The population of GB was estimated to be 57.6 million in 2002, 49.6 million in 
England, 2.9 million in Wales and 5.1 million in Scotland (Table 1.1) (Unpublished 
data, 2001 census). The population size has been increasing at a steady rate since the 
start of the HIV epidemic in the early 1980’s, mainly due to higher net inward than 
outward international migration.
There were 647,200 births in GB in 2002 when the birth rate was 11.2 live births per 
1,000 population and the total fertility rate was 1.74 (8). This is well below the 
average completed family size of approximately 2.1 children per woman needed for 
the population in the long term to replace itself if mortality rates are constant and 
there is no international migration (9). The factors that contribute to the relatively low 
birth rate include trends towards later marriage, postponing having children, a 
preference for smaller families and widespread contraception. While fertility rates 
have fallen for women aged under 30, they have increased for women over 35 years. 
The overall effect of this is that the average age of childbirth has increased from 26.1 
years in the early 1990’s to 29.3 in 2002 (9).
Table 1.1: General statistics in 2002: Great Britain
England Wales Scotland GB
Population size (million)1 49.6 2.9 5.1 57.6
Number of births (thousands) 565.7 30.2 51.3 647.2
Birth rate (per thousand) 11.3 10.3 10.1 11.2
Total fertility ratio2 1.75 1.75 1.60 1.74
Mean age of mother at birth (yrs) 29.4 28.4 29.2 29.3
Source: ONS and GRQ for Scotland. Unpublished 2001 census of population survey and birth statistics 
12001 census of population data
2 Number of children that would be bom to a woman if age-related current patterns of fertility persisted 
throughout her childbearing life
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1.2.1: Size and characteristics o f the ethnic minority population in GB
Overall, according to the 2001 census, the total ethnic minority population in GB was 
estimated to be 4.6 million, 8.1% of the total population (Unpublished data 2001 
census). These figures compare to 3.1 million or 5.5% of the total population in 1991 
(10). Table 1.2 shows that of the individual ethnic minority groups, the south Asian 
population is most numerous followed by black Caribbeans and black Africans. 
Ninety five percent of the ethnic minority population live in England, and the majority 
of these are concentrated in large urban areas such as London where they comprise 
28% of all residents. Three quarters of black Africans and half of Bangladeshis live in 
London whilst other minority ethnic groups are more dispersed throughout GB (10).
Table 1.2: Ethnic minority populations in Great Britain, 2001 Census data
England Wales Scotland GB
White 44,679,361 2,841,505 4,960,334 52,481,200
(90.9%) (97.9%) (97.9%) (91.9%)
Mixed 643,373 17,661 12,764 673,798
(1.3%) (0.6%) (0.3%) (1.2%)
South Asian 2,010,479 21,984 48,811 2,081,274
(4.1%) (0.8%) (1.0%) (3.6%)
Black Caribbean 561,246 2,597 1,778 565,621
(11%) (0.1%) (0.04%) (1.0%)
Black African 475,938 3,727 5,118 484,783
(1.0%) (0.1%) (0.1%) (0.8%)
Black Other 95,324 745 1,129 97,198
(0.2%) (0.03%) (0.02%) (0.2%)
Rest 673,110 14,866 32,077 720,053
(1.4%) (0.5%) (0.6%) (1.3%)
A ll ethnic minority population 4,459,470 61,580 101,677 4,622,727
(% total population) (9.1%) (2.1%) (2.0%) (8.1%)
All Population 49,138,831 2,903,085 5,062,011 57,103,927
Source: Unpublished Census 2001 population survey
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There has been considerable variation in the absolute change in the numbers of people 
in each ethnic minority group, the largest rate of change occurring in the three black 
ethnic groups. Between the early and late 1990’s the black African population 
increased by 37%. Over the same time period there was little change in the number of 
people identified as black Caribbean but a doubling of the number of individuals who 
were classified as black Other. Many individuals of black Caribbean origin classify 
themselves as black British as they had been bom in GB. It is therefore difficult to 
make definitive statements about the characteristics of the population of black 
Caribbean origin (10).
The proportion of each ethnic group bom in GB has been influenced by the timing of 
the various waves of immigration into this country as migrants are mainly young 
adults. Virtually all persons (97%) aged over 44 years from all ethnic groups were 
bom outside the UK. In contrast, 90% of ethnic minority children aged under 15 years 
were bom in the UK. There are considerable differences between the various ethnic 
minority groups, ranging from 25% of Chinese persons bom in the UK to 89% of the 
black Other population (10). Of the 479,665 persons in England and Wales describing 
themselves as black African, 34% were bom in the UK, 16% in Nigeria and 19% in 
other Central and West Africa (Table 1.3). In addition, a high proportion (24%) were 
bom in South and East Africa and 1% were bom in Asia. More persons were 
classified as bom in SSA (740,266) than as black African (479,665) (Unpublished 
census 2001 data). This is because whilst the majority of persons bom in Nigeria were 
black African, many persons bom in Kenya, South Africa, Zimbabwe and other South 
and East Africa were either White or Indian (Table 1.4). The association between 
country of birth and ethnicity is of particular interest to this thesis as some of the key
21
data sources used in analyses can only be presented according to country of birth of 
the woman rather than by ethnicity.
Table 1.3: Population of England and Wales describing themselves as Black 
Africans
Country of birth Black African population
N %
UK 162,330 34
Nigeria 76,291 16
Other Central and West Africa 89,980 19
Kenya 13,421 3
South Africa 4,218 1
Zimbabwe 17,852 4
Other South and East Africa 88,757 18
Asia 2,260 1
Other 24,556 5
TOTAL 479,665 100
Adapted from Table S I02. Census 2001. CD supplement to the National report for 
England and Wales. Unpublished data. Office of National Statistics
Table 1.4: Percentage of people by countiy of birth in each ethic group
____________________________ Ethnic Group________________________
Country of Total White Black African Indian Other
birth_____________ N________ N (%)__________ N (%)_________N (%)_________ N (%)
Nigeria 86,958 5,895 (7) 76,291 (87) 295 (1) 4,477 (5)
Kenya 127,322 16,565 (13) 13,421 (11) 82,727 (65) 14,609 (11)
South Africa 132,301 119,129 (90) 4,218 (3) 3,622 (3) 5,332 (4)
Zimbabwe 47,158 24,664 (52) 17,852 (38) 1,081 (2) 3,561 (8)
Other S and E 235,884 31,606 (13) 88,757 (38) 73,173 (31) 42,348 (18)
Africa 
Rest SSA 110,603 7,251 (7) 89,980 (81) 6,119 (6) 7,253 (6)
Total SSA 740,226 205,110 (28) 290,519 (39) 167,017 (23) 77,580 (10)
Adapted from Table SI02. Census 2001. CD supplement to the National report for 
England and Wales. Unpublished data. Office of National Statistics
The age structure of the ethnic minority groups is also influenced by age at migration 
and differential fertility rates between the various groups. Women bom in developing
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countries tend to have higher fertility rates than women bom in the UK. For example 
total fertility rates for countries in SSA range from 4.1 in Zimbabwe to 4.7 in Kenya 
and 7.0 in Uganda (11). However, fertility in non-UK bom women tends to fall 
gradually with the passage of time following immigration (12).
7.2.2: International Migration
Migration to and from countries outside of GB is currently a major component of 
population change (13). Almost a third of the total migrant population living in GB 
arrived during the last decade, reflecting the increases in migration over this period 
(Figure 1.2). Numbers of applications have increased from all parts of the world, often 
from where there is war or conflict (14), with the most notable increases from Africa, 
Eastern Europe and the Middle East. Whilst the source countries from which migrants 
come are diverse, the current stock of migrants still reflects significant immigration 
waves from the Caribbean, Pakistan and Bangladesh which occurred in the 1960s and 
70s.
F igure  1.2: N um bers of applications received for asylum  in the UK, excluding 
dependen ts by w orld region 1994-2002
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In 2002 the highest number of applications were from nationals of Iraq (14,570), 
Zimbabwe (7,655), Afghanistan (7,205), Somalia (6,540) and China (3,675) (13). A 
consistently high number of applications are received from SSA, an area of the world 
with high HIV prevalence rates. Approximately half of all applications from Africa in 
2002 were from either Zimbabwe or Somalia (Table 1.5). Compared with 2001, large 
increases occurred most notably in the number of applications from nationals of 
Zimbabwe, a country where an estimated 30% of the adult population are infected 
with HIV (13,15). This rise may be temporary however as it reflects current political 
instability of the country.
Table 1.5: Numbers of applications received for asylum in the UK, excluding 
dependents, by country in Africa
Nationality
2002(prov)
(13)
% change HIV Prev.(%) 
2001/2002 (15)
Zimbabwe 7,655 258% 30
Somalia 6,540 2% 1
Dem. Rep. Congo 2,215 62% 4
Angola 1,420 39% 2
Eritrea 1,180 90% 3
Sierra Leone 1,155 -41% 7
Nigeria 1,125 39% 4
Uganda 715 48% 5
Burundi 700 15% 5
Ethiopia 700 14% 12
Migrants are geographically much more concentrated than the GB population as a 
whole, with the majority living in London (16). Recently, increasing numbers of 
migrants have been dispersed throughout GB since the set up of the National Asylum 
Support Service (NASS), a service which provides accommodation and subsistence 
for asylum seekers in GB. Asylum seekers supported in NASS accommodation are 
dispersed throughout GB and the authorities with the highest populations of dispersed
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asylum seekers are: Glasgow, Birmingham, Leeds, Liverpool, Newcastle, Coventry, 
Manchester, Bradford, Sheffield and Nottingham (13).
1.3: HIV/AIDS amongst women: an overview
1.3.1: Introduction
Human Immunodeficiency Virus (HIV) and Acquired Immuno-Deficiency Syndrome 
(AIDS) remains a relatively new, incurable, clinically complex disease with a long 
incubation period between infection and detectable disease. Infection is associated 
with high morbidity and high treatment and care costs (17).
Globally, this disease carries a large health burden, with some countries feeling the 
weight of this burden more than others (Figure 1.3). Sub-Saharan Africa (SSA) 
remains the region worst affected by the HIV/AIDS epidemic, with an estimated 25 
million people living with HIV in 2003 (1). The AIDS epidemic in Eastern Europe 
and Central Asia has shown no signs of diminishing and is being driven by 
widespread risky behaviour, including injecting drug use. Over 6 million people in 
South and South East Asia and nearly 1 million people in East Asia were living with 
HTV in 2003 and recently the epidemic has spread into areas where there was little or 
no HIV present, including China. In high-income countries such as GB the number of 
people living with HIV continues to rise, largely due to widespread access to 
antiretroviral treatment which has delayed disease progression (18). There is evidence 
that prevention activities in several high-income countries are not keeping pace with 
the changes occurring in the spread of HIV (1).
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This section provides an overview of the epidemiology of HIV infection in GB and 
includes a description of the main transmission routes of infection and methods of 
surveillance, and then focuses on the epidemiology of HIV amongst women, the 
population group of interest for this thesis. As this project specifically focuses on the 
use of data from pregnant women, a description of HIV in pregnancy is provided.
Figure 1.3: Adults and children estimated to be living with HIV/AIDS at the end 
of 2003
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1.3.2: Transmission routes o f  infection in GB
An HIV/AIDS reporting system was first established in the UK in 1982 (17). Since 
then the number of HIV reports have increased annually and the total of 5,542 new 
diagnoses in 2002 was almost double the 2,814 diagnoses in 1998 (19). By contrast, 
the numbers of AIDS diagnoses and deaths in HIV-infected individuals has declined 
after the introduction of effective therapies (Highly active anti-retroviral therapy
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(HAART)) in the mid-1990’s (18). Men who have sex with men remain the group at 
greatest risk of acquiring HIV infection in GB. While homosexual transmission still 
accounts for the largest percentage of HIV infection, the proportion infected 
heterosexually increases yearly and this is mirrored by an increasing proportion of 
HIV infection due to vertical transmission. Since 1999, the number of new HIV 
diagnoses in heterosexuals has exceeded the number of new diagnoses in 
homosexual/bisexual men, reflecting a large and increasing impact of migration from 
areas of high HIV prevalence (Figure 1.4). Blood/blood products transfer and 
injecting drug use account for decreasing proportions of infection yearly (19). Apart 
from sudden outbreaks of HIV amongst injecting drug users (IDUs) in Edinburgh and 
Dundee in the mid-1980’s, there has been no evidence of significant HIV spread 
amongst drug users in GB. This largely reflects the successful implementation of 
needle exchange programmes and other interventions such as methadone maintenance 
therapy (20).
F igure 1.4: N um bers of newly diagnosed HIV infections by probable rou te  of 
exposure
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1.3.3: Methods o f surveillance in GB
As HTV has a long incubation period between infection and detectable disease, 
multiple sources of information are needed to fully understand the extent of the HIV 
epidemic. Surveillance systems in GB monitor both diagnoses of HIV infection 
through voluntary reports from clinicians and laboratories and levels of undiagnosed 
infection in the population through the Unlinked Anonymous (UA) programme. As 
the surveillance data are used in analyses throughout the thesis, more detailed 
methodology for the surveillance systems is provided in chapter 3.
New HIV and AIDS diagnoses are received from laboratories and clinicians and 
reported to the Health Protection Agency (HPA) Communicable Disease Surveillance 
Centre (CDSC) and the Scottish Centre of Infection and Environmental Health 
(SCIEH) to form a national HIV/AIDS surveillance system. The national data are 
made available as quarterly surveillance tables and other reports (19,21). As well as 
reports of new diagnoses of HIV/AIDS, numbers of persons currently receiving HIV- 
related care are collated as part of the National Survey of Prevalent HIV Infections 
Diagnosed (SOPHID), which was set up in 1997 in England, Wales and Northern 
Ireland. The data reflect current prevalence of diagnosed HIV infection according to 
both area of residence and area of treatment (22).
HIV/AIDS case surveillance provides some information on HIV infections. However, 
HIV diagnoses are often lacking as in many individuals HIV is undetected. Whilst 
AIDS is a clinically observable syndrome that is clearly defined, many individuals 
with HIV infection have not progressed in their disease to the point that AIDS can be 
diagnosed, so AIDS statistics reflect HIV infections that occurred up to a decade or
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more in the past (17). For these reasons, monitoring HIV seroprevalence is a more 
accurate way of assessing the extent of the epidemic. Arguably the best method for 
such monitoring is UA testing of residues of blood samples taken for other clinical 
purposes, since in theory this should lessen both participation and selection bias (2). 
An accessible population is selected and the residual of blood samples collected for 
other clinical purposes are tested for HIV after the irreversible elimination (unlinking) 
of all personal identifying information from each specimen. The populations that are 
currently part of the UA programme in GB are genito-urinary medicine clinic 
attenders, injecting drug users, antenatal clinic attenders, newborns (dried blood spot 
testing) and pregnant women seeking terminations (23).
In addition to the surveillance systems at CDSC and SCIEH, researchers at the 
Institute of Child Health (ICH) monitor numbers of reported HIV-infected pregnant 
women, diagnosed either before, during or after pregnancy, and numbers of children 
bom to HIV infected mothers through the National Study of HIV in Pregnancy and 
Childhood (NSHPC). Children are followed up until infection status outcome is 
established (24-25).
1.3.4: Characteristics o f HIV/AIDS diagnoses amongst women in GB 
In 2002, women accounted for 42% of new HIV diagnoses, and the proportion of all 
cases that are female continues to grow (Figure 1.5) (19). Most of the new HIV 
diagnoses in females (including women and children) were attributed to heterosexual 
contact (96%), with few cases being attributed to injecting dmg use (1%), mother to 
child transmission (MTCT) (2.5%) and blood/blood products transfer (0.5%). The 
majority of heterosexually acquired cases were recorded as having probably been
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acquired in Africa, predominantly East Africa (for example Uganda). The impact of 
the HTV epidemic in South East Africa in GB is however growing and in 2002 
Zimbabwe was the predominant probable country of infection (26). Where year of 
arrival in the UK was available (839/1757), the majority (60%) of women who had 
probably been infected abroad had arrived in this country in the previous 3 years 
(unpublished data, CDSC reports).
The number of women who were reported as having acquired HIV heterosexually 
from a “high risk” partner (a bisexual man, IDU or someone infected through blood 
transfusion or blood factor treatment) was small; in 2002 only 2% of heterosexually 
acquired infections were in this category and most of these ‘high risk’ partner 
infections occurred in the UK. In contrast, women who acquired HIV heterosexually 
in the UK from a partner who themselves acquired their infection heterosexually, 
formed 10% of the new diagnoses in 2002. This is a decrease from 16% in 1995.
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Figure 1.5: N um ber of HIV diagnoses am ongst adults and  %  of reports in GB: 
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Most reports of HIV diagnoses were amongst women of childbearing age. Generally 
women were younger than men at HIV diagnosis and this difference was particularly 
evident for heterosexually-acquired infections (Figure 1.6) (19). Of the 1,993 women 
infected through heterosexual exposure in 2002, 16% were aged 15-24, 68% aged 25- 
39, 14% aged 40-54 and 2% aged 55 and above. Eighty four percent of infections 
among 15-24 year olds reported in 2002 were among females. Studies in Africa have 
examined factors which may be responsible for this disparity and have concluded that
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either women are more susceptible to infection (27) or that young women are 
becoming infected by older sexual partners (28).
Figure 1.6: Reports of new HIV diagnoses for heterosexually exposed 
individuals by age group in 20031
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1 Reports received to March 2004
As well as numbers of new diagnoses, it is also important to consider the number of 
prevalent HIV infected persons currently receiving HIV-related care. This data allows 
for the fact that HIV infected people may have died or migrated out of the country. 
Approximately 32,000 individuals were seen in E,W & Nl for HIV-related care in 
2002. Of these, 28% (8,967) were women, representing a 3-fold increase in the 
number of women being seen for treatment and care since 1997 (Unpublished data, 
SOPHID survey 2002).
Whilst the vast majority of those HIV-infected are younger adults, the improvements 
in HAART have meant that increasing numbers of HIV-positive women are reaching 
older age. Data from SOPHID indicated that the number of women aged >=45 years
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accessing HIV-related services more than doubled between 1997 and 2002 
(unpublished data, SOPHID data 2002).
1.3.5: Seroprevalence o f  HIV infection amongst neonates
HIV prevalence amongst neonates reflects levels of HIV infection amongst women 
proceeding to a live birth. Over 600 HIV-infected women gave birth in GB in 2002. 
According to the UA dried blood spot survey, 0.40% (422/105,817) of women giving 
birth in London were infected with HIV and levels have risen since 1997. Elsewhere 
in GB prevalence amongst women giving birth has remained lower (0.063% 
(216/345,524)) (Figure 1.7) (29-30).
Figure 1.7: Trends in HIV infection in pregnant women giving birth as assessed 
by neonatal seroprevalence in GB
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Important demographic variations in HIV prevalence amongst women giving birth 
were apparent. Analyses showed that a much greater proportion of HIV infected 
pregnant women bom in SSA were HIV-positive compared with those bom in the UK 
(Figure 1.8); Of all HIV-infected women giving birth in 2001-2002 for whom country 
of birth was known (571/651), 82% (464 of 571) were bom in SSA. Women bom in 
Zimbabwe (10.2%), Zambia (8.4%) and Uganda (8.3%) (all countries classified as 
Eastern or South Eastern Africa) had the highest HIV prevalence.
Figure 1.8: Percentage distribution of HIV seropositive samples amongst 
pregnant women according to country of birth: 2001-2002
Source: Unpublished data, UA neonatal seroprevalence data in the UK, 2002
Migrants from generalised epidemic countries, particularly SSA, are increasingly 
driving the HIV epidemic not only in the UK but throughout Western Europe. Two 
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reflecting the worsening of the HIV epidemic in Africa and changing worldwide 
migration patterns (31). The effect of the African epidemic on national HIV situations 
differs between European countries and reflects past colonial history and current 
migration patterns. The implications have been substantial within GB due to the links 
with Eastern and Southern Africa, countries which have a particular high HIV 
prevalence (1).
1.3.6: H IV screening during p regnancy
In Europe, in the absence of any interventions, HIV infection in pregnancy is 
associated with a risk of mother to child transmission (MTCT) of between 15-20% 
with the higher levels in mothers who breastfeed (32). The ACTG076 trial published 
in 1994 demonstrated that vertical transmission of HTV could be reduced by two 
thirds through the use of a three-part regimen of zidovudine given antenatally, during 
labour and postnatally to the infant for 6 weeks (33). Recently the importance of 
potent antiretroviral therapy in reducing levels of RNA has been highlighted (34-36). 
This has initiated the use of more aggressive combination drug regimens which 
maximally suppress viral replication and many women are now delivering babies with 
undetectable maternal viral loads. In addition, Nduati and colleagues have reported a 
significantly higher rate of MTCT in infants who are breastfed rather than given 
formula feed (37) and trials have shown elective caesarean section (CS) before onset 
of labour and rupture of membranes significantly reduces the risk of vertical 
transmission compared to both vaginal and emergency CS deliveries (38-39). With 
antiretrovial therapy, delivery by CS and avoidance of breastfeeding, transmission 
was shown to be reduced to well under 2% (34-36). There are also increasing benefits 
for the woman herself knowing that she is infected, as early diagnosis of HIV
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infection allows the mother to be prescribed HAART for her own health. The British 
HIV Association (BHTVA) published guidelines for prescribing antiretroviral therapy 
in pregnancy advocating the use of these drugs as the best prospect for prolonged 
health in pregnant women as well as reducing vertical transmission (40) 
(www.bhiva.org/guidelines/2003/hiv/index.html accessed July 2004).
In response to results from trial ACTG076, an appreciation that HIV infection was 
transmitted through breastfeeding and the knowledge that within GB, as elsewhere, 
the majority of HIV infection in children was attributed to MTCT (41), the UK 
Departments of Health recommended that all women resident in areas of high 
prevalence, for example London, and women considered to be at high risk of infection 
should be offered antenatal HIV testing. These recommendations were made in 1992 
and again in 1994 (42-43). Following this in 1996 a set of guidelines for pre-test 
discussion on HIV testing were produced simplifying previous practice which tended 
to emphasise lengthy pre-test counselling (44-45). Despite these recommendations, 
most maternal infections remained undiagnosed and high numbers of children were 
still presenting with an AIDS-defining illness as the first indication of the mothers 
HIV infection (6). This finding led in 1998 to a professional initiative by an 
intercollegiate working party group, the aim of which was to increase the uptake of 
antenatal testing and consequently the reduction in paediatric AIDS cases (46). The 
Working Party made a series of 20 recommendations on improving antenatal HIV 
testing, the focus of which were to integrate antenatal HIV testing with testing for 
other infections. More recently (1999) the Government announced a major policy 
development and the establishment of national targets for antenatal HIV testing in 
England (47). Targets were set to increase both the uptake of antenatal HIV testing to
36
90% and the proportion of HIV infections diagnosed prior to delivery to 80% by the 
end of 2002. Guidance was also issued for the health service in Scotland and Wales 
on universal antenatal HIV testing (48-49).
The proportion of maternal infections diagnosed before and during antenatal care can 
be estimated by comparing reports of diagnosed HIV-infected pregnant women, 
which is collected through the National Study of HIV in Pregnancy and Childhood 
(described further in chapter 3), with the number of seropositive pregnant women 
estimated from the UA surveys. Since the 1998 professional initiative, there has been 
a steady increase in the proportion o f HIV-infected women diagnosed before delivery 
and in 2002 this was over 80% (Figure 1.9).
Figure 1.9: Estimated proportion of HIV infected pregnant women diagnosed 
before delivery*
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The improvement in timely diagnosis in women has resulted in a substantial decrease 
in the number of infected infants (51). The drastic reduction seen in perinatal 
transmission and the availability of HAART may have changed pregnancy decision 
making amongst HIV-infected women and this is discussed in more detail in chapter
2. Such a change in reproductive behaviour would have been reflected in changes in 
estimated levels of HIV amongst pregnant women in seroprevalence studies as HIV- 
positive women would have an increased likelihood of having a live birth and 
therefore appearing in neonatal seroprevalence surveys.
1.4: Importance of monitoring HIV prevalence amongst women
Accurate HTV prevalence estimates have important public health uses as they give an 
appreciation of the total burden of infection within the population, allow objective 
estimates to be made of changes in that burden and assist in the prediction of future 
numbers of HIV infections and AIDS cases that will require care (2). There are many 
difficulties with HIV surveillance: the long latent period means that disease is a 
reflection of historic rather than current spread; and there are biases in who comes 
forwarded for testing (52). These challenges have led to the development of 
surveillance methods which are based on the understanding of the problems 
associated with estimating HIV prevalence.
Deriving estimates of HIV prevalence in women of reproductive age is particularly 
important as, globally, HIV is increasing rapidly among this population group (1). A 
population frequently chosen for this purpose is antenatal clinic (ANC) attendees. 
Pregnant women are a stable sub-group of the total heterosexually active population
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and the trend in HIV infection in pregnant women should mirror that in the 
heterosexual population. The WHO stated in their guidelines in 1989 that UA surveys 
are generally considered an accurate and effective method for public health 
surveillance (53). In a 1998 document of the WHO and The Joint United Nations 
Programme on HIV/AIDS (UNAIDS), it is stated that UA Surveillance through ANCs 
remains the best available option for HIV surveillance (54). An alternative method of 
monitoring HIV seroprevalence amongst pregnant women is to test residual neonatal 
blood spots for passively acquired maternal antibodies, an approach used in GB (55). 
Results from this survey, which have already been summarised in this chapter, are 
analysed further throughout this thesis.
1.5: Developments of methods for estimating HIV prevalence
Neonatal seroprevalence data have already been used to provide estimates of HIV 
infected people in Britain using direct and indirect methods.
In the direct method, estimates of the total number of HIV infections in the population 
were calculated through combining data from three unlinked anonymous surveys with 
estimates of the size of the population in various exposure categories derived from the 
National Survey of Sexual Attitudes and Lifestyles, census 2001 population estimates 
and reports of diagnosed prevalent HIV infections. The total population of GB was 
divided into mutually exclusive behavioural categories relevant to HIV infection risk 
(homosexual men, IDUs and low risk heterosexuals as represented by pregnant 
women). The undiagnosed HIV prevalence for each group was multiplied by its 
population size to determine the total number of undiagnosed HIV infections. These
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were then added to the prevalent diagnosed HTV infections within each group (4-5). 
This technique is currently the preferred method for providing HIV estimates for the 
UK (30) and in 2002 it was thus estimated that 49,500 adults aged 16 years and over 
were living with HIV. Approximately a third of the total numbers of HTV infections 
were estimated as being undiagnosed (Table 1.6).
Indirect methods are based on the proportion of persons recently diagnosed with 
AIDS whose first positive HTV test was probably before any illness associated with 
their AIDS diagnosis (56). This proportion is assumed to indicate the proportion of all 
persons currently infected with HTV without AIDS who have had a voluntary HTV 
test. One key assumption in this method is that the incubation period in persons with 
diagnosed HTV infection is the same as in undiagnosed HTV infected individuals. 
Since 1997 this method has been severly compromised by the effects of anti-retroviral 
therapies as fewer diagnosed HIV infected individuals now progress to AIDS.
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Table 1.6: Estimated prevalent HIV infections, diagnosed and undiagnosed
among adults1 in the UK at the end of 2002
Route of probable infection Number
diagnosed2
Number 
undiagnosed 3,4
Total
Homo/bisexual men 17,100 5,500 (24%) 22,600
Injecting drug use 1,400 300 (18%) 1,700
Sex between men and women 15,100 9,400 (38%) 24,500
Blood products5 700 0 700
Total 34,300 15,200 (31%) 49,500
1 Aged 15-59 inclusive, excludes those who have died during the year
2 Numbers diagnosed obtained from SOPHID and SCIEH, adjusted for under­
reporting and failure to access services
3 Numbers undiagnosed derived for England and Wales using data from SOPHID, 
NATSAL and the UA programme in an extension of a method previously described 
(4)
4 Numbers undiagnosed for Scotland estimated by using exposure group specific 
scaling factors derived for England and Wales
5 All cases infected by blood and blood products or tissue were assumed to be 
diagnosed
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Finally, back-calculation, a different type of technique which has not relied on the use 
of seroprevalence data, has been used to provide estimates of HIV incidence based on 
knowledge of the incubation period from HIV infection to AIDS and of AIDS 
incidence over time (57). From this estimated HIV incidence, after adjusting for 
annual mortality and inward and outward migration, estimates of overall HIV 
prevalence (both diagnosed and undiagnosed) could be derived. Again, however, 
advances in AIDS treatment have made this technique inappropriate and adjustments 
for migration patterns in and out of the country have been inadequate.
Other methods have also been developed for the production of HIV estimates. The 
number of HIV-infected persons in the US was estimated by simply applying 
observed prevalence rates amongst pregnant women proceeding to delivery to all 
women derived from census data, stratifying by race, age and region of residence 
(58). A UN AIDS/WHO Working Group on Global HTV/AIDS and STD surveillance 
produced country-specific estimates for HTV infection. For developing countries with 
generalized epidemics, prevalence estimates were based primarily on surveillance 
data collected from women attending antenatal clinics. The prevalence estimate for 
women was then used to estimate the prevalence among men, based on the assumed 
female-to-male ratio (59).
1.6: Factors to consider when extrapolating neonatal prevalence data to the 
general female population
Concern has been raised over the representativeness of sentinel surveillance using 
pregnant women. The extrapolation of neonatal seroprevalence data to the general
42
population assumes that HIV-infected women have an equal probability of becoming, 
and staying, pregnant as uninfected women and that there is no differential fertility 
between persons at high and low risk of HIV infection (7,60); in other words fertility 
is assumed to be independent of HIV risk. There are a number of reasons why this is 
unlikely to be the case, especially in countries such as GB where underlying fertility 
is relatively low and HIV infection is high in sub-groups with high fertility (7). There 
are important social and behavioural differences between pregnant and non-pregnant 
women, which can make the prevalence of HIV in pregnant women different from 
that in all women. A substantial body of literature which has reviewed fertility in 
HIV- positive women exists and is presented in chapter 2.
In order to determine whether HIV seroprevalence in the sentinel group truly 
represents that of the population at risk, it is necessary to assess the relative likelihood 
of an HIV-infected individual being included in the sentinel group compared to any 
other member of the population. The mathematical relationship is sometimes referred 
to as the relative inclusion ratio or risk (RIR), with an RIR above unity if an HTV- 
infected individual is more likely to be included in the sentinel group than an 
uninfected individual (60). RIRs could also change over time producing spurious 
trends in sentinel group prevalence despite an unchanging prevalence and effectively 
preventing estimating HIV incidence from seroprevalence data (61).
RIRs which differ significantly from unity may reflect behavioural, socio-economic 
and/or cultural differences between infected and uninfected individuals (60). There 
may be different influences on the RIR:
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Pre-diagnosis influence: The RIR may differ from unity because of behavioural or 
demographic risk prior to diagnosis of HTV infection. Differential coverage of 
neonatal dried blood spot screening by ethnicity has been documented (62). In 
particular, coverage was poorer for infants in the African ethnic group compared to 
White infants (63). Since HIV prevalence is higher in African women in GB, extreme 
under-coverage of African infants in the dried blood spot survey could in theory result 
in substantial underestimates of HIV prevalence. In practice however there is 
evidence that this is not the case in GB (62,64).
Post-diagnosis influence: The RIR may differ from unity because of behavioural or 
clinical consequences following diagnosis of HTV infection. For example, some 
studies have shown that higher proportions of women who are seropositive for HIV 
infection elect for a termination of pregnancy compared to seronegative women, 
although sample sizes in these studies were small and the differences did not reach 
statistical significance (65-67). However, if such a differential exists, the serosurvey 
of HTV infections in women having a termination of pregnancy are likely to produce 
higher estimates of seroprevalence of HIV infection in heterosexual women than the 
survey of antenatal clinic attenders or the neonatal dried blood spot survey.
Natural history influence: The RIR may fall below unity as a consequence of disease 
progression. As a woman becomes unwell she may be less likely to become pregnant.
Interpreting HIV prevalence data from pregnant women is therefore difficult and 
estimates are likely to be biased if factors associated with both fertility and HIV risk 
are not accounted for. For the purposes of this thesis, the assumptions associated with
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extrapolating neonatal prevalence to the general population were reviewed and 
summarised below:
Assumption 1: Groups in the population at high and low risk of HIV infection 
have similar underlying fertility patterns.
In GB women bom in SSA and IDUs have the higher HIV prevalence (30). Whilst 
data relating to fertility in IDUs are lacking, African women are known to have higher 
fertility rates than the White population in GB (8). Assumption 1 is therefore violated 
and HIV prevalence in the general population may be overestimated to an unknown 
extent if differential fertility patterns of populations at high or low risk of HIV are not 
taken into consideration. In addition the size of population sub-groups with differing 
HIV risk and fertility patterns in GB may change due to migration or other factors, 
again complicating our understanding of trend data amongst pregnant women.
Assumption 2: Knowledge of HIV status does not alter reproductive decisions
HIV-infected women may reduce their number of live births after HIV diagnosis. 
Results from studies comparing live birth rates before and after HTV diagnosis in 
cohorts of HIV-infected women found that live births decreased after HIV diagnosis 
(68). Whilst a fall in birth rates could be explained by factors other than knowledge of 
HIV status, this assumption needs further investigation. Since these studies were 
carried out, treatments to delay HIV disease progression in adults and interventions to 
reduce MTCT of HIV have improved substantially over the last few years (33-35,ST­
BS,69) and routine antenatal HIV screening programmes have recently been widely 
implemented in GB (50). It is possible that these developments may influence 
intentional fertility decisions amongst HIV-infected women.
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Assumption 3: HIV-infected women have the same biological ability to become 
pregnant and carry a pregnancy to term as HIV-uninfected women.
It is generally assumed that HIV status does not influence unintentional fertility 
except in advanced disease (discussed further in chapter 2). However evidence to 
confirm or refute this assumption is limited and further research is needed. It is 
unclear to what extent a violation of this assumption would operate in GB and bias the 
use of neonatal seroprevalence for the general population.
1.7: Methods to adjust neonatal seroprevalence data
Limited attempts have already been made to devise methods to adjust neonatal 
seroprevalence data to reflect general population prevalence. Zaba et al suggested a 
method for adjustment for the developing world in which the HIV prevalence is 
determined separately for ANC attenders with and without children (70). A separate 
correction factor was applied to each group, based on the HIV prevalence ratio for 
ANC attenders versus women in the general population among parous and nulliparous 
women. This method was shown to work well in two African populations with low 
contraceptive use. This method was then validated in different populations by 
Changalucha et al and Fabiani et all, showing that in some centres more accurate 
estimates were obtained (71-72). This correction factor is most useful in developing 
countries where contraceptive use is low and fertility is high and where women 
acquire HIV at a young age.
Recently a method for adjusting HIV seroprevalence in pregnant women was devised 
in the UK using estimates of fertility rates before and after HIV diagnosis by risk 
group (68) and applying these rates to neonatal seroprevalence data (73). Birth and
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termination rates from women known to be HTV infected were derived from the MRC 
collaborative Study of Women with HIV. These rates were then compared with those 
for HIV-uninfected women using vital statistics to generate a fertility ratio. This ratio 
was then applied to neonatal seroprevalence data to estimate population prevalence 
among all women. Whilst this method was simple and demonstrated that fertility 
effects were important when applied to neonatal seroprevalence results, the data 
available on live births amongst HIV-infected and uninfected women was limited. In 
order to improve these estimates of HIV infection in the general population it is 
therefore important to understand the numerical relationship between HIV and 
fertility fully to then use this information to develop a robust adjustment model.
The purpose of this thesis was therefore to estimate the HTV prevalence in the adult 
female population in GB using neonatal data. The biases associated with each 
assumption discussed above were assessed and quantified and used to extrapolate 
neonatal data to the general female population.
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1.8: Key Points
1. HIV estimates for the general female population are currently based on 
unadjusted neonatal seroprevalence data. It is recognised that these estimates 
are likely to be biased as factors associated with differential fertility between 
persons at high and low risk of HTV have not been accounted for.
2. Previous research has suggested HIV-infected women may experience a 
reduction in the number of live births after diagnosis. It is not known whether 
this decline could be explained by knowledge of HIV status or other factors. It 
is also unknown whether this remains after allowance has been made for the 
total number of births these women would have wanted to have in the absence 
offflV.
3. An increase in neonatal HTV seroprevalence has been recorded in all parts of 
GB since 1997, particularly London. It is unclear whether this rise corresponds 
to a rise in HIV in the general female population, or whether fertility decisions 
amongst HIV-infected women have changed due to increasing availability of 
treatments and interventions. Alternatively the size of groups at risk of HIV in 
GB may have changed.
4. Universal antenatal HIV screening has been implemented in GB and 
increasing proportions o f previously unidentified HIV-infected women are 
having their infection diagnosed. The impact of improved antenatal testing, 
and possible earlier diagnosis, on pregnancy outcome is not known.
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1.9: Outline of thesis
Chapter 2 consists of a review of the literature on fertility in HTV-infected women and 
explores further the biases associated with extrapolating unadjusted neonatal 
seroprevalence data to the general female population. Chapter 3 describes the type of 
analyses done and the datasets used and provides a framework of how the neonatal 
and other data sources will be used for the purposes of this project. The extent of bias 
associated with the assumption that groups in the population at high and low risk of 
HTV infection have similar underlying fertility patterns, is analysed and presented in 
chapter 4. Chapter 5 presents estimates of fertility amongst HTV-infected women 
using established British and European datasets. The methodology and analyses of a 
cross-sectional questionnaire study, the main survey of the PhD project, is then 
presented (chapter 6). Chapter 7 uses all analyses from chapters 4-6 to develop a 
model for estimating female prevalence in the general population from that in 
pregnant women. Finally, chapter 8 consists of the discussion and recommendations 
for future work.
49
Chapter 2: Association of HIV and fertility
2.1: Introduction
During the past decade, there has been a dramatic increase in the number of women 
infected with HIV. One of the most prominent features of HIV infection is that it is 
usually diagnosed during the peak reproductive years. For this reason, there has been 
long standing concern regarding the obstetric implications of HIV infection.
Decisions around childbearing are complex and many factors including maternal HIV 
infection status may influence these decisions (Table 2.1). With the improvement of 
anti-retroviral therapy and as more interventions to reduce the risk of vertical 
transmission are identified, infected women’s reproductive decisions may have been 
influenced.
Table 2.1 Decisions around childbearing
Many factors may influence an HIV-infected women’s decision to have a child or 
continue with a pregnancy. Adapted from Newell et al 1997 (74)
General
Sociocultural factors 
Existing family size 
Past reproductive history
Attitudes towards and policies for termination of pregnancy
HIV-related
Maternal health status
Knowledge of risk of vertical transmission
Availability of interventions to reduce risk of vertical transmission
Family support
Availability of treatment to delay disease progression
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This chapter reviews the literature on the association of HIV and fertility. It begins 
with a review of the magnitude of the differences between the fertility rates of HIV- 
infected and uninfected women. This has been established by gathering evidence from 
prospective studies of the fertility of HIV-positive and HIV-negative women. 
Secondly, the comparison of estimates of the prevalence of HIV among pregnant 
women to all women of reproductive age is investigated. Finally, other studies that 
look at the association between HIV and fertility are reviewed, the majority of which 
look retrospectively at birth histories and pregnancy outcomes for women of known 
HIV status. Whilst many studies reviewed in this chapter were carried out in Africa, 
findings were considered relevant to this thesis as the majority of HIV infection 
among women in GB is associated with time spent in sub-Saharan Africa (SSA) (30).
2.2: Prospective studies of fertility rates among HIV-positive and negative 
women.
Several prospective studies have been carried out to determine the fertility rates 
among women with and without HIV (75-78). These studies have all been located in 
SSA where the epidemic is older and more severe than GB. The main results of these 
studies are shown in Table 2.2. In all four studies, a lower fertility ratio was found 
among HIV-infected women relative to the HIV-uninfected women and odds ratios 
ranged from 0.73-0.81.
Women recruited into the studies were either from a hospital following the birth of a 
child (75) or from a community setting (76-78). Since both the HIV-infected and 
uninfected women recruited from the hospital setting were of proven fertility, their
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subsequent reproductive performance is likely to be higher than that of women in the 
population as a whole. Women suffering from primary and secondary sterility would 
not have appeared in this sample nor would women who were not in active sexual 
partnerships. In addition, a relatively high number of hospital attenders were lost to 
follow-up during the first year, and the infant mortality rate in the children of these 
women was much higher than women who remained in the study. It is difficult to 
predict what the fertility rates would have been in the infected women lost to follow- 
up.
Whilst the four studies reviewed showed a reduction in pregnancy rates in HIV- 
infected women compared to HIV-uninfected women, it remains unclear whether this 
effect was due to biological, behavioural or social factors. Fertility rates may have 
declined in HIV-positive women following knowledge of infection and subsequent 
use of contraceptives that would both prevent pregnancy and HIV transmission. 
However, in 2 studies the majority of women were unaware of their status and use of 
contraception in Africa is rare (76-77). Gray found reduced fertility in HIV-infected 
Ugandan women irrespective of knowledge of serostatus (77). Whilst in the 
Kinshasha study all women were aware of their status, few informed their sexual 
partner which in turn prevented consistent use of barrier contraceptives. The fertility 
rates in these women may have declined because of the intensive education and 
counselling which these women received in the programme. The women were made 
aware of their HIV infection status and the risk that this infection posed to future 
children and the importance of using condoms was repeatedly emphasised (75).
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Previous research has shown women with histories of Sexually Transmitted Infections 
(STIs) have lower fertility rates than similarly aged women without a history of an 
STI (79). Gray found higher proportions of HIV-positive women had been infected 
with syphilis in the past, exposing them to higher risks of foetal loss. When cross­
infection with syphilis was accounted for, there was still a significant reduction in 
fertility in HIV-positive women (77). Ross investigated gravidity (likelihood of being 
pregnant) as well as fertility (likelihood of having live births) and found that almost a 
half of the association between HIV infection and pregnancy incidence was 
contributed by low gravidity prior to HIV infection rather than a direct effect of the 
HTV disease itself. The authors concluded that STIs and HIV are intricately linked, 
and prior STI infection may increase susceptibility to both fertility problems and HIV 
infection (78).
HIV positive women who were symptomatic with HIV infection had lower fertility 
rates than asymptomatic HIV-positive women (75,77). It was not determined whether 
these lower rates were due to lower rates of sexual activity in HIV-positive women or 
due to a primary effect of HIV infection on fecundity (ability to have children). A 
study in 15 hospitals in Uganda of signs and symptoms associated with HIV found 
that amenorrhoea was a common symptom for AIDS in an African population (80). 
This was probably due to the severe weight loss that occurs in the later stages of HIV 
illness and is likely to be less common in developed countries where HIV-related 
treatments are widely available. There may also be repercussions for women’s fertility 
from the biological effects of HIV on their infected partners, who may be further 
along in the course of disease progression and suffer from symptoms such as
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decreased production of spermatozoa (81). However, lower pregnancy rates were still 
observed in asymptomatic HIV-positive women than HIV-positive women with 
symptoms, so clinical AIDS cannot explain all the decrease observed.
In summary, little information was gathered on biological or social factors which 
would help to explain the discrepancy in fertility rates between HIV-positive and 
HIV-negative women. Few of the studies determined marital status of the women, 
health status of the partner or frequency of sexual activity and two of the studies did 
not include the presence of other STIs for inclusion in the analysis. Without such 
information, it is difficult to conclude anything more than an association between HIV 
and fertility.
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Table 2.2: Prospective studies of fertility rates among HIV-positive and negative 
women: Developing countries
Author, year Ryder, 1991 Carpenter,
1997
Gray, 1998 Ross, 1999
Location Kinshasa, 
Zaire a
Masaka,
Ugandan
Rakai,
Uganda*
Masaka, 
Uganda a
Fertility Rate HIV 
positive (per 1000)
190.1 194.8 235 206
Fertility Rate HIV 
negative (per 1000)
265.4 212.3 301 254
Total no. HIV 
positive in study
238 332 692 80
Total no. HTV 
negative in study
315 3352 2382 96
Date 1986-90 1989-96 1994-6 1990-1997
Fertility Ratio 
(infected:uninfected)
0.77* 0.74f
(0.63-0.87)
0.73g 0.81h
* Women recruited from hospital following birth of child. Number of pregnancies per 
1000 women (annual)
b All women 15-49 residing in 15 neighbouring villages. 
c All women 15-49 living in 56 communities.
d HIV infected women recruited in a HIV Natural History Cohort study 
c adjusted for birth control 
f adjusted for age
8 adjusted for age, birth control and breastfeeding 
h adjusted for age, lactation, sexual activity, illness and STI symptoms
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2.3: Comparison of HIV prevalence estimates between pregnant women and 
women in the general population
A number of studies have assessed how well sentinel groups, in particular pregnant 
women, reflect prevalence in the general population (72,82-87). These studies have all 
been carried out in various countries within Africa, and involve comparing estimates 
amongst antenatal clinic attenders (ANC) with estimates from population-based 
surveys of women. In all studies, HIV prevalence among ANC was lower than the 
prevalence amongst women in the general population (Table 2.3). The ratio of HIV 
prevalence in pregnant women to HIV prevalence in all women ranged from 0.66 to 
0.94.
A further study by Fontanet et al estimated the age and sex-specific HIV prevalence in 
the urban community setting of Addis Ababa, Ethiopia in 1994 (88). HIV prevalence 
among women was 6.9% and there was considerable variation in different areas of the 
city (0-21.3%). This data was compared with data collected from four antenatal 
clinics in Addis Abaha in 1996 and a substantially higher HTV prevalence rate was 
found in the pregnant women (17.8%). The authors suggested that this discrepancy to 
previous studies was because some women in the community, with behaviours at high 
risk of HIV, were reluctant to provide blood samples. Alternatively, an explanation 
for the prevalence difference could have been the 2-year interval between data 
collection from the general population and ANC surveys during a period when the 
epidemic may have been growing. In three other studies presented in Table 2.3 
(Lusaka and Mposhi, Zambia and Kagera, Tanzania) the ANC sentinel survey and the
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general population survey were also carried out during different periods of time and 
this may complicate interpretation of results.
Whilst overall HTV prevalence was higher amongst women in the general population, 
in the youngest age group (15-19 years) prevalence was higher in antenatal women in 
some of the studies reviewed (72,82,84,86-87). This may be explained by the fact that 
women who begin sexual activity at an early age are exposed to the risk of both 
pregnancy and HIV. In the older age groups HIV prevalence represents the 
cumulative total of infection over a longer period of time. These women are more 
likely to be sexually inactive, due to the effects of sickness, separation and 
widowhood, and their fecundity will be increasingly affected by biological factors that 
increase in importance with disease duration (89).
An investigation of factors which could account for the difference in prevalence 
between ANC and the general population were assessed in two of the studies. Glynn 
et al found age, marital status, parity, education status and contraceptive use as 
important factors which might influence the differences in HIV prevalence in ANC 
and the population, however the importance of these factors varied between different 
cities (87). Crampin et al found age, area of residence, marital status and moving 
household within the last 5 years to be important factors, although parity did not 
account for any of the difference (86). These studies highlight the difficulties of 
applying standard adjustments for ANC data to population estimates across different 
cities.
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A difficulty when comparing ANC and the general population is ensuring the two 
catchment populations of women are well defined and comparable. Attendance at 
antenatal clinics is variable and on a global basis it has been estimated that a third of 
women receive no antenatal care, although this proportion varies widely according to 
country (90). If some pregnant women in an area do not attend the antenatal clinic, 
and those who do not attend have a different prevalence of HIV from those who do 
attend, a bias would arise. ANCs may be more health conscious and have different 
socio-economic characteristics from pregnant women who do not attend. A different 
type of bias may have been that the studies reviewed here were carried out at various 
times over a number of years. As HIV first entered the different populations at 
different times, the epidemics will have reached different stages of maturity at the 
times of the studies. Therefore, the ratio of HIV prevalence in pregnant women to that 
in all women could vary with stage of the epidemic.
Finally, a health survey in Kenya collected demographic and HIV testing information 
on 9,000 households. Results revealed that women were more likely to be HIV- 
positive than men (9% versus 5%), the proportion of women found to be HIV-positive 
rose rapidly with age from 4% among 15-19 year olds to 12% in 25-29 year olds and 
that HIV prevalence derived from this population survey was similar to estimates 
observed amongst antenatal women (8.7% versus 9.4%) (91).
In summary, findings from these studies indicate that the prevalence in pregnant 
women may underestimate prevalence in the general population and this level of 
underestimate varies by age and area. These data are consistent with results presented
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in the previous section which found lower birth rates in HIV-infected individuals than 
in uninfected individuals. However, these findings apply to SSA and although they 
highlight possible biological and behavioural explanations, it is unclear to what extent 
the same associations hold in GB.
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Table 2.3:Studies comparing HIV prevalence in antenatal clinics with HIV prevalence in the female population: Developing countries
Author, year Kigadye, Kwesigabo, Fylkesnes, Kilian Glynn Glynn Glynn Changalucha Crampin
1993 1996 1998 1999 2001 2001 2001 2002 2003
Location Mwanza,
Tanzania
Kagera,
Tanzania
Lusaka & 
Mposhi 
Zambia
Uganda Cameroon Kenya Zambia Mwanza,
Tanzania
Karonga,
Malawi
Population survey prevalence 15.1% 29.2% L=29.9% 26.0% 7.8% 30.1% 31.9% 4.7% 17%
(unadjusted) M=17.4%
Population survey prevalence - 29.4% L=31.2%, - 7.7%b 31.1%b 32.7%b - 13.9%
(adjusted) M=17.4%,
Prevalence in ANC 11.7% 22.8% L=26.1% 18.4% 5.5% 30.6% 27.3% 3.6% 10.4%
(unadjusted) M=12.6%
Prevalence in ANC - 22.4% L=24.4%* - 5.2%b 29.2%b 26.0%b - 9.2%
(adjusted) M=12.5%a
No. of women in population 589 325 L=1211 527 1017 893 910 5675 342
survey M=426
No. of women in ANC 1820 1292 L=532 477 1532 1480 1021 2265 3013
attenders survey M=422
Year of survey 1990-91 Pop survey 
1987-88 
ANC survey 
1990
Pop survey 
1995/6 
ANC 
survey 
1994/6
1995 1997-1998 1997-
1998
1997-
1998
1991-1994 1998-
2001
Age group 15+ 15-54 15-39 15-49 15-40 15-40 15-40 15-44 15-49
Prevalence Ratio 0.77 0.76 L=0.78
M=0.72
0.71 0.68 0.94 0.80 0.77 0.66
a. Standardised for age using the Zambian 1990 census population as projected for 1995 as standard population, b. Adjusted for age
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2.4: Rates of reproductive events in HIV-positive women before and after 
diagnosis
In developed countries the effects of HIV infection on fertility has commonly been 
measured by comparing rates of reproductive events before and after HIV diagnosis in 
cohorts of positive women (Table 2.4). In the earlier studies, live birth rates decreased 
significantly after HIV diagnosis whilst termination rates increased (68,92-94). A 
French study published in 2001 showed that whilst pregnancy rates after HIV 
diagnosis decreased among European women, incidence of births increased among 
African women with fewer than 2 children, but not among those already having more 
than 2 children (95).
Stephenson et al compared the rates of reproductive events before and after diagnosis 
of HIV in a cohort of 503 HTV-positive women in Great Britain and Ireland in 1992- 
95 (68). For women aged 20-34, the age-adjusted livebirth rate fell by 44% from 10.2 
per 100 women years before diagnosis to 5.7 per 100 women years after diagnosis. An 
increase in termination rates accounted for approximately half the decline whilst an 
increase in the miscarriage rate and a decrease in the pregnancy rate accounted for the 
other half. Similar decreases in incidence of pregnancy and increases in abortion 
were also reported by De Vincenzi (France), Thackway (Australia) and Van Benthem 
(Europe) (92-94). Similar to the findings of Fourquet, Stephenson et al also found 
HIV-positive women of African origin continued to have higher pregnancy rates than 
HIV-positive women of European background. A different study by Forysth showed 
that in a city in America pregnancy rates amongst HIV-infected women were lower 
when compared with HIV-negative women, although this decrease was more striking
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when the women’s history of drug use was taken into consideration (96).
The incidence of pregnancy in a European study was also shown to decrease with 
HIV disease progression and pregnancies after HIV diagnosis were shown to be 
related largely to social and cultural attitudes (94). Pregnancy rates in Southern 
Europe were lower than in Central and Northern Europe and women living with a 
sexual partner were more likely to become pregnant after diagnosis than women 
without such a partner. A later study by Lee et al in the USA researched the effect of 
duration of infection with HIV on fertility by looking at the birth histories of women 
with AIDS and comparing them to uninfected women. The relative risk of giving birth 
in HIV-infected women was low compared to uninfected women and there was a 
clear negative gradient with duration of infection. These results suggested that HIV- 
infected women experience a progressive reduction in births years before the onset of 
AIDS. Demographic characteristics, contraception, induced abortion, fetal loss and 
illicit drug use could not explain the findings (97).
There has been a body of evidence early in the epidemic which suggested that HIV 
infection did not alter the likelihood of women becoming pregnant (67,98), nor did it 
affect the rates of either spontaneous abortions or planned terminations of pregnancy 
(65). The year the studies were carried out, the relatively small sample sizes used and 
the high proportion of drug users amongst the population groups under study may 
explain the discrepancy with the growing body of evidence that there is an effect.
Finally, two recent studies have compared pregnancy rates in HIV-infected women
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pre and post highly active anti-retroviral therapy (HAART), to determine whether 
improvements in HIV management have contributed to changes in pregnancy 
decision-making. Availability o f treatments to delay HIV disease progression have 
made many HTV-infected women feel better which in turn may change their desire for 
future children. Effective interventions to reduce mother to child transmission 
(MTCT) have become widely available and the likelihood of an HIV-infected woman 
having an infected child is now very small. Finally it is not known what effect the 
introduction of routine antenatal HTV testing has had on pregnancy decisions. 
Increasing proportions of previously unidentified infected women are now having 
their infection diagnosed earlier than they would have otherwise and this may impact 
differently on both immediate and future fertility decisions.
A study by Massad et al compared pregnancy rates in a prospective study involving 
2059 HIV-positive women and 569 HIV-negative women (99). The study was carried 
out in the USA between 1994 and 2002 and studied frequency and outcome of 
pregnancy both pre and post HAART. Whilst pregnancy rates were 7.4 and 15.2 per 
100 person-years in seropositive and seronegative women respectively (p<0.0001), 
pregnancy outcomes were similar. The abortion rate of HIV-positive women fell 
about the time of HAART introduction while conception rates remained stable, 
suggesting that positive women who conceived were more likely to continue their 
pregnancies after HAART rather than HAART led women to conceive who would not 
otherwise have done so. Another study in the USA demonstrated modest increases in 
pregnancy rates during the era of HAART and the authors hypothesised that increased 
survival times for women with AIDS as well as delayed progression to AIDS may
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result in greater opportunities to become pregnant. Data on outcome of these 
pregnancies was however unknown (100).
In summary, studies in the developed world which have compared pregnancy rates 
before and after HIV diagnosis have shown overall decreases in live birth rates after 
HIV diagnosis, although this was dependent on the cultural background of the 
woman. Whilst results may suggest an association between HIV and fertility, a causal 
link was not demonstrated and little data were available on whether the association 
was related to decision-making, lifestyle factors such as loss of partner or was a 
biological phenomenon.
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Table 2.4: Rates of reproductive events in HIV-positive women before and after diagnosis: Developed countries
Author, year 
Location
Stephenson, 1996 
UK
De Vincenzi, 
1997
France
Thackway,
1997
Australia
Van Benthem, 
2000b
Europe
Fourquet
2001c
France
Massad
2004c
USA
Live Birth Rate 
HIV positive 
(per 100 PY)
All: 5.7 
Black African: 12.0 
IDU: 5.0 
Rest: 4.4
2.1 30 per 
10,000.
8.2 (0-4 yr) 
6.0 (+4 yr)
Black African: 14.1 
Other:4.5
7.4
Live birth Rate 
HIV negative 
(per 100 PY)
All: 10.2 
Black African: 12.6 
IDU: 11.0 
Rest: 7.5
8.1 63.5 per 
10,000.
8.6 Black African: 8.7 
Other: 5.3
15.2
Total no. HIV 
positive in 
study
503 412 294 449 533 2059
Fertility Ratio All:0.56 
Black African:0.9S 
D)U:0.45 
Rest: 0.59
0.26 0.47 0.95 (0-4 yr) 
0.70 (+4 yr)
Black African: 1.62 
Other: 0.85
0.49
Date 1992-1995 1988-1993 1984-1994 1993-1998 1988-1996 1994-2002
aPregnancy rate per 10,000 women. Control group were all Australian women aged 15-44 years. 
b Live births, still births and spontaneous abortions 
c Incidence of pregnancies per 100 person years
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2.5: Other evidence
Many other studies have looked at the association of HIV and fertility and these 
include retrospective studies of pregnancy rates in HIV-positive women, studies on 
the incidence of pregnancies and studies looking at adverse effects of HIV on 
neonatal outcome and disease progression. Some studies investigate possible reasons 
for the observed associations.
2.5.1: Retrospective studies o f pregnancy rates amongst HIV-positive and HIV- 
negative women
In 1995-6 a retrospective study involving 4,369 women (530 of which were HIV- 
positive) was carried out in Abidjan, Cote d’Ivoire to determine the differences in 
fertility between HIV positive and negative women (101). The mean number of 
pregnancies for the HIV positive compared to the HIV-negative was significantly 
greater for women aged under 20 but significantly lower for HIV-positive women 
aged 25-34 years. HIV infection was also significantly associated with a higher risk of 
abortions (spontaneous and induced combined) and stillbirths. As all women were 
unaware of their infection status, results were unlikely to have been influenced by a 
change in reproductive behaviour and this study therefore suggests HIV has 
deleterious consequences on fertility. A later study by the same investigators, which 
collected more detailed information on fertility history, found that the interval 
between the last pregnancy and the current pregnancy was considerably longer among 
infected women (102). This supports the author’s previous hypothesis that HIV 
lowered fertility among infected women in terms of their ability to become pregnant.
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2.5.2: Incidence o f pregnancies amongst HIV-positive women 
A study of the incidence of pregnancy was carried out after HIV testing and 
counselling in Kigali, Rwanda in 1998 (103). A population-based sample of 1,458 
women aged 18-35 (460 HIV-positive and 998 HIV-negative) of known HIV status 
was followed for two years. At the initial survey, 11% of the HIV-positive women 
were pregnant compared with 17% of the HIV-negative. Even though HIV-negative 
women were significantly more likely to become pregnant in the 2-year follow-up 
period than HIV-positive women (58% vs. 43%), the incidence of pregnancy in HIV- 
positive women was still high. This relationship persisted after adjusting for age, 
marital status and frequency of intercourse.
Rather than compare HTV-positive and negative women, groups which may differ on 
various sociodemographic and behavioural characteristics, other researchers in the 
USA have not used a control group and have studied directly the pregnancy incidence 
in women who were aware of their HTV seropositivity (104-106). These studies have 
explored factors which may intervene in fertility decisions. Nebie et al showed that in 
a cohort of HTV-positive women who were followed for up to four years, pregnancy 
incidence was comparable with that in the general population. Sharing of the HIV test 
result with the male sexual partner was however infrequent and contraceptive use was 
low. Kline et al (105) found that a woman’s reproductive history was important to her 
current reproductive behaviour, whereby women who became pregnant knowing their 
positive status had experienced more previous pregnancies than other women.
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2.5.3: Effect of HIV on neonatal outcome
Several studies have investigated the impact of HTV infection on adverse neonatal 
outcome. This is a critical issue which has major implications for HIV-positive 
women who are considering becoming pregnant. Table 2.5 shows the main results 
from these studies which have been carried out in both developed and developing 
countries. In many studies, there was an increase in risk of miscarriage among HIV- 
infected women compared with HIV-negative women, with reported Relative Risks or 
Odds Ratios (RR and OR) varying from 1.7 to 3.4 (65,102,107-109). This difference 
was not however always statistically significant. Some studies have found an RR/OR 
of greater than 1, varying from 1.3 to 3.1, but with 95% Cl including 1 (67-68,92,110- 
112). Only two studies have calculated an RR/OR of spontaneous abortion that was 
less than 1.0 (75,98). Possible reasons for an adverse effect on neonatal outcome 
include a direct effect of HIV on the placenta, thymic abnormalities, altered cytokine 
production and the cumulative immunosuppressive effect of HIV that may have a role 
in facilitating ascending infection (107). Women with HTV were also more likely to 
have a history of STIs (78) and infection with syphilis is a known cause of fetal loss 
(113).
In a meta analysis of these studies, Brocklehurst and French reported that a modest 
relationship was found between HTV infection and fetal loss (114). However, they 
suggested that these findings might have resulted from inadequate adjustment for 
confounding variables and biases associated with study design. Women infected with 
HIV may have a higher incidence of STIs and, in developed countries, a higher 
incidence of past or current drug use. Observational studies are prone to bias insofar 
as the two groups compared (ie. HIV-positive and HIV-negative women) may be
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dissimilar in other characteristics apart from their HIV status. Further large 
prospective cohort studies which attempt to control for confounding were therefore 
recommended to more accurately define the effect of HIV on spontaneous abortion.
A few studies have also looked at stillbirths as an outcome of pregnancy. A review of 
these studies concluded that there appeared to be no association between HIV 
infection and stillbirth in developed countries, although the total numbers of women 
included in the surveys was small (114). In developing countries there was 
statistically significant evidence that the risk of stillbirth was increased (summary OR 
4.15, 95% Cl 2.81-6.15), although this could now change in the era of HAART.
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Table 2.5: Review of literature on HIV infection on adverse pregnancy outcome*
Author & Year Country Study design No. HIV 
positive
No. HIV 
negative
%  spontaneous 
abortion
%
stillbirth
Risk
Abortion7
95% c r P
value8
Johnstone 1988 Scotland Prospective 61' 751 18.0 vs 5.3 - RR3.4 NR <0.02
Selwyn 1989 USA Prospective 522 732 7.7 vs 5.5 0 vs 0 RR1.4 NR NR
Ryder 1991 Africa Prospective 1972 2952 52.1 vs51.64 RR0.62 NR NR
Sunderland 1992 USA Prospective 371 371 5.4 vs 8.1 - RR0.67 NR NR
Stephenson 1996 UK Prospective 2023 OO o 16.0 vs 10.0 - RR1.6 NR NR
De Vincenzi 1997 Europe Prospective 843 no3 25.4 vs 8.3 - RR3.1 NR NR
Braddick 1990 Africa Retrospective 1772 3272 11.0 vs 8.0 3.0 vs 3.0 RR1.4 NR NR
Miotti 1990 Africa Retrospective 642 3112 28.1 vs 15.1 - OR2.2 NR NR
Temmerman 1994 Africa Retrospective 2812 2752 7.8 vs 3.6 3.8 vs 1.9 OR2.0 0.9-4.8 0.1
De Cock 1994 Africa Retrospective 8391 12201 7.3 vs 5.7 3.0 vs 2.1 RR1.3 NR NR
D’Ubaldo 1998 Italy Retrospective 1752 972 14.3 vs 9.6 - RR1.7 0.71-3.92 0.24
Desgrees du Lou 1999 Africa Retrospective 1691 10131 0.21 vsO.173 - RR1.2 NR 0.38
Coley 2001
l \ t _ . ■ a _
Africa Prospective
T ___ r*_____
5202 4852 3.3 vs 2.36 6.5 vs 6.4 RR1.4 NR 0.34
4 Incidence rate 5 Mean number of miscarriages 6 Percentage of miscarriages as outcome of current pregnancy
7 RR=Relative Risk and OR=Odds ratio 8NR=Not recorded
♦Adapted from D’Ulbado et al (107) and updated with recent studies. Data on stillbirths has been additionally included.
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2.5.4: Effect ofpregnancy on progression o f H IV disease
The effect of pregnancy on the natural history of HIV disease is an important factor 
when counselling HTV-positive women considering pregnancy. Concerns regarding a 
possible interaction between pregnancy and HTV disease progression stemmed from 
early reports of an association between HIV infection and deteriorating maternal 
health (115-116). Both studies found that a certain proportion of HIV-infected 
pregnant women experienced clinical progression. However, these studies lacked a 
control group, and it is likely that the HIV-positive women who were enrolled were 
more immunosuppressed, given that they were identified via recognition of HIV 
infection in their infants. These studies were, however, suggestive and inspired future 
work in this area.
Subsequent findings from prospective studies suggested that pregnancy does not 
affect early progression of HTV disease (117-118). A review of seven prospective 
studies in 1998 did not find significant differences in the risk of death or progression 
to an AIDS-defining illness, although there were trends suggestive that there may be a 
weak association between disease progression and maternal outcome of HIV-infected 
women. Studies reviewed involved relatively small numbers of women making it 
impossible to determine with any certainty the effect of pregnancy on HIV disease 
progression and survival (119).
Finally, some studies have looked at the impact of pregnancy on T-cell lymphocyte 
populations as a measure of immuno-fimction decrease. Data from the European 
Collaborative Study and the Swiss HIV Pregnancy Cohort did not find decreases in 
CD4 cell count percentages throughout pregnancy and up to 6 months after delivery
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(120). In a more recent European study whilst pregnancy was shown not to have a 
statistically significant effect on CD4 lymphocyte counts, median levels pre and post 
pregnancy suggested a temporal decrease (121). It is difficult to determine how 
important this is to HIV disease progression.
2.5.5: Effect o f Sexually Transmitted Infections on infertility
It is well established that STIs can cause infertility, and that infertility can lead to high 
risk behaviour and HIV infection (79). This is of particular importance in SSA where 
the prevalence of infertility is high and in the monitoring of the HIV epidemic as the 
inability to become pregnant affects estimates of HIV prevalence amongst ANC. The 
association of HIV infection and fertility has been investigated by recruiting women 
from either infertility or abortion clinics. A study by Favot in Tanzania between 1994 
and 1995 showed women attending an infertility clinic had a higher HIV prevalence 
than women proceeding to birth in the same hospital (18.2% v 6.6%) (122). This was 
also shown in a study by Schrijvers where infertile women had a HIV prevalence of 
9.3% whilst fertile women had a HIV prevalence of 0.7% (123). The authors 
hypothesised that the higher prevalence of HTV in the group of infertile women could 
reflect the higher level of STIs in this group with the associated higher risk of HIV 
infection.
2.5.6: Factors associated with reproductive-decision making amongst HIV-positive 
women
Finally, some studies have looked at factors associated with pregnancy-decision 
making in cohorts of HIV-infected women, some before and some after improvements 
in HIV-related therapy. All these studies have been undertaken in America (1 OS-
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106,124-126) or the UK (127) and found that an appreciable number of infected 
women desired children and this was associated with factors such as age, marital 
status, partner’s desire for children, partner’s HIV status and personal health status. 
Ethnic differences in the desire for children were apparent (127). In summary, the 
studies showed that women with HIV do not rule out childbirth, although decisions 
surrounding their pregnancies are complex.
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2.6: Key Points
1. A substantial body of evidence exists which indicates that HTV-positive 
women have a lower fertility ratio than HIV-negative women in developing 
countries (OR 0.73-0.81) and in developed countries HTV-positive women 
were found to have a lower live birth rate post HTV diagnosis compared to pre 
HIV diagnosis (OR 0.26-0.95)
2. A number of studies have assessed how well HIV prevalence among pregnant 
women reflects prevalence in the general population and have found the ratio 
of HTV prevalence in pregnant women to HTV prevalence in all women ranged 
from 0.66-0.94.
3. A number of possible reasons for reduced fertility amongst HIV-positive 
women have been suggested; Avoidance of pregnancy to prevent onward 
transmission to a partner or child or to avoid orphanhood; an effect of HIV on 
fecundity; increased adverse outcome of the neonate due to HIV infection or 
other STIs.
4. Since the majority of the studies in the developed world were carried out, 
improvements in the management of HTV have occurred and it is not known 
how this may have affected reproductive decision-making amongst HIV- 
positive women.
5. Although important understanding has been acquired regarding the association 
between pregnancy and the course of HIV infection, much remains to be 
understood. Whilst a fertility differential between HIV-positive and HIV- 
negative women does not invalidate neonatal seroprevalence monitoring, it 
does indicate that extrapolations of seroprevalence from pregnant women to
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all women should be cautious and methods to overcome the fertility bias 
should be developed.
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Chapter 3: Aims, Objectives and Data Sources
3.1: Aims and objectives
The aim of this thesis is to develop a model to estimate the number of HIV infections 
amongst women in the general population using neonatal seroprevalence data. The 
objectives are as follows:
1. To assess the bias of differential fertility patterns between persons at high and 
low risk of HTV when producing general population estimates and to 
determine the important factors associated with fertility and HTV risk (Chapter 
4).
2. To assess current fertility patterns in diagnosed HIV-infected women and to 
explore the impact of improved antenatal testing, and possible earlier 
diagnosis, on pregnancy outcome (Chapter 5).
3. To assess whether fertility decisions amongst HTV infected women have 
changed due to increasing availability of treatments and interventions and how 
any changes would have affected trends in seroprevalence data (Chapter 6).
4. To estimate the Relative Inclusion Ratio (fertility differential) between HIV- 
positive and HIV-negative women, using results obtained under objectives 1 
and 3 (Chapter 7).
5. To define, use and validate a model to adjust neonatal seroprevalence so it 
reflects HIV prevalence in the general population. Data derived from
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objectives 1-4 will be used to help formulate this model. The adjusted neonatal 
prevalence will then be applied to population statistics to derive the number of 
HIV infections amongst women (Chapter 7).
To address these objectives a variety of different data sources were used. A cross- 
sectional questionnaire survey investigating the impact of an HIV diagnosis on 
fertility desire was carried out specifically for the purpose of this thesis. In addition, 
routine data containing information on HIV prevalence in pregnant women, reports of 
newly diagnosed HTV-infected women, prevalence of diagnosed HIV infections and 
reports of HTV-infected pregnant women were extracted from data sources at the HP A 
Communicable Disease Surveillance Centre (CDSC) and the Institute of Child Health 
(ICH). Finally, 2001 census information, birth statistics and information from the 
2001 National Study of Sexual Attitudes and Lifestyles (NATSAL) were used to 
supplement analyses. All this information was then put together to generate the final 
model which adjusts neonatal seroprevalence data (Figure 3.1). A table summarising 
the different data sources used is given at the end of this section (Table 3.2). Results 
from objective 1 were published in Communicable Disease and Public Health in 
March 2004 (Appendix A).
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Figure 3.1: Approach for adjustment of neonatal seroprevalence data to all women
Objective 1
Objective 2 & 3
Objective 4
Objective 5
Population
statistics
Neonatal Seroprevalence 
stratified by risk
Relative Inclusion Ratio
(RiR)
Adjusted neonatal 
seroprevalence by risk
1
Fertility in -----------------► I ■<----------------- Fertility in HIV
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Number of HIV infections 
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3.2: Questionnaire survey to assess impact of HIV on fertility-decision making 
amongst women
3.2.1: Study design
Previous research has shown an association between HIV and fertility, although little 
information has been gathered on factors which would help explain this relationship. 
For these reasons a cross-sectional questionnaire survey was undertaken for the 
purposes of this thesis in order to improve our understanding of reproductive-decision 
making amongst HIV-infected women. The design of this survey enabled the women 
to be directly asked themselves about their desires for children. It was important that 
the data collected were from a representative sample of HTV positive women and that 
enough women were included in order for the data to be robust enough to be included 
in the final model of the thesis. The aims and objectives of this study are described in 
detail in chapter 6.
All HIV-positive women of reproductive age (16-49 years) who were attending one of 
the participating HIV clinics during the time period of the study were asked to 
complete a questionnaire whilst waiting for their clinic appointments. Questions were 
semi-qualitative and the form was self-completed by the women, usually whilst 
waiting for clinic appointments (Appendix Bl). An information sheet was given to all 
women prior to the completion of questionnaires and women agreeing to participate in 
the survey were asked to sign an informed consent form (Appendix B2 and B3). The 
choice of taking the questionnaire home for completion was given and the 
questionnaire was available in French as well as English. After completion of the 
questionnaire a Boots voucher was given to the women as a thank you. For those 
women declining to complete the whole form, basic demographic details (age,
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residence, ethnicity, parity and reason for declining) were requested to inform 
assessment of potential bias.
During the development phase of the survey, comments on the questionnaire (in terms 
of topics covered and format) were received and incorporated from a variety of 
relevant researchers within ICH and CDSC. Prior to the study commencing, the 
questionnaire was piloted on 10 women at Great Ormond Street Hospital and 5 
women at the voluntary organisation Positively Women. During the pilot phase the 
appropriateness of the questions was assessed. In addition, issues of confidentiality 
were assessed prior to the study commencing. No personal identifying information 
was requested on the questionnaire. Whilst subjects were asked to complete a signed 
consent form prior to completion of the questionnaire, the consent forms were stored 
separately in a locked cabinet within clinic. With the exception of Manchester, the 
survey only took place during clinics specifically organised for HIV positive 
individuals. As Manchester did not have any exclusive HTV clinics, patients from that 
centre were asked to complete the questionnaire at home. All women were 
approached sensitively and were given the option of not participating in the survey or 
taking the questionnaire home for completion.
Ethics approval was obtained from the London Multi-Regional Ethics Committee 
(reference 03/2/023 April 2003) and the ethics committees of all institutions involved 
in the study, including Great Ormond Street Ethics Committee which was the main 
research institution of the study.
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3.2.2: Study sites
To ensure a representative sample of HTV-infected women were included in the 
survey, numbers of HIV-positive women currently receiving care by treatment centre 
and risk category was obtained using data from the Survey of Prevalent HIV 
Infections Diagnosed (described in section 3.7) and used to select the HIV clinics in 
Great Britain which participated in the survey. Clinics were selected in areas of 
relatively high prevalence of HIV infection amongst women, with a substantial 
number of HIV-positive women on their case load. After each clinic was personally 
invited to participate in the survey, meetings took place to establish logistics and local 
research teams.
Seven of the eight HIV specialist clinics contacted were included in the study: St 
Mary’s Hospital (London), Newham General Hospital (London), Chelsea & 
Westminster Hospital (London), Nottingham City Hospital, Leicester Royal 
Infirmary, North Manchester General Hospital and Western General Hospital 
(Edinburgh). In addition, women were also recruited from two voluntary 
organisations in London (London East AIDS Network (LEAN) and Positively 
Women) and the family clinic at Great Ormond Street Hospital. The eighth clinic 
contacted declined to participate as it was felt the patients had already recently taken 
part in other research projects. A list of collaborators is detailed in Appendix C.
3.2.3: Sample size and power calculations
It was anticipated that the selected clinics would see approximately 1000 women 
during the survey period (ranging from 40-350 per clinic). Recruitment of 400
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women (300 black African and 100 Rest) was considered to be within the survey 
resources and this was based on the recruitment of 100 women per London centre and 
25-50 women per outside London centre, and knowledge about their HIV risk. A 
similar type of questionnaire survey was carried out recently in London which had a 
65% acceptance rate (128), and we hoped to achieve at least that in this 
epidemiological study in order to reduce any participation bias.
The statistical power of the survey based on recruitment of 400 women was assessed 
prior to implementation. Power calculations were explored focussing on questions 27 
and 28 from the questionnaire, which were central to the research and assessed 
whether or not improvements in HIV management had changed women’s 
reproductive decisions. As there had been little previous research in this area the 
proportion of affirmative responses for each of our sub-groups of interest was based 
on a range of hypothetical values (0.5, 0.25, 0.15 and 0.05). It was found that a likely 
scenario would require differences between the proportions for Africans and Rest of 
6.8% and 15.6% to achieve a significant result with 80% power and 5% significance 
level for one-sided comparisons. The actual number of participants in this study was 
450 women.
3.2.4: Data collection
Data were collected between May 2003 and January 2004 (Table 3.1). The structured 
questionnaire focussed on demographic factors, HIV test history, pregnancy history 
and desire for more children. At the end of the questionnaire a comments section was 
included which requested further information on any additional factors which may 
have influenced pregnancy decision-making, including partner’s feelings, asylum
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status and financial situation. This information was entered onto the computer and 
analysed as free text.
Table 3.1: Recruitment period of clinics involved in the survey
Clinic Start date End date
Great Ormond Street Hospital (Pilot) May 2003 May 2003
Positively Women (Pilot) May 2003 May 2003
St Mary’s Hospital (London) July 2003 September 2003
Newham General Hospital (London) August 2003 October 2003
Chelsea & Westminster Hospital October 2003 January 2004
Leicester Royal Infirmary July 2003 October 2003
Nottingham City Hospital August 2003 January 2004
Western General Hospital (Edinburgh) October 2003 January 2004
North Manchester General Hospital November 2003 January 2004
London East AIDS Network (LEAN) September 2003 September 2003
3.3: Unlinked Anonymous HIV Prevalence Survey amongst Newborns
The prevalence of HIV infection among pregnant women in GB is monitored through 
three surveys within the unlinked anonymous (UA) programme, the dried blood spot 
survey, the antenatal clinic attenders survey and the termination of pregnancy survey 
(23). Only the first two of these surveys will be used for the purposes of this project as 
women in the termination of pregnancy survey were not expected to be representative 
of women in the general population. Overall HIV prevalence amongst pregnant 
women includes those with previously diagnosed infections, those diagnosed through 
antenatal screening and those remaining undiagnosed at delivery.
The Dried Blood Spot survey (DBS) tests residual neonatal dried blood spot samples 
from Guthrie cards used for the screening of infants for metabolic disorders (6). The
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blood sample, which is usually taken by a midwife during the neonates first week of 
life, is blotted and dried on a Guthrie card which includes demographic information 
about the mother and child. Since maternal antibodies cross the placenta, the 
neonate’s antibody status serves as a measure of maternal status with respect to HIV 
(129). The surveys began in 1988 and cover Scotland and the former Thames (which 
includes London), West Midlands, North Western, Mersey and Trent regions. In 2002 
over 450,000 dried blood spots were anonymously tested for HTV, representing 70% 
of all live births in GB that year (23).
Since a criterion of the UA programme is that patients must be informed that their 
samples may be used in the surveys though posters and leaflets, some women may 
object to their samples being used and these are then excluded from the surveys. 
Some residual samples (ie. What is left of the sample after it has been used for the 
purpose it was originally taken) may also be excluded if they are of insufficient 
volume for testing. Objection rates and numbers of insufficient samples are 
continuously monitored and are usually less than 1%. In addition to a sample not 
being available for UA testing, it has been estimated that 4% of infants may not have 
received routine neonatal screening and would therefore not be included in UA testing 
(63). Whilst non-screened infants were found more likely to be black African, it was 
not thought this would represent a bias to the DBS survey (62).
All regions participating in the DBS survey collect data by area of residence (provider 
code pre-1992). However, between 1997-2000 the survey was enhanced in 3 areas 
(former North Thames, South East Thames and North Western Regions) to include 
linkage of birth registration data and information from the child’s Guthrie card to
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dried blood spots prior to anonymisation (29,55). This enhancement enabled the 
collection of additional information for the mother, including country of birth and age. 
In 2002 approximately 40% of samples (and all samples in North and South East 
London) collected though the DBS survey were covered by this linkage facility.
The UA antenatal survey tests left over blood samples taken at antenatal clinics for 
rubella serology. Data on age group is collected but not details on country of birth. 
Antenatal surveys began in 1990 in three regions, Thames, Yorkshire and North 
Western. Surveys in the first two regions are on-going, but the one in North Western 
ended in 1992. As data from Thames is also included in the DBS survey, only the 
Yorkshire data has been included in this project. Results of HIV prevalence amongst 
women receiving antenatal care were assumed to be the same as that amongst women 
proceeding to live birth.
For areas not participating in the UA surveys, prevalence estimates amongst women 
with live births were obtained based on a regression of the proportion of seropositives 
against data on the number of diagnosed women in districts of residence participating 
in the UA surveys. The latter data were collected in the Survey of Prevalent HIV 
Infections Diagnosed (SOPHID) (130). The fitted regression equation is applied to 
SOPHID data to generate prevalence estimates in areas not covered by UA testing. 
Figure 3.2 shows geographical coverage of the DBS survey, enhanced DBS survey 
and the antenatal clinic attenders survey. The UA annual report provides further 
details about these surveys (23).
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Figure 3.2: Coverage of UA surveys which monitor HIV seroprevalence 
amongst pregnant women in GB
UA neonatal dried blood spot survey (with Country Of Birth information) 
UA neonatal dried blood spot survey (no Country Of Birth information) 
UA survey amongst antenatal clinic attenders 
No UA survey underway
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3.4:European Collaborative Study
The European Collaborative Study (ECS) is a prospective cohort study of children 
bom to HTV infected mothers in 26 centres throughout Europe (35). At participating 
centres, all pregnant women are screened for HIV infection and those found to be 
infected are invited to participate in the study. Information on mother’s date of birth, 
child’s date of birth, country of birth, HIV risk group (including injecting drug use 
and trimester of last use) and date of first HTV positive test was collected. In addition 
details on obstetric history were gathered, including information on number of 
previous live births, terminations of pregnancy, miscarriages and stillbirths. 
(Questionnaire shown in Appendix D).
3.4:National Study of HIV in Pregnancy and Childhood
Since 1989 pregnant women known to be infected with HTV, and infants bom to HIV 
infected women, have been notified to the National Study of HIV in Pregnancy and 
Childhood (NSHPC) through two confidential active reporting schemes (24). New 
cases of paediatric HTV, and infants bom to HIV infected women, are reported 
through the British Paediatric Surveillance Unit. Pregnant women with HTV are 
notified through a scheme run under the auspices of the Royal College of 
Obstetricians and Gynaecologists. Laboratory reports are also incorporated. Repeated 
contacts with reporting clinicians provide information on outcome of pregnancy and 
paediatric infection status, and there is annual follow up of infected children to 
monitor symptoms and treatment, progression to AIDS and death. Names of women 
and children are not sought or recorded, but reports are linked using date and place of 
birth.
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The obstetric scheme has had a response rate in excess of 95% since 1998 (131) and 
the paediatric scheme consistently reports a response rate in excess of 92% (132). It is 
not known how many women are diagnosed but not reported by the units who do not 
respond to the scheme, but multiple source ascertainment and repeated contact with 
respondents who fail to return their reporting cards is believed to keep this to a 
minimum. The effect of reporting delay has been monitored, and although there is 
considerable local variation in promptness of reporting, very few reports are made 
more than one year in arrears. The number of reported pregnancies diagnosed prior to 
delivery in 2002 is unlikely to increase substantially (Questionnaire shown in 
Appendix E).
3.6: Voluntary reports of newly diagnosed HIV infections
Voluntary confidential reports of new HIV diagnoses are received from laboratories 
and additionally since 2000, from clinicians (18). Date of birth, probable route of 
exposure, country of birth and parity are collected for all clinician reports. New AIDS 
diagnoses are reported by clinicians using the European AIDS case definition (133). 
Deaths occurring in HTV-infected individuals are reported by clinicians or ascertained 
through indirect matching with Office for National Statistics (ONS) death records. 
Since the beginning of 2000 information on previous live births have been included 
on the HIV infection reports in anticipation of this project.
3.7: Survey of Prevalent HTV infections diagnosed
The Survey of Prevalent HIV Infections Diagnosed (SOPHID) provides the number 
of individuals living with diagnosed HIV infection in E, W& NI. At the beginning of 
each year, all centres providing statutory health care for individuals with diagnosed 
HIV infection are asked to submit information on all those patients seen for care in
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the previous year (134). Information collected includes gender, area of residence, 
ethnic grouping, probable exposure, age, most advanced clinical stage of illness and 
level of antiretroviral therapy. The data reflect numbers of persons currently receiving 
HIV-related treatment, whereas the voluntary confidential HIV reports include all 
people diagnosed with infection and will include persons who have subsequently died 
or who have maybe left the country. Numbers of prevalent diagnosed HIV positive 
women receiving care in Scotland was obtained from CD4 surveillance, a measure of 
the number of women who had undergone immunological testing for their HIV 
infection in the previous year (135).
3.8: Census of England & Wales and Scotland
The census is a population survey legally required to be answered by everyone and is 
carried out every 10 years. It is the most complete source of information about the 
population that we have in GB. The last census was carried out in 2001 and includes 
information on age, residence, country of birth and ethnicity.
Data from the census has been made available by ONS (England and Wales) and 
General Register Office (GRO) (Scotland) in the form of excel spreadsheets and these 
tables have been used to estimate the numbers of persons bom in SSA and Rest of the 
world by current area of residence in GB. The definition for SSA was taken from the 
United Nations Classification of Countries by Development Region and Geographical 
area and consisted of Eastern Africa, Middle Africa, Southern Africa and Western 
Africa (136).
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3.9: Birth Statistics
Information is collected at civil registration of every birth (unpublished, ONS 
(England) and GRO (Scotland)) and information requested includes age of mother, 
date of child’s birth, area of residence and mother’s and father’s country of birth. An 
extract containing number of live births to women according to country of birth, age 
group and residence for 2002 was obtained from ONS and GRO.
3.10: National Survey of Sexual Attitudes and Lifestyles
The National Survey of Sexual Attitudes and Lifestyles (NATSAL) is a population 
survey carried out between 1999-2001 on a random sample of 4,762 men and 6,399 
women aged 16-44 years, resident in GB. The survey provides estimates of patterns of 
sexual behaviour at the turn of the millennium, based on computer-assisted 
interviewing methods. One of the principal aims of NATSAL was to improve our 
understanding of HIV & STI epidemiology and in informing the development of 
future public health strategies in the field of sexual health. Topics included personal 
background, family, sexual experience, attitudes and lifestyle. The response rate was 
63.1% (137). A stratified sample of addresses was selected, using a multistage 
probability cluster design with over-sampling in Greater London, where prevalence of 
risk factors was thought to be higher. The data were then weighted to adjust for the 
unequal probabilities of selection. In addition to the main study, a focussed study 
among Britain’s ethnic minorities was undertaken to enable reliable analyses across 
ethnic groups.
A reduced dataset from NATSAL, containing the variables relevant to this project, 
was obtained from the Centre for Infectious Disease Epidemiology at the Royal Free 
and University College Medical School. A proposal for the analyses for this thesis
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were reviewed by the NATSAL project team. The dataset was received as a STATA 
file and all analyses were performed using the complex survey functions of STATA.
3.11: Role of the Researcher
Over the last 8 years I have been involved in the Unlinked Anonymous HIV 
Prevalence Surveys amongst Pregnant Women, carried out at both CDSC and ICH. I 
was the survey co-ordinator of the UA DBS survey between 1996 and 2000 and 
during that time developed the surveys in order to collect more detailed demographic 
data, results of which have been extensively used throughout this thesis. Between 
2000 and 2004 I carried out the project presented in this thesis as part of an MRC 
training fellowship, whilst at the same time maintaining an advisory role on the UA 
programme. I conceived the idea and objectives of the project, together with my 
supervisors at ICH and CDSC.
I was the main investigator for the cross-sectional questionnaire survey to examine 
fertility-decisions amongst HIV-positive women (chapter 6). This involved 
development of the protocol and questionnaire, ethics approval, identification of 
collaborators, meetings with local investigators, survey co-ordination across all local 
sites, data collection in the London clinics, data management and data analysis. 
Results from this survey have been presented at the British HIV Association 
Conference April 2004.
The data analysed in chapters 4 and 5 were provided to me by epidemiologists at 
CDSC and ICH. I was given the responsibility for the analysis of the data, with the 
aim of clarifying the patterns of HIV risk and fertility amongst women in GB. The
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modelling work carried out in chapter 7 was developed and undertaken by myself. 
The direction and nature of the analyses were agreed in consultation with my 
supervisor, Professor Marie-Louise Newell, and co-supervisor Dr Mario Cortina- 
Boija.
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Table 3.2: Data sources used in the analyses
Data Source Information provided Coverage Objectives to which data contributed
Unlinked Anonymous (UA) neonatal 
dried blood spot survey
a) HIV prevalence amongst pregnant 
women proceeding to birth by residence,
age and country of birth
b) HIV prevalence amongst pregnant 
women proceeding to birth by residence
a) Former N Thames, SE Thames & 
North Western regions 
b) Former SW Thames, Eastern (part), 
Trent, Mersey, West Midlands & 
Scotland
Objective 1 & 5
Unlinked Anonymous (UA) antenatal 
clinic attenders survey
HIV prevalence amongst women 
receiving antenatal care by age & 
residence
Yorkshire Objective 1 & 5
Cross-sectional questionnaire survey to 
monitor impact of HIV diagnosis on 
fertility decisions
Demographic data, HIV test history, 
fertility history and fertility desire for 
HIV-infected women
7 clinics and 2 voluntary organisations in 
England and Scotland
Objective 3 & 4
Survey of Prevalent HIV Infections 
Diagnosed (SOPHID)
Numbers of HIV-infected women 
receiving care by residence
England, Wales and Northern Ireland Objective 2, & 5
Reports of newly diagnosed HIV 
infections
New reports of HIV-infected women by 
COB, age, parity, country of previous 
live births and year of previous live 
births
United Kingdom Objective 2 & 4
National Study of HIV in Pregnancy & 
Childhood
Reports of HTV-infected pregnant 
women by residence, COB, parity, age, 
IDU history and timing of diagnosis (pre, 
during or alter antenatal care)
United Kingdom & Eire Objective 1, 2,4 & 5
European Collaborative Study Reports of HIV-infected pregnant 
women by country of residence, COB, 
parity, age and IDU history
26 centres in Europe Objective 1, 2 & 4
NATSAL Ethnicity, COB, age, residence, marital 
status, fertility history
Great Britain Objective 2 & 4
Birth Statistics Numbers of live births by residence, age 
group and COB
United Kingdom Objective 1
Population Census Numbers of women resident in the UK 
by residence, age and COB
United Kingdom Objective 1 & 5
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Chapter 4: The importance of differential fertility between women at high and 
low risk of HIV infection on interpretation of neonatal seroprevalence data 
4.1: Introduction
Whilst seroprevalence data amongst pregnant women have been used to provide 
estimates of HTV-infected people in Britain (4-5), overall HIV prevalence in the 
general heterosexual population is unlikely to be similar to the unadjusted 
seroprevalence amongst pregnant women in areas with substantial adult populations 
from Africa (7). Women bom in Africa who are resident in GB experience higher 
fertility than women bom in the UK (8). These same women are also at increased risk 
of being HIV-infected (18). Injecting drug users are another sub-group of the 
population at increased risk of HIV infection but little is known about their fertility 
patterns. In the absence of published fertility data, previous estimates of persons in the 
general heterosexual population may have been biased upwards (4).
In order to derive more accurate estimates of HIV infection among the general 
population, this chapter explored the bias associated with differential fertility patterns 
in population sub-groups in GB at different risk of HIV and highlights the 
demographic factors which should be included in any adjustment model. The 
population was categorised into the three main groups of women at varying risk of 
HIV infection; women bom in Sub-Saharan Africa (SSA), injecting drug users (IDUs) 
and women without either of these factors (‘Rest’) (18). Firstly, HIV risk amongst our 
sub-groups of interest were derived using neonatal seroprevalence data. As fertility 
rates in our population sub-groups are not published, routinely available population 
and births data from the Office of National Statistics (ONS) (England and Wales) and
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General Register Office (GRO) (Scotland) and behavioural data from the National 
Study of Sexual Attitudes and Lifestyle (NATSAL) were analysed. Finally, as 
population and behavioural data on IDUs were limited, fertility information was 
supplemented with data gathered from a European prospective cohort of HIV-infected 
pregnant women (ECS). The number of drug using women participating in the ECS is 
high due to the inclusion of centres in Southern Europe, an area of the world with a 
relatively high prevalence of drug use. All data sources used in this analysis were 
described in detail in chapter 3.
4.2: Estimate of HIV risk amongst women
HIV prevalence for the sub-groups of women aged 16-44 years were estimated using 
neonatal seroprevalence data (50). Separate estimates were obtained for three 
geographical areas (London, Scotland and the Rest of GB) and four age groups (<20, 
20-24, 25-29 and >=30) to allow for differences in fertility and HIV risk between 
these categories.
Information on country of birth was collected in some areas (predominantly South 
East including most of London) where unlinked anonymous (UA) testing was taking 
place. However, as no information on injecting drug use was retained with the 
prevalence data, the distribution of HIV by population category was supplemented 
using reports of diagnosed HIV-infected pregnant women received through the 
National Study of HIV in Pregnancy and Childhood (NSHPC) with number of live 
births for that year (24).
For areas not participating in the UA surveys, estimates were obtained either using 
UA data amongst ANC (Yorkshire) or they were based on a regression of the
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proportion of seropositives against data on the number of diagnosed women in 
districts of residence participating in the UA surveys (as described in chapter 3). The 
latter data were collected in the Survey of Prevalent HIV Infections diagnosed 
(SOPHID). The fitted regression equation was then applied to SOPHID data to 
generate prevalence estimates in areas not covered by UA testing. A high correlation 
coefficient (measure of association between SOPHID and UA data), R=0.98, was 
found for the fitted regression.
UA surveillance indicated that in 2002 the overall neonatal prevalence of HIV 
infection was 0.38% in London, 0.058% in Scotland and 0.050% in the rest of GB 
(Table 4.1). HTV seroprevalence by Strategic Health Authority (England), Scotland 
and Wales in 2002 is shown in Figure 4.1. Within London, prevalence ranged from 34 
to 45 per 10,000 pregnant women. Outside London prevalence varied substantially 
from 1.8 in Yorkshire to 16.6 in Bedfordshire and Hertfordshire. In Wales and 
Scotland prevalence was 3.3 and 5.8 per 10,000 pregnant women respectively. These 
ranges in prevalence largely reflect the uneven distribution of African women resident 
throughout GB. Figure 4.1 also indicates whether or not a UA survey was being 
undertaken for each local area.
Women bom in SSA had the highest HIV prevalence in all areas of GB. The HIV 
prevalence ratio for women bom in SSA versus Rest was 37 (2.50% versus 0.068%) 
in London, 44 (1.98% versus 0.045%) in Scotland and 140 (2.25% versus 0.016%) in 
the rest of GB. HIV risk amongst drug users was substantially lower than women bom 
in SSA, although higher than amongst other women. For IDUs the prevalence ratio
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versus rest was 4 (0.29% versus 0.068%) in London, 10 (0.43% versus 0.045%) in 
Scotland and 27 (0.43% versus 0.016%) in the rest of GB (Table 4.1).
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Table 4.1: Estimates of the HIV risk, population size and numbers of live births 
by population sub group: 2002
London Scotland Rest (
HIV prevalence in pregnant women in 20021 0.38% 0.058% 0.050
(422/105,817) (30/51,288) (234/469
Prevalence in women bom SSA2 2.50% 1.98% 2.25®
(prev. ratio women bom in SSA vs rest)3 (37) (44) (140
Prevalence in Injecting drug users2 0.29% 0.43% 0.43®
(prevalence ratio IDU vs rest)3 (4) (10) (27)
Prevalence in Rest 0.068% 0.045% 0.016
Number of live births in 20024 103,135 52,527 485,4
% bom SSA 13.04% 0.52% 1.37®
% Rest (including IDUs) 86.96% 99.48% 98.63
Population size (females aged 16-44 years)5 1,737,820 1,062,239 8,778,1
% bom SSA 9.2% 0.6% 1.3®/
% IDU 0.5% 0.9% 0.3®/
% Rest
"i v . . __ , v  ..................... ,
90.3% 98.5% 98.4C
Data analysed from the unlinked anonymous neonatal seroprevalence survey 
2Using reports of HIV infected women made to the National Study of HIV in Pregnancy and Childhood 
it was estimated that in London 84% of infection was in women bora in SSA, 1% of infection was in 
IDUs and 15% of infection was in Rest. In Scotland 18% of infection was in women bom in SSA, 5% 
of infection was in IDUs and 77% of infection was in Rest. In rest of GB 64% of infection was in 
women bom in SSA, 4% of infection was in IDUs and 32% of infection was in Rest. These estimates 
combined with numbers of live births were used to derive category-specific prevalences for pregnant 
women. For example HIV prevalence in women bora in SSA and resident in Scotland was 
((30*0.18)/(52527*0.0052)* 100). An estimate of numbers of live births to IDUs were estimated using 
data from NATSAL previously analysed by Ades et al (138).
3 The ratio by which the prevalence of infection is greater than the prevalence in ‘Rest’ women
4 Unpublished data from birth registration records obtained from the ONS and GRO
5 Unpublished data from the 2001 census of population survey obtained from the ONS and GRO
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Figure 4.1: Neonatal HIV seroprevalence in 2002
Prevalence expressed 
Per 10,000 pregnant women
UA neonatal dried blood spot survey (with Country of Birth information)
UA neonatal dried blood spot survey (no Country Of Birth information)
UA survey am o n g st antenatal clinic attenders
No UA survey underway. P revalence estim ates derived using SOPHID data
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4.3: Estimate of live birth rates using routine data
4.3.1: Population size
The number of female IDUs in GB was derived using published estimates of drug 
prevalence (139). An age breakdown of the IDU population was estimated using 
reports of female drug users notified to the drug misuse database (140-141). An 
injecting drug user was defined as current or ever having injected drugs in the 
previous 5 years. Estimates of drug use within GB have limitations, for example 
under reporting (139).
The total number of women aged 16-44 resident in GB and bom in SSA was 
estimated from the 2001 Census of population. The number of women in the ‘Rest’ 
category was calculated by subtracting the estimated numbers of women bom in SSA 
and female injecting drug users from the total number of women aged 16-44.
The distribution of population sub-groups varied by geographic area (Table 4.1). The 
majority of the population were categorised as Rest, a low risk HIV category which 
includes women with a mixture of ethnicities and countries of birth outside SSA. A 
relatively high proportion within London were women bom in SSA (9.2%), although 
few women bom in SSA were resident outside London. The proportion of the female 
population who were a current or had a history in the past 5 years of injecting drug 
use was low and estimated to be less than 1% (0.5% in London, 0.9% in Scotland and
0.3% in rest of GB).
4.3.2: Live births
Numbers of Live births for women bom in SSA and ‘Rest’ in 2002 were estimated 
using birth registration records which include information on country of birth
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(unpublished data obtained from ONS (E&W) and GRO (Scotland)). Routinely 
available fertility information amongst IDUs was limited and was not estimated in this 
particular analysis. Live birth rates (number of live births divided by population size) 
were estimated and expressed as rates per 1000 women. Logistic regression analysis 
was used to obtain odds ratios (OR) and 95% Confidence Intervals (Cl) using ST AT A 
8.2 (142).
Live birth rates varied by country of birth, age group and area of residence. Women 
bom in SSA and resident in London had higher fertility rates than other women and 
the peak age group of fertility for all women was 25-29 years (Figure 4.2). The live 
birth rates for women bom in SSA and Rest were 73.7 and 55.1 per 1000 women 
respectively (Table 4.2). Adjusting for age and area, women bom in SSA were 1.3 
times more likely to have a live birth than Rest (OR 1.33, Cl (1.31,1.35), /K0.0001) 
(Table 4.2).
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Figure 4.2: Live birth rate1 by age: Great Britain
Live Birth rate: Women bom in SSA
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Live Birth Rate by age: Women not bom in SSA
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1 Live birth rate estimated using birth registration records and 2001 census of 
population data. Unpublished data obtained from ONS and GRO.
London 
Rest EW 
Scotland
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Table 4.2: Adjusted Odds Ratios for Live births in women in Great Britain using 
population data
Women bom in SSA Rest
Live Birth Rate (per 1000)1 73.7 55.1
Odds ratio (95% Cl) 1.36(1.34-1.38) p<0.0001 1.00
Adjusted2 Odds ratio
1 T • _____________J  •
1.33 (1.31-1.35) p<0.0001 1.00
Live birth rate estimated using birth registration records and 2001 census of 
population data. Unpublished data obtained from ONS and GRO.
2 adjusted for age group of mother and area of residence
Live birth rates according to specific country of origin in SSA were also analysed for 
the main sub-groups of African women resident in GB (Table 4.3). This analysis was 
restricted to data collected in 2 former Thames regions where country of birth 
information is retained with neonatal samples. Women bom in Nigeria, GB’s largest 
group of African women, had a higher live birth rate (87.6 per 1000) and a lower HIV 
risk (0.71%) than other women bom in Africa. In contrast women bom in Kenya, a 
country from where lots of migration to GB took place in the past, had a live birth rate 
of 32.0 per 1000 women and an HTV prevalence of 1.69%. The majority of recent 
migration into GB has been from Zimbabwe. This analysis found than Zimbabwean 
women resident in GB had both a high live birth rate (77.8 per 1000) and a high HIV 
risk (10.26%) compared to other women originating from Africa.
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Table 4.3: HIV Prevalence and Live Births amongst women in Thames1 by 
Country of birth within Africa in 2002
HIV Prevalence (%)2 
(No. Positive/No. 
Tested)
Population size3 Live birth rate (per 
1000)4
Nigeria 0.71 (13/1839) 25,287 87.6
Kenya 1.69 (13/771) 24,494 32.0
South Africa 1.32 (9/684) 17,078 49.8
Zimbabwe 10.26 (47/458) 7211 77.8
Other 2.38(151/6336) 83,093 119.8
Total 2.31 (233/10088) 157,163 91.4
2 Estimates derived from unlinked anonymous testing of pregnant women
3 Estimates derived from 2001 census of population data (unpublished data)
4 Live birth rate estimated using birth registration records and 2001 census of 
population data. Unpublished data obtained from ONS and GRO.
In summary, women bom in SSA experienced both higher live birth rates and HIV 
risk than the rest of the population, and HIV prevalence and fertility varied 
substantially depending on which country of Africa the woman had been bom in. The 
following numerical example shows the effect of differential fertility amongst 
Africans on HIV prevalence estimates using data presented in Table 4.1. Within 
London, an area with substantial adult populations from Africa, application of a dried 
blood spot prevalence (0.38%) to a population unadjusted for country of birth 
(1,737,820) would overestimate the total number of infections amongst women by 
approximately 30% (6600 unadjusted compared with 5100). Outside London numbers
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of infections would be overestimated by approximately 10% (4400 unadjusted 
compared with 4050 adjusted). This analysis highlights the importance of ongoing 
monitoring of differential fertility and HIV patterns amongst women bom in SSA 
when interpreting neonatal seroprevalence data as changes in these patterns will be 
reflected in trends of HIV prevalence.
4.4: Fertility in women who first tested HIV-positive during pregnancy
As we were unable to obtain reliable estimates of numbers of live births to IDUs, 
results from the previous analysis were supplemented with fertility information 
(previous live births, terminations, miscarriages and stillbirths) collected as part of a 
European cohort study of diagnosed HIV-infected pregnant women which includes 4 
centres in GB (35). This supplementary analysis was restricted to fertility prior to HIV 
diagnosis as knowledge of HIV status may influence future fertility decisions. 
Fertility amongst IDUs was analysed separately for current and past injectors and this 
was based on the assumption that patterns may vary amongst the two groups of drug 
users. A current injecting drug user was defined as having injected dmgs during 
pregnancy and/or evidence of drug withdrawal symptoms in the neonate. A past IDU 
was defined as having injected drugs prior to, but not during, pregnancy. Univariate 
and multivariate logistic regression was used to obtain ORs and 95% Cl, using 
STATA version 8.2(142).
By May 2004 4541 HIV-infected women had enrolled in the ECS. The number of 
patients recruited from each country ranged from 20 in Denmark to 1363 in Italy. One 
hundred and fifteen women were enrolled from GB, the majority of which were from 
Edinburgh. Analyses were restricted to previous live births in 1698 women who had 
been pregnant before the time of their first HIV test. Twenty three percent (393/1698)
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were bom in SSA, 18% (314/1698) of the women were current IDUs, 20% 
(341/1698) were past IDUs and 33% (560/1698) were women in the Rest category. In 
90 (5%) cases there was insufficient demographic information to assign a risk 
category. Women in Spain, Poland and Italy were more likely to have a history of 
drug use than women in the other countries. Few (5) women bom in SSA had a 
history of drug use.
A woman’s fertility was associated with the population subgroup she belonged to; 
53% (203/383) of women bom in SSA had had at least 1 previous live birth compared 
to 37% (108/292) for current IDUs, 28% (90/320) for past IDUs and 35% (187/537) 
for Rest (Table 4.4). Adjusting for age at HTV diagnosis, women bom in SSA were 
1.99 (Cl (1.51-2.63),/K0.001) times more likely to have had a previous live birth than 
women categorised as Rest. Current IDUs also had a higher likelihood of having had 
a previous livebirth, although this was not significant (OR 1.15, 0(0.85-1.55), 
/ f=0.38). Past IDUs were less likely to have had a previous live birth (OR 0.69, 
CI(0.51 -0.95), p=0.02).
Current and past IDUs were more likely to have had a termination than women 
categorised as rest (OR 1.48 and 1.51 respectively). Women bom in SSA were also 
more likely to have had a previous termination, although this was not statistically 
significant (Table 4.4). Previous studies have also observed black women were more 
likely to have had an abortion than other women (143-144). No differences between 
the sub-groups of women were found in the likelihood of having a previous 
miscarriage or stillbirth (data not shown).
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The biases associated with differential fertility in IDUs in relation to the interpretation 
of neonatal seroprevalence data have not been considered prior to this analysis. 
Results showed that IDUs were less likely to have had a previous live birth than other 
women, and more likely to have had a previous termination. Previously published 
literature in this area, though limited, is consistent with these results (68,145-146). 
Whilst uncertainty remains in the fertility of IDUs in GB, these analyses highlight that 
drug users constitute a relatively small proportion of the British population and their 
HTV risk in women who become pregnant is low. Any biases associated with this 
group in estimating population prevalence will therefore be limited. Based on results 
from these analyses, IDUs will not be included in the final adjustment model as a 
separate sub-group of women.
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Table 4.4: Pregnancies in women who first tested HIV positive during pregnancy (ECS)1
SS Africa (n=393) Current IDU (n=314) Past IDU (n=341) Rest (n=560)
Numbers of previous live births
0 180 (47%) 184 (63%) 230 (72%) 350 (65%)
1 or more 203 (53%) 108 (37%) 90 (28%) 187 (35%)
Not Known3 10 22 21 23
Odds Ratio (95% Cl) 2.11 (1.61-2.76)/?<0.001 1.09 (0.82-1.48)/?=0.53 0.73 (0.54-0.99/?=0.004 1.00
Adjusted2 Odds Ratio (95% Cl) 1.99 (1.51 -2.63)/?<0.001 1.15 (0.85-1.55)p=0.38 0.69 (0.51-1.95)/t=0.02 1.00
Numbers of previous Terminations
0 271 (73%) 199 (69%) 215 (68%) 402 (76%)
1 or more 102 (27%) 91 (31%) 101 (32%) 124 (24%)
Not Known3 20 24 25 34
Odds Ratio (95% Cl) 1.22 (0.90-1.65)p=0.19 1.48 (1.07-2.04)p=0.02 1.52 (1.12-2.08)/?=0.01 1.00
Adjusted2 Odds Ratio (95% Cl)
”1" r V  ___• O. J •
1.20 (0.89-1.63)/>=0.23 1.48 (1.08-2.05)/?=0.02 1.51 (1.10-2.06)p=0.01 1.00
1 The European Collaborative Study includes 20 centres from 10 countries in Western Europe, including GB
2 adjusted for age group of mother at time of HIV diagnosis
3 Cases not known were not included in the analysis
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4.5: Fertility in women participating in a behavioural study in GB
The National Study of Sexual Attitudes and Lifestyle (NATSAL) is a population 
survey carried out to provide an insight into behavioural patterns in GB. In addition to 
the main study, a focussed study among Britain’s ethnic minorities was undertaken to 
enable reliable analyses across ethnic groups. Data from NATSAL are commonly 
presented as weighted values to adjust for the unequal probability of selection (137). 
Firstly, the demographic characteristics of African women compared to other women 
was assessed using descriptive statistics. Finally, the likelihood of having had a 
previous livebirth and the factors associated with this were analysed using a logistic 
regression analysis.
Table 4.5 shows the demographic composition of the women participating in 
NATSAL. As expected, since NATSAL is a random sample, most women (86.7%) 
lived outside of London. Most of the women in the study were white (91.7%), 2.9% 
were south Asian, 1.1% were black African and 2.0% were black Caribbean. The 
equivalent figures in the 2001 census were 91.9% white, 3.6% south Asian, 0.8% 
black African, 0.9% black Caribbean and 2.8% Other. Differences reflect the ethnic 
boosting of the NATSAL sample. The greatest proportion (62.9%) of women were 
either married or co-habiting and only 7.6% were divorced, separated or widowed 
(Table 4.5). Compared to other women, black Africans were more likely to live in 
London, be older and be more likely to be divorced/separated or widowed than other 
women (data not shown).
Among women in NATSAL, 28.6% (1986 of 6942) had had a birth in the last 5 years. 
The proportion of women with a live birth was highest in black African women
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(45.0%), among women aged 25-34 years (41.0%) and amongst women who were 
married (39.9%) (Table 4.6). Among women who had a child, 54.5% were married, 
compared to 16.0% among women without a child (Data not shown). Compared to 
other women, African women were less likely to have no children (30.8% compared 
to 40.3%), more likely to have 3+ children (32.3% compared to 16.3%), more likely 
to have had a miscarriage (31.7% compared to 20.7%) and more likely to have had a 
termination of pregnancy (38.5% compared to 16.6%) (data not shown).
Logistic regression confirmed that fertility was significantly associated with age, 
ethnicity and marital status after adjusting for age, ethnicity, marital status and 
residence (Table 4.6). Black African women were over twice as likely to have had a 
livebirth in the past 5 years than other women (OR 2.85, 95% Cl 2.14-3.80, /K0.001), 
confirming our previous analyses in this chapter. South Asian women had 
significantly higher fertility than White women, although this was not significant after 
adjustment for age, partnership status and residence. Women who were single were 
nearly 5 times less likely to have had a livebirth in the previous 5 years than married 
women (OR 0.18, 95% Cl 0.15-0.21,/K0.001).
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Table 4.5: Demographic profile of women in NATSAL*
Demographics Total (%)
Residence London 13.3%
Rest GB 86.7%
Age group 16-24 25.7%
25-34 37.6%
35-44 36.8%
Partnership status Married 44.6%
Div/sep. 7.3%
Widowed 0.3%
Single 29.5%
Co-habiting 18.3%
Ethnicity White 91.7%
S. Asian 2.9%
Black African 1.1%
Black Caribbean 2.0%
Other 2.4%
Weighted, unweighted base 5785, 6942
* Analysis of NATSAL restricted to women aged 16-44 years. All percentages are of 
column weighted base.
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Table 4.6: Odds ratio of having had a live birth in the previous 5 years (NATSAL)
Total
(n)
Birth last 5 
years 
N (% of n)
Crude OR P value Adjusted OR P
value
Total 6942 1986
(Unweighted)* (28.6%)
Ethnicity
White 5697 1537(26.9%) 1.0 1.0
Black African 271 122 (45.0%) 2.22(1.73-2.85) <0.001 2.85(2.14-3.80) <0.001
Black Caribbean 354 110(31.1%) 1.22(0.97-1.54) 0.094 2.10(1.62-2.72) <0.001
South Asian 410 149 (36.3%) 1.55(1.26-1.91) <0.001 1.26(0.99-1.58) 0.051
Other 186 65 (34.9%) 1.46(1.07-1.98) 0.017 1.45(1.03-2.04) 0.033
Residence
London 5112 1438(28.1%) 1.0 1.0
Outside London 1830 548 (29.9%) 1.09(0.97-1.23) 0.140 0.96(0.83-1.10) 0.539
Age group
16-24 1567 334 (21.3%) 1.0 1.0
25-34 2748 1127 (41.0%) 2.57(2.23-2.96) <0.001 1.30(1.10-1.53) 0.002
35-44 2627 525 (19.9%) 0.92(0.79-1.08) 0.302 0.35(0.28-0.42) <0.001
Partnership
Married 2721 1087 (39.9%) 1.0 1.0
Co-habiting 1038 332 (31.9%) 0.71(0.61-0.82) <0.001 0.52(0.44-0.61) <0.001
Div./Sep./Wid. 783 184 (23.5%) 0.46(0.38-0.55) <0.001 0.43(0.36-0.52) <0.001
Single 2383 380(15.9%) 0.29(0.25-0.33) <0.001 0.18(0.15-0.21) <0.001
*Data presented as unweighted values in order to maximise sample size
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4.6: Key points
1. This analysis has quantified the fertility differentials in the main population 
sub-groups at varying risk of HIV infection in GB using a number of different 
data sources. It has identified data sources available for inclusion in an 
adjustment model to improve the interpretation of neonatal data for differential 
patterns of HIV and fertility amongst women in GB.
2. Women bom in SSA experienced both higher live birth rates (73.7 versus 55.1 
per 1000) and HTV risk (2.5% versus 0.38%) than the rest of the population 
and HIV prevalence and fertility varied substantially depending on which 
country within Africa the woman had been bom in, area of residence within 
GB and age group. These results suggest that without adjusting for country of 
birth, previous estimates of HIV in the general heterosexual population may 
have been biased upwards.
3. The biases associated with differential fertility in IDUs have not previously 
been considered. Results showed that IDUs were less likely to have had a 
previous live birth than other women (OR 0.69) and more likely to have had a 
previous termination (OR 1.51), a finding consistent with previously published 
literature. This analysis highlighted that drug users constitute a relatively small 
proportion of the British population (<1%) and their HIV risk in women who 
become pregnant is low (0.29% in London). Any biases associated with this 
group in estimating general population prevalence will therefore be limited.
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4. Within Britain the size of population sub-groups bom abroad and HIV risk of 
different groups is a changing dynamic. The ongoing monitoring of fertility 
and HTV risk amongst women bom abroad will be important and if any 
changes occur, the adjustment model will need to be adapted accordingly.
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Chapter 5: Characteristics of diagnosed HIV infected women in GB: Review of
routine datasets
5.1: Introduction
This chapter presents analyses undertaken to assess current fertility patterns in 
diagnosed HTV-infected women. As presented in more detail in the methods chapter, 
the data sources for this chapter are numbers of prevalent HIV infections received 
through the Survey Of Prevalent HIV Infections Diagnosed (SOPHID), reports of 
newly diagnosed HIV infections and reports of HIV-infected pregnant women 
received through the National Study of HTV in Pregnancy and Childhood (NSHPC). 
Where appropriate the outcomes of these analyses were included in the final
adjustment model in chapter 7 to improve the interpretation of neonatal
seroprevalence data. With the exception of SOPHID which only collects information 
on ethnic origin, analyses have been stratified according to whether or not the woman 
was bom in SSA to ensure results are consistent for use with the neonatal
seroprevalence data. Within the UK the majority of HIV-positive women were bom in 
SSA, with few non-Africans bom in SSA (2%) and few HTV-positive black Africans 
(6%) bom outside SSA (unpublished data, CDSC).
5.2: Profile of HIV-infected women receiving care
The demographic profile of HIV-infected women currently receiving care in England, 
Wales and Northern Ireland (E,W & NI) was analysed using SOPHID data relating to 
women currently accessing health care in order to provide an insight in fertility 
patterns one may expect from such a group of women (130). A requested set of 
aggregate tables was obtained from CDSC and the age, risk group and clinical stage 
of illness was explored using 2002 data, as well as changes in characteristics of
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prevalent diagnosed infections since 1997. Rates of diagnosed HTV infection among 
women aged 15-54 years were estimated based on population data for England and 
Wales from 2001 census information (Unpublished data, census 2001). The census 
has previously been described in chapter 3. An analysis of under-reporting and non- 
attendance of SOPHID data to provide a more accurate assessment of caseload has 
been undertaken, and is estimated to be 13.5% (134,147). SOPHID data were 
therefore adjusted by this factor when used in the final model in chapter 7.
In 2002 30,281 individuals, including children, were seen for care in E, W & NI, of 
whom 30% (8967) were women (Table 5.1). Between 1997 and 2002 the number of 
women with HTV increased 3.2 fold (2776 to 8967) whilst over the same period the 
number of men with HIV increased 1.9 fold (11,460 to 21,314). Explanations for this 
rise in prevalence amongst women include improvements in diagnosing new 
infections during routine antenatal screening, reduction in HIV-related deaths due to 
advancements in antiretroviral therapies and the movement of HIV-infected people 
from countries with a high HTV prevalence to the UK.
Two thirds (64%) of women were aged between 25-39 years, the peak age group for 
fertility, although the proportion of women aged 40 and over has risen over time from 
16% (429/2776) in 1997 to 23% (2038/8967) in 2002. The rate of diagnosed HIV 
infection among women aged 15-54 years in 2002 was 6.3 per 10,000 and this varied 
according to ethnic group; 374.2 per 10,000 for black Africans, 15.6 per 10,000 for 
black Caribbean’s, 1.3 per 10,000 for Whites and 1.6 per 10,000 for south Asians 
(Indian, Pakistani and Bangladeshi) (Table 5.1). Since 1997 there has been more than 
a 4.4 rise in the number of women of black African (1416 to 6205) and a 3 .8 fold rise
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in women of black Caribbean (79 to 297) ethnicity seen for HIV-related care. During 
the same time period there was a 2.3 fold increase and 1.7 fold increase in the number 
of women of south Asian and White ethnic group respectively. The rise in number of 
HIV-positive African women is attributed to recent immigration from countries of 
high HIV prevalence to the UK. The increased HIV prevalence amongst black 
Caribbean’s is also unsurprising given that HTV is well established in the Caribbean, 
continuing inward migration to GB is occurring from that area, and a high incidence 
of bacterial STIs among Britain’s black Caribbean community has been reported 
(148,149).
Whilst the majority of adult women with diagnosed HTV infection were resident in 
London (59%), the proportion of diagnosed women resident outside London has 
increased from 31% in 1997 to 41% in 2002 (Table 5.1). This is partly explained by 
the dispersal of new migrants, including asylum seekers, to different parts of the 
country. The prevalence of diagnosed HTV infection amongst women in London was 
23.5 per 10,000 population aged 15-54 years, and in 2002 76% of those HIV-infected 
women resident in London were of black African ethnicity. Outside of London the 
prevalence of HTV diagnosed amongst adult women per 10,000 population was 2.9, 
and 62% of these were of black African ethnicity. The majority of women probably 
acquired their infection through heterosexual contact (88%), whilst few cases were 
attributed to injecting drug use (3%) or mother to child transmission (6%) (Table 5.1).
It has been suggested that improvements in HTV-related therapies have made many 
women feel better, which may in turn positively influence reproductive decision­
making, the topic of interest in this thesis. Clinical stage of illness was reported for
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8640 women in 2002, of whom 45% were asymptomatic. Thirty one percent had 
HTV-related symptoms but not AIDS and 22% had an AIDS diagnosis. For women for 
whom therapy was reported in 2002 (95%), 63% were on therapy of whom 96% were 
on triple or more drugs (Table 5.1). In contrast in 1997, 39% of women were 
asymptomatic, 55% were on some sort of therapy, and of those on therapy 61% were 
taking 3 or more drugs (Table 5.1). No differences were observed in the clinical stage 
of illness and level of therapy between African and Non-African women.
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Table 5.1: Characteristics of diagnosed prevalent HIV infections amongst 
women and % change between 1997 and 2002: England, Wales and 
Northern Ireland
1997 2002 % Proportion 
of all cases 
(2002)
Rate per 
10,000 
population*
Fold change 
between 
1997-2002
No. of women 2776 8967 - 6.3 3.2
Age Group
0-14 161 475 5% 0.9 3.0
15-24 177 713 8% 2.3 4.0
25-39 2009 5735 64% 9.8 2.9
40-54 370 1800 20% 3.4 4.9
55+ 59 238 3% - 4.0
Not Known 0 6 - - -
Ethnicity
Black African 1416 6205 69% 374.2 4.4
Black Caribbean 79 297 3% 15.6 3.8
White 959 1663 19% 1.3 1.7
South Asian 44 103 1% 1.6 2.3
Other/NK 278 699 8% - -
Area of residence
London 1864 5175 59% 23.5 2.8
Rest EW&NI 850 3605 41% 2.9 4.2
Other/Abroad 8 12 <1% - 1.5
Not Known 54 175 - - -
Exposure
Heterosexual 2214 7920 88% 3.6
Injecting drug use 292 292 3% - -
Mother to Child 158 496 6% - 3.1
Other/NK 112 259 3% - -
Stage of illness
Asymptomatic 1034 3883 45% 3.8
Symptoms pre-AIDS 896 2666 31% - 3.0
AIDS 635 1902 22% - 3.0
Other 114 189 2% - 1.7
Not Known 97 327 - - -
HIV Therapy
None 910 3161 37% 3.5
1-2 drugs 436 207 2% - 0.5
3+ drugs 682 5143 61% - 7.5
Not Known 748 456 - - -
*Per 15-54 women.
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5.3: Newly diagnosed HIV infections amongst women
Another source of information on women with diagnosed HIV is available from 
infection reports (18-19). This analysis focused on age, reason for HIV test and 
number of previous live births in women newly diagnosed with HTV infection in GB, 
with results providing a useful input in the modelling of reproductive decisions. 
Reports of newly diagnosed infections were analysed using a dataset obtained from 
CDSC which contained the variables of interest for this project (Age, reason for test, 
ethnic group, country of birth, year of arrival in UK, probable route of exposure, date 
of positive test, previous live births and whether or not the woman had been pregnant 
at diagnosis). Fertility information has been included on the new HIV infection 
reports since 2000 on my request for this project and justification for this was 
submitted and approved by the project review team at CDSC in August 1999.
Data on parity, age, pregnancy at diagnosis and reason for HIV test were abstracted 
and analysed from 2,163 HTV reports received between January 2000 to August 2002. 
From these reports, information on previous live births was available on 1,646 (76%) 
records and whether or not the woman had been pregnant at diagnosis was available 
for 1,902 (88%) of records. Whilst little difference was observed in the proportion of 
missing information on previous live births for women bom in SSA versus other 
women (23% versus 27%), women older than 45 were significantly more likely to 
have missing information than younger women (32% versus 23%). It is uncertain 
whether or not this would lead to an overestimate or underestimate in the number of 
previous live births in older women, however it is not likely to bias the final 
adjustment model as women older than 45 at diagnosis are assumed to no longer be of 
childbearing age and their parity information is not therefore included in the model.
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The final analysis of this section looks at parity amongst all HIV-infected women 
compared with more general women surveyed through NATSAL, a survey carried out 
on a random sample of the population.
5.3.1: Ape at diagnosis
Nearly 70% of the newly diagnosed HIV-infected women were aged 25-39 years 
(Table 5.2), the peak years o f fertility. The mean age at diagnosis of women bom in 
SSA and Rest was 31 (range 15-74) and 32 (range 16-78) years respectively. Routine 
statistics for England & Wales show that in the general population on average women 
of this age group (30-34) have a live birth rate of 94.9 births per 1000 women and this 
rate is similar to that seen in women aged 25-29 years (8). Few women (2.2%) were 
under 20 years and 8.9% were aged over 45 years (Table 5.2). The proportion of 
women aged 45 and above has not changed since the early 1990’s (21). Women bom 
in SSA were less likely to be under 20 or over 45 than other women.
Table 5.2: Age of newly diagnosed HIV-infected women
Number of reports (%)
SSA Rest Total
15-20 24 (1.4%) 22 (5.8%) 46 (2.2%)
20-24 168 (9.9%) 60 (15.8%) 228 (11.0%)
25-29 417 (24.7%) 90 (23.7%) 507 (24.5%)
30-34 511 (30.2%) 71 (18.7%) 582 (28.1%)
35-39 298 (17.6%) 51 (13.5%) 349 (16.9%)
40-44 139 (8.2%) 33 (8.7%) 172 (8.3%)
45+ 133 (7.9%) 52 (13.7%) 185 (8.9%)
Total 1690 (100%) 379 (100%) 2069 (100%)
5.3.2: Parity at diagnosis
Thirty nine percent of women bom in SSA and 29% of women bom elsewhere had 
had at least two live births at the time of their HIV diagnosis. The mean number of 
births was 1.4 for women bom in SSA compared to 1.1 for other women. Figure 5.1
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shows numbers of live births by age category. Few women aged less than 24 years old 
had had more than 1 child and the majority had had none. Approximately a third of 
women bom in SSA and half of women bom elsewhere who were aged 45 or under 
had had less than 2 children. Assuming that the average desired number of children 
for women bom in SSA is 2.51 and other women is 2.1 (150), many of these women 
have yet to complete their family size at time of diagnosis.
Figure 5.1: Parity by age group and risk for newly diagnosed women
Women bom in SSA Women born elsewhere
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A comparison of age and parity amongst newly diagnosed HIV-infected women and 
all women (HIV status unknown) surveyed through NATSAL, stratified by whether 
or not the woman was bom in SSA, suggested that birth rates before HTV diagnosis in 
this data set were comparable with birth rates in a more general population in 
NATSAL.
Over 80% of newly diagnosed women were bom outside the UK, and approximately 
70% of these women had arrived in the UK less than 2 years before diagnosis. This is 
of interest in the interpretation of neonatal seroprevalence data as previous livebirths 
in these women would have occurred abroad and not within the UK, thereby lessening
122
the likelihood of these women appearing in UK neonatal seroprevalence surveys. We 
therefore explored country of all previous live births in newly diagnosed women to 
determine the likelihood of births in undiagnosed HIV-infected women being sampled 
in UK neonatal surveys. Of the 926/1337 women bom in Africa who had had a 
previous live birth recorded on the report form, 92% of the live births were outside the 
UK.
5.3.3: Reason for HIV test
Reason for HTV test was analysed for all newly diagnosed women between 2000 to 
2002 in order to gain an understanding of why infections become diagnosed and the 
impact routine antenatal screening has had on trends of new diagnoses (n=2,014). The 
highest proportion of newly reported women were diagnosed due to symptoms 
(36.4%), 20.4% of women were diagnosed through antenatal screening, 12.7% due to 
identification of HTV in a partner and 6.8% were confirmation in the UK of a previous 
positive test (Table 5.3). In addition to the 410 women diagnosed during antenatal 
care, an extra 73 women were pregnant at diagnosis, although the reason for the HTV 
test was HIV-related symptoms or identification of HTV in their partner. Women 
presenting with HIV-related symptoms were more likely to be bom outside the UK 
than other women. Women having a confirmation of a known positive sample were 
most likely confirming a previous HIV diagnosis they had had outside the UK.
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Table 5.3: Reason for HIV test for newly diagnosed women
Reason for HIV test n (%) % born 
outside 
UK
% of those born 
outside UK who 
arrived within 2 
years of diagnosis
Symptoms 733 (36.4%) 91.2% 68.7%
Known +ve partner 236 (11.7%) 82.9% 65.8%
Risky behaviour 146 (7.2%) 86.0% 73.6%
Antenatal 410 (20.4%) 89.6% 65.1%
Confirmation of known 136 (6.8%) 93.2% 86.7%
+ve
Other* 71 (3.5%) 78.3% 67.5%
Not Known 282 (14.0%) - -
Total 2,014 (100%) 86.2% 69.2%
♦includes women diagnosed through blood donation and insurance/visa screening
5.4: National Study of HIV In Pregnancy and Childhood
Characteristics of diagnosed HIV-infected pregnant women in the UK were explored 
using data form the National Study of HIV in Pregnancy and Childhood (NSHPC) 
(25). Briefly, all pregnant women known to be identified with HIV are notified 
through the NSHPC through a confidential reporting scheme run under the auspices of 
the Royal College of Obstetrics and Gynaecologists. Further details about this 
surveillance scheme are provided in chapter 3. A reduced dataset was obtained from 
the ICH containing information on demographic characteristics, year of positive test, 
parity, whether or not the HTV infection had been diagnosed during or before 
pregnancy and outcome of pregnancy. To help understand reproductive-decision 
making at the time of diagnosis, logistic regression analyses were performed to 
compare factors associated with being diagnosed during pregnancy and factors related 
to terminating a pregnancy after being diagnosed during antenatal care. Finally, 
subsequent child-bearing patterns after an HIV diagnosis were explored, in particular 
whether or not HIV-infected women were now more likely to want to become 
pregnant because of improvements in HIV management.
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5.4.1: Characteristics of all reported HIV-positive pregnant women 
By April 2004, 4,434 pregnancies had been reported to the NSHPC since obstetric 
surveillance began in 1986. Many women have had more than one pregnancy reported 
and the 4,434 pregnancies were in 3,626 women. The number of diagnosed pregnant 
women reported has increased substantially, from 86 in 1992 to 890 in 2003, a time 
when the general birth rate has remained stable (8). This rise was particularly apparent 
from 1999 onwards, when routine antenatal HTV testing was widely implemented 
throughout the UK (51).
Maternal characteristics are shown in Table 5.4. Eighty seven percent of women were 
bom outside the UK, the majority of which were bom in SSA. The proportion of 
women with a history of injecting drug use was 11% overall although this has 
declined significantly over the course of study, from 21% in 1990 to less than 1% in 
2003 (chi-squared test for trend 55.2, /K0.001). HIV-infected women were shown to 
be having their children at an increasingly older age; average maternal age at time of 
HTV diagnosis increased from 21 years in 1984 to 28 years in 2004.
Table 5.4: Maternal characteristics for women reported through the NSHPC
system (N=3626)
Maternal factor it %
Residence (#i=3499) London 2060 59%
Elsewhere 1439 41%
Area of birth (#1=2983) SSA 2316 78%
UK 394 13%
Rest 273 9%
History of H)U (#1=3344) Yes 377 11%
No 2967 89%
Parity («=2,512) 0 976 39%
1 879 35%
2 402 16%
3+ 255 10%
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Information on previous live births was available for 69% (2512/3626) of the women, 
although since 1994 birth information has been missing from only 15% of reports and 
missing information was not associated with whether or not the woman had been bom 
in SSA and age of the mother.
Thirty nine percent of women had had no previous children, 35% had had 1 previous 
child, 16% had had 2 previous children and 10% had had 3 or more. Women with a 
history of injecting drug use and women bom in SSA were more likely to have had a 
previous live birth than other women (OR 1.79, 95% Cl 1.11-2.86, 0.016 and OR
1.39, 95% Cl 1.14-1.69, p=0.001 respectively).
5.4.2: Timing of HIV diagnosis amongst HIV-positive pregnant women
Approximately half of the women (49%, 2188/4434) reported through the NSHPC 
were diagnosed during the current pregnancy, increasing from 31% (26/83) in 1990, 
to 42% (112/265) in 1999 to 58% (514/890) in 2003 (Figure 5.2). Two thousand one 
hundred and sixty (49%) of the women were aware of their HTV diagnosis prior to 
their pregnancy, of these a proportion (18%, 391) had been diagnosed previously in 
antenatal care and were going on to have a further birth. Increasing numbers of HIV- 
positive women know they are infected at the time they become pregnant, rising from 
55 (66% of all infections) in 1990 to 145 (55%) in 1999 to 368 (41%) in 2002. A few 
women (2%) have been reported as having been diagnosed after the birth of their 
child, often because their child was unwell and was diagnosed as having HIV-related 
illnesses within the first 3 months of life.
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Figure 5.2: Timing of maternal HIV diagnosis for women reported through 
the NSHPC* (V=4434)
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*The numbers for recent years are likely to increase when late obstetric reports are 
incorporated and an increasing proportion of previously undiagnosed infected women 
have been diagnosed during pregnancy.
Table 5.5 shows the unadjusted and adjusted odds ratios for women diagnosed during 
pregnancy as compared to women who were aware of their infection outside of 
pregnancy for selected maternal characteristics. Women with a history of injecting 
drug use were significantly less likely to have been diagnosed during pregnancy than 
other women (and thus more likely to have been picked up before), and this remained 
significant after adjustment for residence, age and country of birth (AOR 0.44, 95% 
Cl 0.32-0.63,/K0.001). In contrast women bom in SSA were 1.6 times more likely to 
have been diagnosed during pregnancy than other women (AOR 1.62, 95% Cl 1.32- 
1.99, /K0.001). Other factors significantly related to having had a diagnosis during 
pregnancy were residence outside London and older age (Table 5.5).
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Table 5.5: OR and Adjusted OR of women diagnosed during 
pregnancy by demographic characteristics.
Total
(n)
Diag. 
during 
Preg 
N (%)
OR P value AOR P value
Residence London 2659 1517(57%) 1.00 1.00
RestEW 1372 877 (64%) 1.30 0.002 1.38 0.001
Scotland 403 188 (47%) 0.50 <0.001 1.33 0.129
Injecting No 3887 2365(61%) 1.00 1.00
Drug use Yes 547 217(40%) 0.39 <0.001 0.44 <0.001
Country of Rest 1545 747(48%) 1.00 1.00
birth SSA 2889 1835(64%) 1.56 <0.001 1.62 <0.001
Age <20 137 106(77%) 1.00 1.00
category 20-24 717 481(67%) 1.01 0.944 0.85 0.339
25-29 1502 900(59%) 1.49 0.012 1.11 0.522
30-34 1259 685(54%) 1.99 <0.001 1.44 0.042
1 A
35+ 649 311(48%) 2.61 <0.001 1.99 0.002
Adjusted odds ratio allows for the effects of IDU, country of birth, age and residence.
5.4.3: Outcome of pregnancy in newly diagnosed HIV- positive women 
The management of pregnancy in HIV-positive women has varied over time, 
reflecting available scientific knowledge. Some HIV-infected women opt for 
voluntary termination of pregnancy (TOP) and others choose to carry their pregnancy 
to term. Decision making is likely to be influenced by what is known about the effects 
of HTV on the woman and the risk of transmission to the child. This analysis looked at 
risk factors associated with pregnancy outcomes in newly diagnosed women to assess 
reproductive-decision making at time of diagnosis. Outcomes were compared prior to 
1994 and 1994 onwards, as the first evidence of a sign of reduction in risk of MTCT 
with Zidovudine became available in early 1994. Whilst data are requested for the 
outcome of all pregnancies reported through the NSHPC, it is likely that notification 
of pregnancies not ending in a live birth is only partial but there is no reason to 
suggest changes over time. Odds ratios for factors related to TOP were calculated
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separately for each period with 95% confidence intervals. Confounding factors were 
analysed by logistic regression for each period.
Of the total of 2,188 women newly diagnosed during antenatal care, 1,733 (79%) 
proceeded to a livebirth, 128 (6%) terminated the pregnancy, 60 (3%) had a 
spontaneous abortion, 18 (1%) had another outcome and in 80 (3%) cases the 
outcome was unknown. In addition a further 169 (8%) pregnancies were continuing to 
term. Outcome of pregnancy has changed over time. The proportion of pregnancies 
ending in a termination decreased from 42% in 1984-1990 to 3.5% from 2000 
onwards (Figure 5.3).
Figure 5.3: Outcome of pregnancy in women newly diagnosed during 
Pregnancy
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After adjustment, age at diagnosis, country of birth (SSA versus Rest) and injecting 
drug use was not significantly associated with the decision to interrupt or continue the 
pregnancy during either period (Table 5.6). The following variables were significantly
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associated with pregnancy outcome: residence outside London since 1994 and having 
1 or more child since 1994. Women resident outside London were twice as likely to 
have a TOP than women resident in London (AOR 2.02, 95% Cl 1.11-3.67, p=0.02). 
This difference was not apparent pre-1994 when interventions to reduce MTCT were 
less available. Previous pregnancy was associated with the decision of TOP since 
1994, with a higher probability of TOP among multiparas (AOR 2.27, 95% Cl 1.07- 
4.79,/f=0.03) (Table 5.6).
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Table 5.6: OR and 95% Cl for risk factors of TOP before and after 1994 in women newly diagnosed as HIV positive during antenatal 
care (n=2163*)________________________ ______ _____________ _________________ ___________________________________ _
Total
(“ )
No. with TOP 
(N)
Pre-1994
OR AOR P
value
Total
...(!nL
1994 onwards 
No. with TOP OR AOR
(N)........... .
Total 263 57 1900 67
Likely Risk of
HIV(«=2163)
Rest 37 2 1.0 1.0 364 15 1.0 1.0
IDU 124 29 3.43 3.98 (0.77-20.73) 0.10 26 1 1.40 1.78 (0.20-15.85
Bom in SSA 105 10 1.73 1.19(0.21-6.60) 0.84 1507 51 1.00 1.28 (0.57-2.84;
Residence («=1999)
London 105 21 1.0 1.0 1155 33 1.0 1.0
Rest EW 73 9 1.55 1.36 (0.49-3.76) 0.56 548 30 1.86 2.02 (1.11-3.67;
Scotland 85 27 1.92 1.21 (0.46-3.15) 0.79 33 2 2.05 1.18(0.13-10.57
Age at diagnosis
(w=2128)
<20 42 7 1.0 1.0 94 3 1.0 1.0
20-24 126 19 0.94 1.38(0.48-3.93) 0.55 358 12 1.06 0.54(0.13-2.15;
25-29 94 17 1.23 2.14(0.69-6.59) 0.18 667 17 0.85 0.48 (0.13-1.84;
30+ 60 3 1.63 2.19(0.65-7.39) 0.21 687 26 0.87 0.48(0.12-1.92;
Previous live birth
(«=1662)
No A 673 13 1.0 1.0
Yes A 989 41 2.13 2.27(1.07-4.79;
A Data on parity pre-1994 not completed sufficiently enough to include in analysis
*2163 of the 2188 women who were newly diagnosed as HIV positive during antenatal care had sufficient information on year of diagnosis to be 
included in the analysis
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5.4.4: Likelihood of subsequent live births in HIV- infected women 
To inform the debate on whether diagnosed HIV-infected women are now more likely 
to want to become pregnant than before because of the substantial reductions in 
vertical transmission and the improved quality of life associated with HAART, 
subsequent childbearing of HIV-positive women reported through the NSHPC was 
analysed. All women reported through the NSHPC have had at least one pregnancy 
(index pregnancy). These women were categorised into 2 groups: Group 1 consisted 
of women who did not yet go on to have a subsequent live birth after their index 
pregnancy. Group 2 consisted of women who had one or more live births after their 
index pregnancy.
Firstly the characteristics of women with at least one subsequent live birth were 
compared with those without in a multivariate logistic regression analysis. Kaplan- 
Meier estimates of the time to subsequent live birth were obtained to find the 
cumulative proportion of women having a subsequent live birth according to the time 
period of their diagnosis (pre-1994 and 1994 onwards), and a log rank test was used to 
test the statistical significance of this analysis.
Sufficient data to determine subsequent live births was available for 3477/3626 (96%) 
of women reported through the NSHPC, of which 1292 (37%) have had a subsequent 
pregnancy. The main characteristics of these women are shown in Table 5.7. Women 
who were more likely to have a subsequent live birth in univariate analyses were more 
likely to have a history of injecting drug use, live in London or Scotland, be younger 
at diagnosis or to have already had 2 children. Women bom in SSA were less likely to 
have had a subsequent live birth than other women. Years since diagnosis was
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associated with having a subsequent live birth, although only 11% of women who had 
had a subsequent live birth had been diagnosed in the previous 3 years. In multivariate 
analyses all these factors remained significantly associated with subsequent 
pregnancy. Women bom in SSA remained less likely to have a pregnancy than other 
women (OR 0.73, 95%CI 0.57-0.93,/K0.044).
Information on subsequent live birth and timing to live birth was available for 2,875 
women. A Kaplan-Meier analysis showed a significant decrease in time to subsequent 
live birth over time (chi square 124.87, /K0.001), suggesting the number of women 
who have subsequent live births is increasing over the years (Figure 5.4). Women 
diagnosed from 1994 onwards had a significantly shorter time to livebirth than 
women diagnosed before 1994, with 38% having a subsequent livebirth within 5 years 
of the index delivery, compared to 23% for women diagnosed pre-1994.
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Table 5.7: OR and 95% Cl for risk factors related to having had a subsequent live birth in women aware of their HTV infection
Total
(n=3477)
Subsequent
pregnancy
(n=1292)
OR P
value
AOR P value
Residence
(n-3189) London 2055 811 (39%) 1.00 1.00
RestEW 877 253 (29%) 0.62 (0.52-0.74) <0.001 0.52 (0.41-0.66) <0.001
Scotland 257 129 (50%) 1.54(1.19-2.00) 0.001 1.78(1.01-3.14) 0.045
Injecting drug use
(n=3370) No 2993 1038 (35%) 1.00 1.00
Yes 377 209 (55%) 1.65 (1.28-2.14) <0.001 2.22(1.17-4.25) 0.001
Country of birth
(n=3477) Rest 1172 515 (44%) 1.00 1.00
SSA 2305 777 (34%) 0.68 (0.57-0.81) <0.001 0.73 (0.57-0.93) 0.044
Age at diagnosis
(n=3045) <20 225 104 (46%) 1.00 1.00
20-24 800 359 (45%) 0.95 (0.70-1.27) 0.72 0.85 (0.55-1.33) 0.25
25-29 1062 386 (36%) 0.66 (0.49-0.88) 0.006 0.63 (0.41-0.98) 0.036
30-34 687 211(31%) 0.51 (0.38-0.69) <0.001 0.42 (0.26-0.66) 0.004
35+ 271 57 (21%) 0.32 (0.21-0.48) <0.001 0.22 (0.13-0.39) <0.001
Parity
(n=2602) 0 881 253 (29%) 1.00 1.00
1 947 391 (41%) 1.75 (1.44-2.12) <0.001 2.16(1.71-2.75) <0.001
2 432 198 (46%) 2.10(1.65-2.67) <0.001 2.48 (1.84-3.35) <0.001
3+ 342 125 (37%) 0.62 (0.07-5.57) 0.03 0.48 (0.83-1.35) 0.89
Yrs since diagnosis
(n=3477) <3 876 140 (16%) 1.00 1.00
3-5 1084 326 (30%) 2.26(1.81-2.82) <0.001 4.02 (2.90-5.59) <0.001
5-10 574 364 (63%) 9.11 (7.11-11.68) <0.001 17.70(12.40-25.19) <0.001
10+ 943 462 (49%) 5.05 (4.04-6.30) <0.001 53.11 (30.64-92.77) <0.001
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5.5: Key points
1. The number o f women with diagnosed HIV infection accessing health care has 
increased over 3-fold in the last 5 years. The majority of these women were 
black African, within child-bearing age, and without AIDS-related symptoms.
2. Newly diagnosed HTV reports indicate many infected women would not 
appear in neonatal surveys, either because they were not of childbearing age or 
they had already had their children at time of diagnosis; 9% of infections were 
amongst women aged >=45 years and 39% of women bom in SSA and 29% of 
other women had already had 2 or more live births by the time of diagnosis 
and unlikely to have more. Over 90% of live births to women bom abroad had 
been outside the UK and would not have been picked up in the British 
neonatal seroprevalence surveys.
3. Whilst the number o f newly diagnosed HIV infections amongst women aged 
>=*45 years has remained steady over time, the proportion of diagnosed 
prevalent HTV infections amongst older women has risen due to longer 
survival of HIV-infected patients.
4. Increasing numbers of HIV-positive women proceeding to live birth have been 
reported, from 86 in 1992 to 890 in 2003. Over half (58%) of women reported 
in 2003 had been diagnosed during the current pregnancy.
5. The proportion of pregnancies amongst women newly diagnosed during 
antenatal care ending in a termination has declined from 42% in 1984-1990 to 
3.5% from 2000 onwards. Decision to terminate a pregnancy was related to 
residence in E&W outside London (AOR 2.02) and having 1 or more child 
(AOR 2.27).
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6. Women resident in E&W outside London, older women and women bom in 
SSA were less likely to have a pregnancy subsequent to their HIV diagnosis 
than other women.
7. The proportion of HIV-positive women with subsequent live births after their 
diagnosis has been increasing over the years.
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Chapter 6: The impact of an HIV diagnosis on fertility: Main findings from a
cross-sectional survey
‘7 certainty want more children. The problem is having the confidence of having a 
baby and then going through the tests after the birth. The waiting is traumatic. It is
hard enough I am positive ”
(African mother with 2 HIV negative children)
6.1: Introduction
This chapter describes results from a questionnaire survey carried out amongst 
diagnosed HTV- positive women to assess whether improvements in treatments which 
delay HTV disease progression and the increasing availability of effective 
interventions to reduce mother to child transmission (MTCT) are associated with 
changes in reproductive decision-making amongst women. Results from this survey 
are then used in chapter 7 to interpret whether changes in decision-making have been 
reflected in increases in neonatal HTV seroprevalence.
The chapter is divided into 2 sections. The first section summarises the demographic 
characteristics, clinical condition, pregnancy history and desire for children in women 
recruited into the questionnaire survey. As the study population consisted of a high 
proportion of black African women and fertility is strongly associated with ethnic 
grouping, the demographic profile of African women was compared to other women. 
The second section assesses the representativeness of HIV-positive women surveyed 
compared with all women receiving HIV-related care in E&W as gathered by 
SOPHID. In addition, a comparison is made of the pregnancy history in women 
recruited into the survey with all women in the general population surveyed through 
NATSAL. Finally the limitations of the questionnaire survey are discussed.
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Section 6A: Main findings from questionnaire survey
6A.1: Introduction
The methodology of the survey was described in detail in chapter 3. In summary, the 
study involved HTV positive women aged 16-49 years receiving care in centres in GB 
selected according to their caseload of HIV-positive women. Women self-completed a 
questionnaire which requested details about their demographic and clinical 
characteristics and their fertility history. This section begins with detailing study 
objectives and describing data preparation and analyses. The study population 
characteristics are then presented followed by results from the main analyses of this 
survey. Additional results from analyses are presented in appendix F.
6A.2: Study Objectives
The study had three main objectives:
• To identify factors associated with desire for children.
• To investigate whether improvements in treatments which delay HTV disease 
progression and interventions which reduce vertical transmission have altered 
women’s desire for children.
• To subsequently apply the results from this survey to evaluate whether HTV- 
positive women desire and expect fewer children than the general British 
population and eventually to inform the interpretation of trends in HIV 
prevalence in GB using neonatal samples.
6A. 2.1: Data Preparation
Responses were entered onto the computer into an Access database. The distribution 
of each variable was checked by one-way frequency tables for categorical variables
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and by histograms and the calculation of summary measures (means, standard 
deviations, medians and ranges) for quantitative variables. Consistency checks were 
performed by searching for inconsistent information between variables.
6A.2.2: Variables and outcome measures
All the variables examined in section A were collected as part of the questionnaire 
survey. Variables were divided into four main groups (demographic, HIV history, 
pregnancy history and desire for children).
Five different outcomes were measured
• Desire for (more) children
• Impact of an HIV diagnosis on fertility desire
• Association of fertility desire and improvements in treatments to delay HTV 
disease progression
• Association of fertility desire and improvements in interventions to reduce 
MTCT transmission
• A pregnancy subsequent to HTV diagnosis
6A. 2.3: Data analysis
Univariate analysis was performed to determine factors associated with fertility. 
Variables found to be significantly associated with fertility (P<0.05) were included in 
a multivariate logistic regression analysis to determine factors independently 
associated with childbearing. All analyses were carried out using the ST AT A 
computer program (142).
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6A.3: Population studied
The study population consisted of 450 HIV-positive women (Table 6.1) which 
represented 39% (450 of 1160) of all women receiving HIV-related care at the 
participating centres during 2002. In total 20 of the 450 women participating in the 
survey had taken a questionnaire home for completion. In addition an extra 26 women 
took a questionnaire home but failed to return it. Overall, 86% (range 63-100%) of 
women invited to participate in the survey completed a questionnaire.
Table 6.1: Recruitment of HIV-positive women
Clinic No. of 
women 
attending 
clinic*
No. of 
women 
invited to 
participate
No. of 
questionnaires 
completed
%
response
St. Mary’s 342 117 101 86%
Newham 172 116 90 78%
Chelsea & West. 277 95 79 83%
Leicester 58 51 51 100%
Manchester 68 30 19 63%
Nottingham 42 30 28 93%
Edinburgh 201 48 47 98%
Other - 35 35 100%
Total 1160 521 450 86%
^according to SOPHID or clinic-based 2002 data
Of the 72 women who were invited to participate in the survey but did not complete a 
questionnaire, limited data were available on 28 (39%). These women were similar to 
all women in terms of age and parity and the most common reason for not completing 
a questionnaire was lack of interest. Of the remaining 44 women, 26 had taken the full 
questionnaire home for completion but had failed to return it and 18 declined interest 
in the project.
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6A.4: Population characteristics
The demographic and main clinical details of the 450 HIV-positive women taking part 
in the survey are shown in Table 6.2. The majority of women were African (324/450 
(72%)) and 79% of all participants were bom outside the UK. Sixty three percent 
were resident in London, 27% in the Rest of England and 10% in Scotland. Compared 
to other women, African women were over 3 times more likely to live in London, 
reflecting the demographic patterns of settlement throughout GB (Table 6.3). The 
median age was 35 years (range 20-49) at the time of the questionnaire and the 
median time since diagnosis was 3 years (range 0-19). African women were older at 
diagnosis (p=0.004) and more likely to have had a recent diagnosis (/K0.001) than 
other women (Table 6.3). Most of the women not bom in the UK came from 
Zimbabwe and Uganda (Figure 6.1). Many of the women (56%) bom outside the UK 
had arrived in the country within the last 5 years, reflecting recent migration patterns 
between the UK and countries with high HIV prevalence.
Figure 6.1: Predominant countries of birth for women born outside UK
Ethiopia
Somalia
Ghana 
Malawi 
Kenya 
Congo 
South Africa 
Zambia 
Uganda 
Zimbabwe
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Table 6.2: Summary of demographic and main clinical details. Number (%)
Demographic
Factor
N (%)
Ethnicity (n=450) African 324 (72%)
Non-African 126 (28%)
Born in UK (n=450) Yes 95 (21%)
No 355 (79%)
Residence (n=450) London 284 (63%)
Rest of England 120 (27%)
Scotland 46 (10%)
Age (n=430) <=29 88 (20%)
>29 342 (80%)
Years in UK (n=310)1 <=5 years 175 (56%)
>5 years 135 (44%)
In a Partnership (n=450) Yes 233 (52%)
No 217 (48%)
Ever injected drugs (n=445) Yes 35 (8%)
No 410 (92%)
HIV status of partner2 (n=233) Positive 108 (46%)
Negative 88 (38%)
NK/Not tested 37 (16%)
Current HIV symptoms (n=433) None 234 (54%)
Mild/moderate 173 (40%)
Severe 26 (6%)
CD4 count (n=345) <350 194 (56%)
>=350 151 (44%)
Current HIV therapy (n=445) Yes 304 (68%)
No 141 (32%)
Ever pregnant (n=450) Yes 377 (84%)
No 73 (16%)
Pregnant at HIV diagnosis (n=450) Yes 130 (29%)
No 320 (71%)
Number of children (n=450) 0 124 (28%)
1 130 (29%)
2+ 196 (43%)
Previous Miscarriage/TOP (n=450) Yes 181 (40%)
No 269 (60%)
Trying for a pregnancy >6 months3 (n=336) Yes 73 (22%)
I t- __________________.  ;  . . TTTT .
No 263 (78%)
For women bom outside the UK. Year of arrival was not known for 45 women bom outside the UK 
2 For women who had a partner 3 Only women who had wanted to become pregnant included
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Overall few women had a history of injecting drug use (8%), and those that had were 
mainly resident in Scotland, the area of GB which experienced the most severe HIV 
epidemic amongst IDUs in the 1980’s and early 1990’s (20). Drug users were more 
likely to be older, of White ethnicity and to have been diagnosed with HIV infection 
longer than other women.
Just over half (52%) of women were in a partnership (Table 6.2): Thirty-six percent of 
women described themselves as either married or co-habiting, 16% had non­
cohabiting partners, 27% were single and 21% were widowed, separated or divorced. 
Widowhood was most likely to be associated with their HTV infection. Of those 
women with a partner, 46% had a positive partner (“Concordant partnership”), 38% 
had a negative partner (“Discordant partnership”) and 16% didn’t know, often 
because the partner had not been tested. African women were more likely to be single 
(30% versus 21%) or widowed (10% versus 6%) than other women. Of women in a 
partnership, African women were also twice as likely to have a positive partner and 
more likely to not know their partner’s status than other women (Table 6.3).
Most of the women were in relatively good health. Approximately half of the 
participants had no HIV-related symptoms (54%) and few (6%) had severe symptoms. 
Of the 77% of women who knew their current CD4 cell count, 56% had counts <350 
cell/ml (Table 6.2 and Figure 6.2). Two thirds of the women were taking anti­
retroviral therapy, in the majority (162, 53%) of cases 3 drugs. Disease progression 
and HIV symptoms were not related to ethnicity.
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Table 6.3: Comparison of demographic profile of African women and other 
women
Factor1 Total
<«)
African 
N (% of n)
OR 95% Cl P
value
Residence (n=450)
Non-London
London
166
284
91 (54.8%) 
233 (82.0%)
1.00
3.76 2.44-5.79 <0.001
Born in UK (n=450)
No
Yes
355
95
310(87.3%) 
14 (14.7%)
1.00
0.03 0.01-0.05 <0.001
In a partnership (n=450)
No
Yes
217
233
166 (76.5%) 
158 (67.8%)
1.00
0.65 0.43-0.98 0.041
Age at diagnosis (n=450)
<=29
>29
211
239
138 (65.4%) 
186 (77.8%)
1.00
1.85 1.22-2.82 0.004
Years since diagnosis (n=433)
<=5 years 
>5 years
286
147
230 (80.4%) 
81 (55.1%)
1.00
0.30 0.19-0.46 <0.001
History of injecting drug use (n=445)
No
Yes
410
35
313 (76.3%) 
6(17.1%)
1.00
0.06 0.03-0.16 <0.001
Partner HIV status (if in partnership) 
(n=196)2
Negative
Positive
88
108
49 (55.7%) 
79 (73.1%)
1.00
2.17 1.19-3.94 0.011
No. of children pre-diagnosis (n=450)
0
1
124
130
81 (65.3%) 
94 (72.3%)
1.00
1.39 0.81-2.36 0.230
2 114 83 (72.8%) 1.42 0.82-2.47 0.214
3+ 82 66 (80.5%) 2.19 1.13-4.23 0.020
Ever had a miscarriage /TOP (n=450)
No
Yes
269
181
205 (76.2%) 
119(65.7%)
1.00
0.60 0.40-0.91 0.016
Trying for a preg. >6 months (n=336)
No
Yes
~ 1  ^  •  1 . 1 ________________________  •  - 1-
263
73
178 (67.7%) 
59 (80.8%)
1.00
2.01 1.06-3.81 0.032
symptoms, CD4 count, current HIV therapy, Age at first child and pregnant at HIV 
diagnosis
2 Partner’s HIV status NK/Not Tested in 37 cases
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Figure 6.2: CD4 count and therapy for women in the study
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The majority of the survey population had been pregnant (84%), while another 25 
women (6%) were pregnant at the time of completion of the questionnaire. Many 
women (29%) were pregnant at the time of their HIV diagnosis, mostly as a result of 
the routine antenatal HIV screening programme in the UK. The mean age at first birth 
was 25.3 years for African women and 24.3 for non-African women. This data will 
be compared to all women regardless of HIV status in the next section.
The number of children a woman expects to have in her life time is associated with 
her ethnicity, and in general African women desire a mean number of 2.5 children 
whilst White women desire a mean number of 2.1 children (150). In this study 28% of 
women had no children, 29% had 1 child and the remaining 43% of women had 2 or 
more children (Table 6.2). As you would anticipate based on population statistics, 
African women were twice as likely to have 3 or more children than other women 
(Table 6.3). The number of children a woman had was also strongly associated with 
age and of those women aged over 40, 58% had had 2 or more children, the number
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of children one would expect for this age group, whilst 20% had no children (Figure 
6.3). Therefore whilst this cohort of women had already had many pregnancies, the 
number of children you would expect has not so far been achieved.
Figure 6.3: Number of children by age group
100
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□ 0 
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□ 2+
20
10
40+30-34 35-39<30
Age category
Forty percent of women had had either a previous miscarriage or TOP. Whilst data 
were collected separately for miscarriage and termination, interpretation was 
problematic as the terms used in the questionnaire were often misunderstood by the 
study participants and spontaneous terminations were often confused with elected 
terminations. Twenty two percent (73/336) of women stated they had been trying for a 
pregnancy for more than 6 months; 46 (63%) of these women had sought medical 
help for fertility and 64 (88%) had a previous pregnancy recorded on the 
questionnaire. In univariate analyses, women who had been trying for a pregnancy for 
more than 6 months were more likely to be African (Table 6.3) and more likely to 
have been diagnosed with HIV for more than 5 years. No association with age was 
observed.
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6A.5: Desire for (more) children and association of improvements in treatments 
and interventions
One of the main objectives of this study was to describe pregnancy decisions among 
HIV-positive women in light of improvements in HIV management.
Fifty-one percent (229/450) of participants stated they wanted (more) children, 36% 
(161/450) did not want (more) children and 13% (60/450) of women did not know 
(Table 6.4). Our finding that 51% of women desired children translates into over 
4,000 positive women in GB.
In 45% (201/450) of cases the HIV diagnosis had reportedly not affected decision­
making; 16% (72/450) had already had all the children they wanted to have, 3% 
(12/450) never wanted children anyway and 26% (117/450) intended to carry out their 
child-bearing plans regardless of their HTV infection. Of the 72 women who stated 
they had already had their children at diagnosis, 84% had had 2 or more children at 
that time. Overall 42% of women stated that their HIV diagnosis had affected their 
decisions; 11% (50/450) wanted children sooner whereas 31% (139/450) did not want 
children anymore (Table 6.4).
Factors found to be significantly associated with desire for (more) children in a 
multivariate analysis were partnership status, number of children the woman had 
already had at diagnosis and whether or not the woman had been trying for a 
pregnancy for more than 6 months (Table 6.5a). Women who had a partner were 
nearly twice as likely to desire children than other women whilst women who already 
had 2 or more children at diagnosis were 0.28 times as likely to desire more children.
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A history of miscarriage or abortion was associated with desire for children in a 
univariate analysis (OR 1.55, 95% Cl 1.06-2.28, /t=0.024), but this did not remain 
significant in the multivariate model. Whilst African women were more likely to 
desire children than other women, this difference was also found not to be significant 
(AOR 1.39, 95% Cl 0.77-2.49,p=0.27).
Logistic regression was also carried out to assess factors related to not wanting a child 
after diagnosis (155 women). Women aged older than 29 years at diagnosis and 
women who already had had 2 or more children were less likely to not want children 
whilst women who had been diagnosed for more than 5 years were more likely to not 
want children in univariate analyses (OR 0.53, 95% Cl 0.35-0.81, /?=0.003 and OR 
0.46, 95% Cl 0.30-0.71, /K0.001 and OR 1.74, 95% Cl 1.11-2.74, p= 0.016 
respectively), although these associations did not remain significant in the 
multivariate model (Table 6.5b). African women were both more likely to desire 
children and to not want children after their HIV diagnosis than other women, 
although this was not significant in multivariate analyses. Whilst this finding may 
appear contradictory, African women were shown to be more likely to change their 
mind about desire for children since improvements in HIV management.
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Table 6.4: Association of knowledge of an HIV diagnosis and improvements in treatments which delay HIV disease and 
interventions which reduce perinatal transmission on desire for children
Response African
women
Other women Total
Women who want 164 (51%) 65 (52%) 229 (51%)
children
HIV diagnosis had no effect 91 (28%) 26 (21%) 117(26%)
Wanted children sooner 32 (10%) 18 (14%) 50 (11%)
Didn't want children when diagnosed, although 
improvements in HIV management have made me 
desire children
41 (13%) 21 (17%) 62 (14%)
Women who do not 122 (38%) 39 (31%) 161 (36%)
want children
Never wanted children anyway 6(2%) 6(5%) 12 (3%)
Already had had children at time of diagnosis 55(17%) 17 (13%) 72 (16%)
Didn't want children when diagnosed and 
improvements in HIV management have not made me 
desire children
61 (19%) 16 (13%) 77 (17%)
NK/Other 38(11%) 22 (17%) 60 (13%)
Total 324 (100%) 126 (100%) 450 (100%)
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Table 6.5a: Adjusted Odds of desiring (more) children after receiving an HIV 
diagnosis
Total
(n)
Desire 
children 
N (% of n)
AOR 95% Cl P value
Ethnicity
Non-African 126 45(36%) 1.0
African 324 140(43%) 1.39 0.77-2.49 0.27
Residence
Non-London 166 65(39%) 1.0
London 284 120(42%) 0.65 0.35-1.19 0.16
Years in UK
<=5 yrs 175 75(43%) 1.0
>5 yrs 135 63(47%) 1.41 0.77-2.59 0.27
Partnership
No 217 71(33%) 1.0
Yes 233 114(49%) 1.97 1.16-3.34 0.013
Age at diagnosis
<=29 years 211 91(43%) 1.0
>29 years 239 94(39%) 1.04 0.58-1.88 0.89
Years since diagnosis
<=5 years 286 124(43%) 1.0
>5 years 147 55(37%) 0.71 0.35-1.44 0.34
History of IDU
No 410 169(41%) 1.0
Yes 35 13(37%) 1.67 0.36-7.76 0.51
HIV-related therapy
No 141 69(49%) 1.0
Yes 304 115(38%) 0.88 0.50-1.55 0.66
No. of children at diagnosis
<2 254 127(50%) 1.0
>=2 196 58(30%) 0.28 0.15-0.51 <0.001
Ever misc/abortion
No 269 99(37%) 1.0
Yes 181 86(48%) 1.10 0.65-1.88 0.72
Trying for a preg >6 mo.
No 263 92(35%) 1.0
Yes 73 53(73%) 3.46 1.68-7.13 <0.001
Factors not found to be significant with childbearing in univariate analyses and were 
therefore not included in multivariate analyses were: partner’s HIV status, whether the 
woman had been pregnant at diagnosis, current HIV symptoms, CD4 count and 
whether or not the woman had had a previous HIV positive child.
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Table 6.5b: Adjusted Odds of not wanting a child after receiving an HIV
diagnosis*
Total
(n)
Not want a 
child 
N (% of n)
AOR 95% Cl P value
Ethnicity
Non-African 90 41(46%) 1.0
African 266 114(43%) 2.01 0.78-5.13 0.15
Residence
Non-London 123 57(46%) 1.0
London 233 98(42%) 0.83 0.40-1.74 0.63
Years in UK
<=5 yrs 182 85(47%) 1.0
>5 yrs 138 57(41%) 1.29 0.64-2.60 0.48
Partnership
No 178 82(46%) 1.0
Yes 178 73(41%) 0.83 0.44-1.56 0.56
Age at diagnosis
<=29 years 157 82(52%) 1.0
>29 years 199 73(41%) 0.93 0.47-1.85 0.84
Years since diagnosis
<=5 years 224 88(39%) 1.0
>5 years 117 62(53%) 1.75 0.76-3.99 0.19
History of IDU
No 329 140(43%) 1.0
Yes 23 13(57%) 1.73 0.26-11.77 0.57
HIV-related therapy
No 102 48(47%) 1.0
Yes 249 105(42%) 0.65 0.33-1.29 0.22
No. of children at diagnosis
<2 187 98(52%) 1.0
>=2 169 57(34%) 1.46 0.70-3.01 0.31
Ever misc/abortion
No 213 88(41%) 1.0
Yes 143 67(47%) 1.11 0.59-2.09 0.75
Trying for a preg >6 mo.
No 302 133(44%) 1.0
Yes 54 22(41%) 0.61 0.27-1.36 0.23
* Comparison of women who did not want a child after diagnosis with women who 
said HIV had had no effect on their childbearing intentions
Factors not found to be significant with childbearing in univariate analyses and were 
therefore not included in multivariate analyses were: partner’s HIV status, whether the 
woman had been pregnant at diagnosis, current HTV symptoms, CD4 count and 
whether or not the woman had had a previous HIV positive child.
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The majority of women in the study were aware of the availability of treatments 
which delay disease progression and interventions which reduce MTCT after they had 
had their HIV diagnosis (95% and 91% respectively). Women who were unaware of 
interventions which reduce MTCT transmission were more likely to be older and to 
have already completed their family than other women.
The impact of improvements in treatments and interventions was analysed for the 
women who stated that an HIV diagnosis made them not want children any more, 
excluding women who stated they did not know whether they now desired children. 
Changes in decision-making in response to improvements in treatments and 
interventions to reduce MTCT was highly correlated and has therefore been presented 
together in Table 6.4. Forty-five percent (62/139) of women changed their minds after 
improvements in treatments or interventions (Table 6.4). The overall proportion of 
women changing their desire for children after improvements was modest (14% of the 
total cohort of HIV positive women).
In multivariate analysis, partnership status, taking HTV-related therapy and number of 
children at time of diagnosis were all strongly associated with changing desire for 
children since improvements in treatments which delay disease progression (Table 
6.6). Women in a partnership were over 8 times more likely to change their desire for 
children than women without a partner, and women currently taking HTV-related 
therapy were 6 times more likely to change their desire than women who were not 
taking therapy. In contrast women with 2 or more children were over 6 times less
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likely to desire more children than women with less than 2 children, suggesting that 
women who have less than 2 children and who haven’t completed their family size 
were now more hopeful in the light of improvements in HIV management.
The results of the multivariate analysis for the effect of increasing availability of 
interventions on desire for children are also shown in Table 6.6. Women who already 
had 2 or more children were less likely to desire children. Women who were in a 
partnership were over 5 times more likely to desire children than women without a 
partner. Women resident in London were more likely to desire children, although this 
did not remain significant in multivariate analyses (OR 2.24, 95% Cl 1.00-4.99, 
/ j=0.048).
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Table 6.6a: Adjusted Odds of wanting a child since knowledge of HIV-related 
treatments
Total
<n)
Wanted a child 
since improvements 
in HIV-related 
treatments1
AOR 95% C l P value
Ethnicity
Non-African 39 15(39%) 1.0
African 105 34(32%) 1.25 0.19-7.85 0.81
Residence
Non-London 51 12(24%) 1.0
London 93 37(40%) 1.21 0.31-4.75 0.78
Years in UK
<=5 yrs 81 28(35%) 1.0
>5 yrs 54 18(33%) 0.90 0.26-3.10 0.87
Partnership
No 76 16(21%) 1.0
Yes 68 33(49%) 8.24 1.87-36.13 0.005
Age at diagnosis
<=29 years 74 27(37%) 1.0
>29 years 70 22(31%) 0.94 0.26-3.46 0.93
Years since diagnosis
<=5 years 81 26(32%) 1.0
>5 years 59 22(37%) 1.15 0.25-5.30 0.85
History of IDU
No 129 45(35%) 1.0
Yes 13 (3(23%) 0.27 0.01-9.54 0.47
HIV-related therapy
No 41 12(29%) 1.0
Yes 101 37(37%) 6.67 1.44-30.80 0.015
No. of children at diagnosis
<2 87 35(40%) 1.0
>=2 57 14(25%) 0.15 0.03-0.65 0.011
Ever misc/abortion
No 80 28(35%) 1.0
Yes 64 21(33%) 0.68 0.21-2.18 0.51
Trying for a preg >6 mo.
No 123 39(32%) 1.0
Yes
—
21 10(48%) 2.38 0.52-10.79 0.26
cases consisted of women who initially did not want a child following an HIV 
diagnosis but then changed their minds in light of improvements in HTV management
Factors not found to be significant with childbearing in univariate analyses and were 
therefore not included in multivariate analyses were: partner's HTV status, whether the 
woman had been pregnant at diagnosis, current HTV symptoms, CD4 count and 
whether or not the woman had had a previous HIV positive child.
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Table 6.6b: Adjusted Odds of wanting a child since knowledge of HIV-related
MTCT interventions
Total
(n)
Wanted a child 
since improvements 
in interventions 
which reduce 
MTCT1
AOR 95% Cl P value
Ethnicity
Non-African 38 18(47%) 1.0
African 91 36(40%) 1.70 0.28-10.37 0.57
Residence
Non-London 47 15(32%) 1.0
London 82 39(48%) 1.77 0.42-7.44 0.44
Years in UK
<=5 yrs 74 34(46%) 1.0
>5 yrs 48 17(35%) 1.84 0.54-6.25 0.33
Partnership
No 62 18(29%) 1.0
Yes 67 36(54%) 5.34 1.29-22.21 0.021
Age at diagnosis
<=29 years 68 33(49%) 1.0
>29 years 61 21(34%) 1.20 0.33-4.38 0.78
Years since diagnosis
<=5 years 70 27(39%) 1.0
>5 years 56 26(46%) 1.28 0.28-5.81 0.75
History of H>U
No 115 48(42%) 1.0
Yes 12 5(42%) 0.49 0.01-19.63 0.70
HIV-related therapy
No 38 17(45%) 1.0
Yes 89 37(42%) 3.81 0.86-16.98 0.079
No. of children at diagnosis
<2 80 41(51%) 1.0
>=2 49 13(275) 0.15 0.03-0.64 0.010
Ever misc/abortion
No 71 27(38%) 1.0
Yes 58 27(47%) 1.09 0.32-3.67 0.14
Trying for a preg >6 mo.
No 108 44(41%) 1.0
Yes 21 10(48%) 1.25 0.26-5.90 0.78
cases consisted of women who initially did not want a child following an HTV 
diagnosis but then changed their minds in light o f improvements in HTV management
Factors not found to be significant with childbearing in univariate analyses and were 
therefore not included in multivariate analyses were: partner’s HTV status, whether the 
woman had been pregnant at diagnosis, current HIV symptoms, CD4 count and 
whether or not the woman had had a previous HIV positive child.
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6A.6: Pregnancies subsequent to HIV diagnosis
Among the 450 HIV-positive women in the study, 16% (73/450) of women had at 
least one pregnancy subsequent to their HTV diagnosis. Sixty one women (13%) had 
one pregnancy and 12 (3%) had two.
Analyses to determine factors associated with subsequent pregnancy was restricted to 
312 women who had been diagnosed for at least 2 years in order to give the women a 
reasonable opportunity of becoming pregnant. Pregnancies varied by demographic 
and clinical factors: Overall women were more likely to have become pregnant 
subsequent to their diagnosis if they lived in London or Scotland, were 29 years or 
less, had been in the UK for 5 or more years, were in a partnership, had injected 
drugs, had no HIV-related symptoms, had been pregnant at diagnosis, had stated they 
wanted children sooner after their diagnosis and if they had already had one children 
at the time of their diagnosis (Table 6.7).
In multivariate analyses, women were most likely to have become pregnant if they 
were African, had been diagnosed for more than 5 years and in a partnership (Table 
6.8). Women older than 29 years and women who had 2 or more children at time of 
diagnosis were less likely to have had a subsequent pregnancy, although this was not 
significant in multivariate analyses. These findings are consistent with other studies 
that have also shown HIV-positive black women (151) and HIV-positive younger 
women (100,106,151) to have more further pregnancies than other women, and with 
results in the general population (8).
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After adjustment for all factors detailed in Table 6.8, having had a subsequent 
pregnancy was associated with women’s desire for children at the time of their 
diagnosis: Women who didn’t want a child were 0.29 times as likely to have had a 
pregnancy than women who stated HIV had had no effect (AOR 0.29, 95% Cl 0.09-
0.90, p=0.033). Women who wanted children sooner had more pregnancies 
subsequent to diagnosis than women who stated no effect, although this was not 
significant (AOR 1.51, 95% Cl 0.43-5.28, p=0.521). It may be assumed women who 
change their minds about fertility due to improvements will temporarily affect trends 
in neonatal prevalence.. Further analyses indicated however that whilst these women 
had had more pregnancies than women who did not change their mind, this was not 
significant.
Whilst many women desired children, it was clear barriers existed against achieving 
this. There are many influences on an HIV-positive woman’s life that may affect 
pregnancy decisions and a comments section within the questionnaire was used to 
gather further information about such factors. Key themes apparent from the 
comments section were that many women had no partner and a lot of those who did 
have a partner were in a discordant relationship. A high proportion of the women had 
been recently diagnosed and were still coming to terms with their condition. A 
disproportionately large segment of those women affected by HIV were from 
minority groups, often financially disadvantaged with uncertainties regarding their 
asylum status in the UK. Many of these women commented in the questionnaire that 
at present they were unable to contemplate getting pregnant. We did not specifically 
ask about partner’s desire for children. However a previous study by Chu et al found 
that a similar percentage of HIV-positive men desired children as women, although
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the fertility desires of HIV-infected individuals did not always agree with those of 
their partner (151). It was not known from the questionnaire survey whether women 
were concerned about becoming pregnant whilst on ART. This may have contributed 
to the fact that only half of the women changed their mind about desire for children in 
light of ART. It was not known why the other half of women did not change their 
mind.
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Table 6.7: Percentage of women pregnant since HTV diagnosis by maternal
characteristic (N=312)1
Demographic Factor Pregnant
after
diagnosis
(%)
Residence (n=312) London 22.2%
Rest of England 20.0%
Scotland 30.0%
Ethnicity (n=312) African 22.7%
Non-African 22.9%
Age at diagnosis (n=312) <=29 32.1%
Years in UK2 (n=205)
>29 12.7%
<=5 years 20.2%
>5 years 25.9%
In a Partnership (n=312) Yes 27.2%
No 18.0%
Ever injected drugs (n=310) Yes 30.3%
No 22.0%
HTV status of partner* (n=144) Positive 28.2%
Negative 28.8%
NK/Not tested 17.9%
Current HIV symptoms (n=303) None 25.2%
Mild/moderate 20.3%
Severe 14.3%
CD4 count (n=239) <350 20.5%
>=350 21.4%
Pregnant at HTV diagnosis (n=312) Yes 30.6%
No 19.8%
Number of children pre-diagnosis (n=312) 0 18.7%
1 35.7%
2+ 14.3%
Effect of HTV diagnosis (n=283) No effect 22.1%
Wanted children sooner 37.5%
Didn’t want children anymore 16.7%
1 Analysis restricted to women who had been diagnosed for at least 2 years
2 For women bom outside the UK 
For women who had a partner
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Table 6.8: Odds and adjusted odds of having had a pregnancy subsequent to 
HIV diagnosis1
Total
(n)
Subsequent 
Pregnancy 
N (% of n)
AOR 95% Cl P value
Ethnicity
Non-African 105 24(23%) 1.0
African 207 47(23%) 3.93 1.21-12.80 0.02
Residence
Non-London 100 24(24%) 1.0
London 212 47(22%) 1.21 0.41-3.58 0.73
Years in UK
<=5 yrs 89 18(20%) 1.0
>5 yrs 116 30(26%) 0.95 0.40-2.28 0.91
Partnership
No 150 27(18%) 1.0
Yes 162 44(27%) 2.29 1.05-5.01 0.04
Age at diagnosis
<=29 years 162 52(32%) 1.0
>29 years 150 19(13%) 0.54 0.23-1.28 0.16
Years since diagnosis
<=5 years 148 18(12%) 1.0
>5 years 147 53(36%) 4.94 1.91-12.79 0.001
History of IDU
No 277 61(22%) 1.0
Yes 33 10(30%) 1.55 0.25-9.67 0.64
HTV-related therapy
No 88 23(26%) 1.0
Yes 220 46(21%) 0.76 0.33-1.77 0.53
No. of children at diagnosis
<2 221 58(26%) 1.0
>=2 91 13(14%) 0.48 0.18-1.31 0.15
Ever misc/abortion
No 180 38(21%) 1.0
Yes 132 33(25%) 0.69 0.31-1.53 0.36
Trying for a preg >6 mo.
No 257 57(22%) 1.0
Yes
1 A 1 . • . t  . ________________
55 14(26%) 0.60 0.23-1.60 0.31
Analysis restricted to women who had been diagnosed for at least 2 years
Factors not found to be significant with childbearing in univariate analyses and were 
therefore not included in multivariate analyses were: partner’s HIV status, whether the 
woman had been pregnant at diagnosis, current HIV symptoms, CD4 count and 
whether or not the woman had had a previous HIV positive child.
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6A.7: Summary of analyses of factors associated with fertility
The main associations of demographic and clinical factors with fertility are 
summarised below and in Table 6.9. Full analysis results are in appendix F. These 
findings are in line with previously reported findings (chapter 4 and 5) from other data 
sources and they therefore highlight the consistency of associations between HIV and 
fertility in GB.
Ethnicity
Compared to other women, African women were older at diagnosis, more likely to 
have had a recent diagnosis, less likely to have a partner and more likely to have 3 or 
more children at diagnosis. African women were also more likely to have had a 
further pregnancy after diagnosis. It will be important to stratify neonatal 
seroprevalence according to African and non-African in the final adjustment model in 
chapter 7.
Number of children
Women with fewer children were significantly more likely to desire more children or 
have changed fertility desire due to improvements in HTV-related treatments and 
interventions which reduce MTCT than women with 2 or more children. Therefore 
the number of children a woman has had at diagnosis will be an important factor to 
include in the adjustment model. Neonatal seroprevalence will be stratified according 
to whether or not the woman has had less than 2 children at time of diagnosis in the 
final adjustment model in chapter 7.
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Partnership status
Women who were currently in a partnership (married, co-habiting or non-cohabiting 
partner) were more likely to desire children and have changed fertility desire due to 
improvements in treatments and interventions than women who were single, 
widowed, divorced or separated. Women who had a partner were also more likely to 
have had a pregnancy after their HTV diagnosis. As little data are available on 
partnership status of HIV-positive women, the effect of this factor will not be 
quantified in the final model. However, the possible influence of partnership status 
on the neonatal data will be discussed in chapter 8.
Age
African women were significantly older at diagnosis than other women and older 
women have a higher HTV prevalence than younger women. For these reasons, age 
will be included in the final adjustment model.
Years since diagnosis
Women who had been diagnosed for more than 5 years were more likely to have had 
a pregnancy after diagnosis than women who had been diagnosed 5 years or less. This 
relationship may reflect greater exposure to the risk of pregnancy and will not be 
included in the final model.
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Table 6.9: Factors associated with reproductive-decision making amongst HIV-positive women: Results from univariate and 
multivariate analysis
Factor Want (more) Pregnancy after Did not want a knowledge of Knowledge of 
children diagnosis child after HIV treatments MTCT
diagnosis interventions
Demographic factors
Ethnicity HIHBHIlHi
Residence
Years in UK / Bom UK
status
History of drug use
Clinical factors
Age at diagnosis
Years since diagnosis
Partner’s HIV status
HIV symptoms
CD4 count
HIV therapy HHHHHHI
Pregnancy factors
Number _ _ _ _ _ _ _
Having had a positive child
Previous miscarriage/TOP
Pregnant at diagnosis
Trying for pregnancy >6 months
Significant in multivariate analysis
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6A.8: Key points
1. In over half (56%) the cases of women an HTV diagnosis either did not affect 
women’s desire for children or had made women want children sooner. Whilst 
in the remainder of cases women decided they no longer wanted children after 
an HTV diagnosis, nearly half of these women changed their mind once they 
had become aware of the advancements made in HIV management.
2. The overall proportion of women changing their fertility desire in response to 
knowledge of improvements in HIV management was modest (14% of the 
total cohort of HTV-positive women). It is unlikely therefore that changes in 
childbearing intentions would have greatly impacted on the doubling of 
neonatal seroprevalence observed between 1997 and 2002, although this will 
be explored in greater detail in chapter 7.
3. Number of children, partnership status and ethnicity was strongly related to 
women’s desire for children. Women with more than 1 child were 0.28 times 
as likely to not want children and 0.15 times as likely to change their mind 
because of improvements in HIV management. African women were 3.93 
times more likely to have had a pregnancy subsequent to HIV diagnosis. 
Women with a partner were 1.97 times more likely to desire children than 
other women.
4. Many of these factors for which African women differ from other women, for 
example partnership status, partners HIV status and age at diagnosis, may
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affect fertility decision-making. Adjustment of neonatal seroprevalence data 
will therefore be stratified by ethnicity.
5. Sixteen percent of HIV-positive women had had a pregnancy subsequent to 
their diagnosis and this was related to decision-making at the time of their 
diagnosis.
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Section 6b: Generalisation of survey findings
6B.1: Introduction
The generalisability of results from the questionnaire study to the HIV-positive 
population at large depends on how representative the study cases were of all 
diagnosed HIV- positive women in the population. This section presents results from 
analyses comparing women participating in the survey with that of all diagnosed 
prevalent HTV infections amongst women (Survey of Prevalent HIV Infections 
Diagnosed (SOPHID)). In addition, characteristics and pregnancy history of women 
participating in the questionnaire study were compared with women surveyed through 
the National Study of Sexual Attitudes and Lifestyles (NATSAL) to assess possible 
fertility differences between HTV positive women and a general population of all 
women whose HTV status was unknown. Finally, limitations of the survey are 
discussed.
6B.2: Comparison of survey population with all HTV-positive women
The demographics of the HTV-positive women participating in the survey were 
compared with that of all diagnosed prevalent HTV infections amongst women in GB 
in 2002 using a chi-square statistic. The 2 groups were compared in terms of drug use, 
ethnicity and age group, factors collected in both surveys. Women in the survey 
resident in Scotland were not included in this analysis as SOPHID data was not 
collected.
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Eight thousand nine hundred and sixty-seven women received HTV-related care in 
England, Wales and Northern Ireland in 2002. Of these women, 393 (4.4%) were 
surveyed in the questionnaire for the purposes of this thesis. Survey women were 
more likely to be of black African ethnicity than all HIV-positive women (Table 6.10) 
and this reflects the higher sampling of clinics in the London area. The oversampling 
of African women will improve the interpretation of survey data as it is has been well 
documented that African women are more likely to have babies and are therefore 
more likely to be in included in neonatal prevalence data. Importantly, no apparent 
differences were found in the age distribution of women sampled through the 
questionnaire and all diagnosed HTV-positive women. Childbearing is strongly 
associated with the woman’s age, thereby making age an important factor to take into 
account when understanding fertility-decision making amongst women.
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Table 6.10: Comparison of survey women with all diagnosed prevalent HIV
infections amongst women in England
Survey
women
SOPHID
(2002)
P value
No. of women 393 8967
History of IDU
Yes
No
19 (5%) 
369 (95%)
290 (3%) 
8675 (97%) 0.07
Ethnicity
Black African 
Black Caribbean 
White 
South Asian 
Other
307 (78%)
14 (4%) 
48 (12%)
9 (2%)
15 (4%)
6205 (69%) 
297 (3%) 
1663 (19%) 
103 (1%) 
278 (8%) 0.003
Age Group
15-24
25-39
40-49
22 (6%) 
268 (71%) 
87 (23%)
713 (8%) 
5735 (66%) 
1800 (26%) 0.16
6B.3: Comparison of survey women with all women surveyed through NATSAL
To help understand the effects of HIV on fertility, the characteristics, including 
fertility history, of survey women and women surveyed through NATSAL (a 
population-based survey carried out in GB) were compared. Women from NATSAL 
were assumed to be HIV-negative, a reasonable assumption given that HIV 
prevalence amongst women in GB is low. The methodology for NATSAL was 
described in chapter 3 whilst the characteristics of NATSAL women were analysed in
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chapter 4. The variables used to compare the groups of women were: Residence, age 
group, ethnicity, marital status, previous pregnancies and dates of previous 
pregnancies, previous miscarriages and terminations, periods of infertility and 
whether the woman had received help for infertility. In total there were 461 African 
and 10,343 non-African women surveyed through NATSAL.
The ethnic distribution of HTV-positive women compared to women whose HIV 
status was unknown was different. Of the 450 HIV-positive women in the survey, 
19.3% were White, 2.0% were Asian, 3.1% were black Caribbean, 72.0% were black 
African and 3.5% other. The equivalent figures in NATSAL were 91.7% White, 2.9% 
south Asian, 2.0% black Caribbean, 1.1% black African and 2.4% other. These 
discrepancies reflect the increased risk of HIV infection amongst black African 
women and, to a lesser extent, black Caribbean women.
Compared to women whose HIV status was unknown and regardless of ethnicity, 
HIV-positive women were older, less likely to be married, more likely to be single 
and less likely to have 3+ children (Table 6.11).
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Table 6.11: Comparison of NATSAL women to survey women
African women Other women
NATSAL Survey P NATSAL Survey P
(%) C /.) value (*/.) (% ) value
Age group
16-24 18.5% 6.1% 25.8% 4.1%
25-34 40.0% 43.2% 37.5% 33.3%
35-44 41.5% 50.6% 0.004 36.7% 62.6% <0.001
Partnership status
Married 44.6% 26.9% 44.6% 23.8%
Div/sep. 15.4% 11.4% 7.2% 13.5%
Widowed 1.5% 10.2% 0.3% 5.6%
Single 32.3% 45.4% 29.4% 38.9%
Co-habit 6.2% 6.2% 0.010 18.4% 18.3% <0.001
No. children
0 30.8% 25.0% 40.3% 34.1%
1 16.9% 29.0% 17.5% 28.6%
2 20.0% 25.6% 25.9% 24.6%
3+ 32.3% 20.4% 0.050 16.3% 12.7% 0.013
Ever miscarriage
Yes 31.7% 17.6% 20.7% 23.8%
No 68.3% 82.4% 0.012 79.3% 76.2% 0.42
Ever termination
Yes 38.5% 23.8% 16.6% 33.3%
No 61.5% 76.2% 0.011 83.4% 66.7% <0.001
Trying preg 6 mths
Yes 12.3% 24.9% 16.2% 14.1%
No 87.7% 75.1% <0.001 83.8% 85.9% 0.56
Sought help infertility
Yes 6.3% 11.3% 9.1% 8.9%
no 93.7% 88.7% 0.25 90.9% 91.1% 0.92
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Whilst African HTV-positive women in the survey were less likely to have had a 
previous miscarriage or termination of pregnancy and more likely to have been trying 
for a pregnancy for greater than 6 months than African women whose HTV status was 
unknown, the reverse was true when other HTV-positive women were compared to 
other women whose HIV status was unknown. Data on miscarriages and terminations 
of pregnancy should be interpreted with caution as it was apparent from the 
questionnaire returns that many women confused these terms.
As HTV-positive women were significantly older than the general population, they 
would be expected to be more advanced in their child-bearing decisions. The mean 
number of children for each group of women was compared, stratified by age group 
(Figure 6.4). African HTV-positive women had a lower mean number of children than 
all African women at all age groups and this was most apparent in women aged 25 
years and over. Other HIV-positive women had similar mean number of children at 
ages 16-34 years, but lower number of births at age 35 and over.
173
Figure 6.4: Mean number of children by HIV status, ethnic status and age 
category
♦ —African: HIV
* —African:HIV status NK
Other HIV
Other HIV status NK
16-24 25-34
Mother's age category
The association of a previous live birth and HIV infection was investigated further 
using logistic regression. After adjustment in the model for factors significant in 
univariate analysis (age group, residence, partnership status, previous miscarriage, 
previous terminations and medical help for fertility), HIV-positive women regardless 
of ethnicity were less likely to have had a previous live birth than other women, 
although this was not statistically significant (OR 0.78, 95% Cl 0.48-1.28, /?=0.331 
for African women and OR 0.66, 95% Cl 0.40-1.08, p=0.097 for non-African women) 
(Table 6.12 and 6.13). These results agree with other studies that compared pregnancy 
rates before and after HIV diagnosis and found that after HIV diagnosis women were 
less likely to become pregnant (68, 92- 93).
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Table 6.12: Likelihood of a previous livebirth in HIV-positive women compared to all women: African
Previous live 
birth 
N (%)
Total 
n (% of N)
Crude OR P value Adjusted OR P value
HIV status
HIV status NK 190 (41%) 461 1.0 1.0
HIV positive 162 (41%) 394 0.99(0.67-1.45) 0.18 0.78(0.48-1.28) 0.33
Age group
16-24 13 (17%) 78 1.0 1.0
25-34 142 (42%) 335 11.14(5.60-22.13) <0.001 9.22(4.32-19.67) <0.001
35-44 189 (45%) 421 17.58(8.79-35.13) <0.001 11.93(5.43-26.22) <0.001
Residence
London 286 (41%) 702 1.0 -
Outside London 66 (43%) 152 1.43(0.84-2.43) 0.38 -
Partnership
Married 127 (46%) 276 1.0 1.0
Co-habiting 20 (37%) 54 0.25(0.11-0.56) 0.002 0.33(0.13-0.81) 0.02
Div./Sep./Wid. 92 (45%) 206 1.79(0.69-4.64) 0.08 1.59(0.59-4.28) 0.16
Single 112(34%) 327 0.19(0.11-0.32) <0.001 0.29(0.16-0.54) <0.001
Previous miscarriage
No 258 (40%) 642 1.0 1.0
Yes 91 (44%) 205 1.93(1.17-3.20) <0.001 1.13(0.63-2.04) 0.56
Previous abortion
No 231 (40%) 573 1.0 1.0
Yes 119(43%) 276 1.50(0.98-2.31) 0.03 1.38(0.85-2.23) 0.19
Medical help
No 316(42%) 761 1.0 -
Yes 29 (37%) 78 0.59(0.32-1.08) 0.06 -
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Table 6.13: Likelihood of a previous livebirth in HIV-positive women compared to all women: Non-African
Previous live 
birth 
n (%)
Total 
N(% of n)
Crude OR P value Adjusted OR P value
HIV status
HTV status NK 3882 (38%) 10,343 1.0 1.0
HIV positive 47(35%) 135 0.76(0.50-1.16) 0.19 0.66(0.40-1.08) 0.09
Age group
16-24 326(18%) 1783 1.0 1.0
25-34 1578(38%) 4158 5.46(4.72-6.33) <0.001 2.43(2.05-2.87) <0.001
35-44 2022(45%) 4530 14.43(12.32-16.91) <0.001 4.86(4.04-5.87) <0.001
Residence
London 779(34%) 2269 1.0 1.0
Outside London 3150(38%) 8209 1.51(1.34-1.69) <0.001 1.61(1.39-1.86) <0.001
Partnership
Married 2149(46%) 4715 1.0 1.0
Co-habiting 547(35%) 1562 0.23(0.19-0.27) <0.001 0.30(0.25-0.36) <0.001
Div./Sep.AVid. 612(46%) 1332 1.13(0.89-1.43) 0.29 1.05(0.82-1.35) 0.22
Single 620(22%) 2865 0.07(0.06-0.09) <0.001 0.14(0.12-0.16) <0.001
Previous miscarriage
No 2690(35%) 7781 1.0 1.0
Yes 1175(46%) 2554 5.14(4.39-6.02) <0.001 3.47(2.89-4.15) <0.001
Previous abortion
No 3023(37%) 8282 1.0 1.0
Yes 844(41%) 2058 1.69(1.48-1.93) <0.001 1.57(1.35-1.85) <0.001
Medical help
No 3439(37%) 9301 1.0 1.0
Yes 429(41%) 1039 1.67(1.39-2.00) <0.001 0.63(0.50-0.78) <0.001
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The association of previous live births and HTV status was also analysed by 
comparing HIV-positive and HIV-status unknown women with none versus 1+, <2 
versus 2+ and <3 versus 3+ live births. The purpose of this analysis was to assess 
whether or not HIV infection was associated with birth order. After adjustment, 
multivariate logistic regression showed that the association of fertility with HTV 
infection increased with higher birth order (Figure 6.5). Diagnosed HTV-positive 
African women were 0.46 (OR 0.46, 95% Cl 0.26-0.79, p=0.005) times less likely to 
have 3+ children than other African women. HIV-positive non-African women were
0.50 (OR 0.50, 95% Cl 0.22-0.80, p=0.039) times less likely to have 3+ children than 
other non-African women. These results may suggest that whilst HIV-positive women 
do have children, fertility is reduced or delayed.
Figure 6.5: Adjusted Odds ratios’* comparing the likelihood of a diagnosed 
HIV-positive Woman versus an HIV-status unknown woman having children
African women Other women
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* Adjusted for age group, partnership status, residence, ever had a miscarriage or 
terminations, ever received help for fertility.
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6B.4: Limitations with survey methodology
A major strength of the cross-sectional questionnaire study was the direct 
measurement of fertility decisions in a sample of HIV-positive women. However, a 
number of limitations to the interpretation of results should be noted.
• The overall sample size was sufficient and came within the original sample 
size calculation conducted at the beginning of the study. However, once 
results were stratified by different demographic factors, numbers were small in 
some cells. This may have led to non-significant results.
• Whilst the study looked at desire for children, data was not collected on 
whether women achieved or thought they would achieve their desires. Whilst 
pregnancies subsequent to HIV diagnosis were explored, many of the women 
had been diagnosed within the previous 2 years, and so had not been given the 
chance yet to achieve their fertility potential.
• Birth rates among HIV-positive women in this survey were unknown, 
precluding a comparison to rates amongst the general population.
• The terms termination of pregnancy and miscarriage were often 
misunderstood by participants, limiting the usefulness of these variables.
• Many of the women participating in the survey were recent immigrants to the 
UK and had unresolved asylum status. Due to the sensitivity of this issue, a
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direct question on asylum status was not requested on the questionnaire. This 
factor could not therefore be included in analyses.
• Many HIV-positive women in GB are diagnosed due to routine antenatal HIV 
screening. This may mean that if a woman has become pregnant she will be 
more likely to be diagnosed, possibly leading to an overestimate of fertility in 
this survey population.
• The cross-sectional questionnaire survey provided an important insight into 
reproductive-decision making amongst HTV positive women, although some 
important issues which had not been included in the questionnaire, for 
example partner’s desire for children, may have been under-estimated. Whilst 
a more qualitative approach to the questionnaire would have given a better 
insight into childbearing decisions, this approach was not utilised in this thesis 
as data from a representative sample of women was required for the final 
model. The development of the questionnaire however would have benefited 
from a focus group analysis.
• The questionnaire was undertaken among a heterogenous population where 
English was often not the first language. Validation of responses to the 
questions would therefore have been useful and would have confirmed 
whether or not the questions had been interpreted correctly. Validation could
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have been carried out using a focus group analysis or by asking a sample of 
women to complete the questionnaire twice.
• Current CD4 count was not found to be significantly related to reproductive 
decision-making. An alternative measure of well-being may have been CD4 
count at diagnosis or lowest ever CD4 count
6B.5: Key Points
1. HIV-positive women sampled through the survey were representative of all 
diagnosed HIV-positive women in terms of age. This is important when 
studying fertility decisions.
2. Compared to all women, HIV-positive women were older, less likely to be 
married, more likely to be single and less likely to have 3+ children.
3. HIV-positive women were less likely to have had a previous live births than 
all women, although this difference was not significant (OR 0.78, 95% Cl 
0.48-1.28, /?=0.331 for African women and OR 0.66, 95% Cl 0.40-1.08, 
p=0.091 for non-African women).
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Chapter 7: Estimating HIV prevalence amongst women in the general
population in GB from neonatal seroprevalence data
7.1: Introduction
In many countries, including GB, HTV prevalence estimates among women are based 
on the observed prevalence amongst pregnant women (4,58). This estimation assumes 
that HIV-infected women have an equal probability of being pregnant than uninfected 
women (7). However, on the one hand women bom in SSA have both higher HIV and 
fertility rates than other women (chapter 4), while on the other hand there is some 
evidence to suggest that HIV infection can impair female fertility or the ability to 
have a successful pregnancy (chapter 6), which would mean that HTV-infected women 
maybe less likely to become pregnant or to have a live birth. This means that neonatal 
seroprevalence, the commonly used measure in GB of HTV prevalence among 
pregnant women, needs to be adjusted taking into account the fertility differences 
between HIV-positive and HTV-negative groups.
The results from the investigations presented in chapters 4-6 were used in the final 
stage of the project to develop a model which would enable the extrapolation of 
neonatal prevalence data to give reliable estimates of HIV in the general female 
population. This chapter begins with a summary of factors affecting interpretation of 
neonatal prevalence which the adjustment model will need to account for. The model 
developed for this project is then described, together with a description of parameter 
estimation, results and validation analyses.
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7.2: Summary of factors affecting interpretation of neonatal HIV prevalence
Analyses in chapters 4-6 showed the following factors affected child-bearing and HIV 
prevalence, which in turn affect the interpretation and extrapolation of neonatal 
seroprevalence. In summary:
• Women bom in SSA have higher overall fertility rates and a higher HIV risk 
than women bom elsewhere.
• Women in urban areas, for example London, are at higher risk of HTV 
infection than those in more rural areas. This is unrelated to their country of 
birth.
• Both total number of children and HTV prevalence are associated with age.
• Knowing ones HIV positive status leads to a reduced desire for children, 
resulting in the fertility of women who know themselves to be HIV positive to 
be lower than what it would have been based on cultural/ethnic factors.
• The number of children a woman has had at the time of HTV diagnosis was 
strongly associated with future reproductive-decision making.
These factors therefore should be included in any model which extrapolates neonatal 
seroprevalence data to the general population. To quantify the effect of each variable 
for use in the model, the following is needed: fertility relative to a reference group, 
HIV prevalence and the population size. Analyses in chapter 4 provided the HIV 
prevalence and population size data whilst the results from logistic regression models 
from the survey presented in chapter 6 provided the fertility measures.
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7.3: Estimates of HIV amongst women in the General Population using neonatal
seroprevalence data
The number of diagnosed and undiagnosed HTV infections amongst women in the 
general population in a given year was estimated using a model consisting of 2 
separate components (Figure 7.1). The first component comprised of women aged 15- 
44 years who were at risk of having a live birth, thereby likely to appear in the 
neonatal surveys. The second component consisted of women who were not at risk of 
having a live birth, either because they were not of child-bearing age (45 years and 
over), they had never wanted to have any children or they had completed their family 
prior to their HIV diagnosis. This model was repeated for 4 separate years (1997, 
2000, 2001 and 2002) to assess changes over time and to validate the model.
Figure 7.1: Overall model to estimate HIV amongst women in the general
population
Number of HTV Number of HTV Number of HIV
infected women in = infected women at risk + infected women not
the general of pregnancy at risk of pregnancy
population (component 1) (component 2)
7.3.1:Number of HIV-infected women at risk of pregnancy using neonatal 
seroprevalence data
The first component of the model was based on neonatal seroprevalence data. For a 
woman to be picked up in neonatal seroprevalence surveys, she has to become 
pregnant and have a live birth. From analyses in chapter 6 it was apparent that the 
diagnosis (ie. knowledge) of HIV infection reduced the likelihood of a woman having 
a live birth and that this reduction in fertility was dependent on the number of children 
the woman had already at the time she was diagnosed. This effect may be termed
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fertility differential. It was assumed that an undiagnosed HIV-infected woman would 
not intentionally reduce her fertility. Any reduction in fertility in this group of women 
would therefore be unintentional and this was assumed to be extremely low and was 
therefore not included in the model.
Based on this information, neonatal seroprevalence was stratified by whether or not 
the woman was bom in SSA, area of residence (London versus rest), whether or not 
infection was likely to be diagnosed and, for women with diagnosed infection, the 
number of children they had had at the time of diagnosis. Prevalence rates were then 
adjusted for differences in fertility risk between HIV-positive and HIV-status 
unknown women. Figure 7.2 shows the detailed structure of component 1 o f this 
model.
Figure 7.2: Structure of model to estimate number of HIV-infected women at 
risk of pregnancy (Component 1)
Adjusted prevalence 1 Adjusted prevalence 2
F ertility  d iffe re n tia l  w ith HIV 
n e g a t iv e  w o m e n
F ertility  d iffe re n tia l  w ith HIV 
n e g a t iv e  w o m e n
Proportion of women 
with <2 children
Proportion of women 
With 2+ children
Neonatal Prevalence
Adjusted prevalence 3
Proportion of infections 
undiagnosed
Proportion of infections 
diagnosed
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In mathematical terms, for each stratified prevalence:
Let P=Neonatal HTV seroprevalence
D=Proportion HIV infections diagnosed 
U=Proportion HTV infections undiagnosed (or 1-D)
A=Proportion of women with <2 children at time of HIV diagnosis 
B=Proportion of women with 2 or more children at time of HTV diagnosis (or 
1-A)
Fl=Fertility differential in women after HIV diagnosis in women with <2 
children
F2=Fertility differential in women after HIV diagnosis in women with >=2 
children
Prevalence in women at risk of pregnancy =Adjusted prevalence 1 + Adjusted 
prevalence 2 + Adjusted prevalence 3
= ((P*D*A*F1) + (P*D*B*F2) + (P*U»
The final stage of this model involves the application of adjusted neonatal prevalence 
rates to the general female population to generate numbers of HIV infected women in 
GB in a given year.
7.3.2: Number of HIV- infected women not at risk ofpregnancy 
The second component of the model, which relates to the number of diagnosed and 
undiagnosed HIV infected women not at risk of having a live birth, included women 
who were 45 years and older, women who had already completed their family size at 
diagnosis and women who never wanted children regardless of their HIV status.
185
These parameters were estimated using results presented in chapters 5 and 6. 
Analyses in chapter 5 provided data on numbers of diagnosed prevalent HIV 
infections according to age category whilst analyses in chapter 6 provided information 
about child-bearing history at time of diagnosis. Older women and women who never 
wanted children contributed to both a diagnosed and undiagnosed fraction of the 
model. In order to be consistent with component 1, results were stratified according to 
risk, residence and whether or not the woman had been diagnosed.
In mathematical terms, for each stratification:
Let: A=Number of HIV-infected women aged 45 years and over (Diagnosed)
B= Number of HTV-infected women aged 45 years and over (Undiagnosed) 
C=Number of HTV-infected women aged 15-44 who have completed then- 
family at time of diagnosis (diagnosed)
D=Number of HIV-infected women aged 15-44 who never wanted children 
(Diagnosed)
E=Number of HTV-infected women aged 15-44 who never wanted children 
(Undiagnosed)
No. of women not at risk of pregnancy=A+B+C+D+E
The estimated numbers from component 1 and 2 were then added together to provide 
an overall estimate (diagnosed and undiagnosed) of the number of HIV infections 
amongst women in GB in a given year. Finally, the age-specific numbers of infections 
among women in GB were generated by applying the age distributions of diagnosed
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HIV-infected women reported to SOPHID to the estimated number of infections 
among women generated by the model.
7.4: Parameter Estimation for numbers of HIV infections amongst women
In summary, the following parameters were needed for the model:
• Neonatal seroprevalence by risk (whether or not the woman was bom in SSA)
and area of residence (Component 1)
• Proportion of infections diagnosed by risk, area of residence and age 
(Component 1 and 2)
• Proportion of HTV-positive women with <2 children at time of diagnosis by 
risk and area of residence (Component 1)
• Fertility differential between diagnosed HTV-positive and HTV- negative 
women by risk, residence and number of children at time of diagnosis 
(Component 1)
• Age-distribution of neonatal prevalence (Component 1 and 2)
• Population estimates for women by risk and residence and age (Component 1 
and 2)
• Number of HIV-positive women 45 years and older by risk and residence 
(Component 2)
• Proportion of HIV-positive women who have completed family at diagnosis 
(Component 2)
• Proportion of HIV-positive women who never wanted children (Component 2)
The following section describes how the parameters were estimated and which results 
will be used in the final model.
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7.4.1: Neonatal HIV seroprevalence
Overall neonatal HIV prevalence, adjusted for areas not included in the UA 
programme, was derived for 2002 in analyses in chapter 4. This analysis was repeated 
for 1997, 2000 and 2001 for use in the model and results are shown in Table 7.1 with 
95% confidence intervals. Prevalence was highest in London among women bom in 
SSA, and levels of HIV have risen from 1.49% in 1997 to 2.32% in 2002. Whilst rates 
in the other group were substantially lower, prevalence has also increased over time 
(Table 7.1).
Table 7.1: Neonatal HIV Prevalence by residence and risk, adjusted for areas 
not included in the UA programme
HIV Prevalence (%)
(95% confidence intervals)
1997 2000 2001 2002
London SSA 1.494 1.887 2.222 2.316
(1.490-1.498) (1.880-1.894) (2.215-2.229) (2.309-2.323)
Other 0.042 0.049 0.064 0.062
(0.041-0.042) (0.048-0.050) (0.063-0.065) (0.061-0.063)
Rest GB SSA 0.652 1.068 0.991 1.367
(0.649-0.655) (1.058-1.078) (0.981-1.000) (1.356-1.377)
Other 0.0096 0.013 0.015 0.019
(0.0095-0.0096) (0.013-0.014) (0.014-0.015) (0.019-0.020)
7.4.2: Proportions of HIV infections diagnosed
It is important to estimate the proportion of infections amongst HTV-positive women 
diagnosed as an HTV diagnosis was shown to affect subsequent desire for children 
(chapter 6). Proportion diagnosed was estimated by comparing the number of women 
diagnosed prior to pregnancy reported to the National Study of HIV in Pregnancy and 
Childhood (NSHPC) with the number of seropositive neonatal samples estimated 
from the unlinked anonymous surveys (Chapter 3). This comparison works on the 
principle that the neonatal seroprevalence survey collects data on all infections 
amongst women having live births, whether diagnosed or undiagnosed, whilst the
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NSHPC collects data only on diagnosed and reported infections. Only women 
diagnosed prior to pregnancy were included so as not to bias the results with increased 
number of reports detected as a result of antenatal screening. Both the NSHPC and the 
neonatal seroprevalence survey collected information on mother’s country of birth, 
mother’s area of residence and year of child’s birth.
Table 7.2 presents the results from this analysis for 1997 and 2000 to 2002. The 
proportion of infections diagnosed has increased between 1997 to 2002 in all groups 
of women, possibly reflecting improvements in HTV testing services (30). Between 
2000 and 2002 the proportion of diagnosed infections amongst women within London 
increased significantly (p=0.003 for women bom in SSA and /K0.001 for other 
women), and separate yearly rates will therefore be included in the model. For women 
resident outside London, where lower numbers of infections were observed, no 
significant change between 2000-2002 was observed and therefore an average yearly 
proportion will be included in the model.
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Table 7.2: Estimated proportion of diagnosed HIV infections among women
% (no. of reports from NSHPC/no. of positive 
neonatal samples)*
1997 2000 2001 2002
London SSA 20% 42% 43% 52%
(40/196) (107/255) (130/299) (174/334)
Other 39% 21% 61% 51%
(15/38) (9/43) (39/64) (34/67)
Rest GB SSA 16% 49% 46% 47%
(7/45) (39/80) (47/102) (71/152)
Other 25% 39% 27% 32%
(13/53) (32/82) (25/94) (41/128)
*0.8% of reports from the NSHPC and 11% of HTV positive neonatal samples had 
missing information on mother’s country of birth. These cases were therefore 
proportionally distributed across the table.
7.4.3: Fertility differential between diagnosed HIV-positive and women whose HTV 
status was unknown
The final parameter needed for component 1 of the model was the fertility differential 
for HTV-positive compared to HTV-negative women. The fertility differential in HIV- 
positive women compared to HIV-negative women has previously been termed the 
Relative Inclusion Ratio (RIR) (60), the relative probability of including HTV-infected 
and uninfected women in a seroprevalence survey. This differential is equivalent to 
the ratio of live birth rates in HTV-infected women to live birth rates in uninfected 
women (see below formula). Once this differential is obtained, the prevalence in the 
population group of interest can be estimated as the prevalence observed among 
pregnant women multiplied by the differential. Fertility differentials were described in 
more detail in chapter 2.
Fertility differential P (HTV +ve) ~ P (live birth inHTV +ve)
P (HTV -ve) P (live birth in HTV-ve)
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Based on results from chapter 6 a fertility differential was estimated for HIV-positive 
women, according to whether or not the woman wanted children after diagnosis, 
whether the woman was bom in SSA, was resident in London or elsewhere and 
whether or not the woman had <2 children at diagnosis. Women with >=2 children 
were expected to have little HIV-related fertility decline as they had been diagnosed 
later in the course of their infection. The influence of improvements in HIV 
management on trends in HTV prevalence were investigated as part of a detailed 
sensitivity analysis (section 7.6).
One third of women did not want children after their HTV diagnosis and two thirds of 
these women had <2 children at time of diagnosis. For the model, it was assumed that 
women who did not want further children after their HIV diagnosis would indeed not 
have any more children. Therefore the mean number of children they had already had 
at time of diagnosis was estimated and divided by the number of children one would 
expect these women to have, (2.51 for women bom in SSA and 2.1 for other women, 
published data from the General Household Survey on number of children a woman 
expects to have in her lifetime) (150), to provide a fertility differential. It was 
assumed that the remainder of diagnosed HIV- positive women who stated an HTV 
diagnosis had had no effect and HTV-positive women who were unaware of their 
infection would have a fertility differential of 1.0, i.e. their fertility would be 
unaffected by their HTV status.
When stratified by country of birth and whether or not the woman had had <2 
children at diagnosis, the fertility differential for women who no longer wanted 
children after diagnosis was substantially lower in women with <2 children (range
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0.18-0.23) while, as expected, nearly 1 in women with >=2 children (range 0.88-1.0) 
(Table 7.3). The overall fertility differential for all diagnosed HIV-positive women 
was significantly smaller than 1 (0.79 in women resident in London and 0.80 in 
women resident elsewhere), which confirms a trend of decreased fertility in the HTV- 
infected group. Few differences were observed between women bom in SSA and 
women bom elsewhere and between women resident in London compared to other 
women. These results support the argument that the effect of an HTV diagnosis 
decreases the total number of children a woman will have and that they will therefore 
be less likely to appear in neonatal seroprevalence surveys than other women. The 
effect of this is that if neonatal seroprevalence data are not adjusted for a fertility 
differential amongst HTV- positive and HTV-negative women, the number of 
infections amongst the general population will be underestimated.
7.4.4: Estimating number of women aged > =45 years
The number of women aged 45 years and above with a diagnosed HTV infection was 
obtained from SOPHID. The number of undiagnosed women aged 45 years and above 
was estimated assuming the proportions presented in Table 7.2 for HTV-positive 
women aged 15-44. This may be an underestimate, as older women may be more 
likely to have their infection diagnosed if they have been infected longer, have had 
more time to develop symptoms and have had more opportunities to have been in 
contact with health care services. This was not accounted for in the model as the 
consequence of this underestimate would be expected to have a small effect on the 
overall results.
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Table 7.3: Estimation of fertility differential in diagnosed HIV-positive women
Women who did not want children at time of their HIV diagnosis 
(3% of cohort of women)3
All diagnosed HIV 
positive women
Women with <2 children 
(70% of cohort of women)4
Women with >=2 children 
(30% of cohort of women)4
Mean no. of Fertility 
children at differential1 
diagnosis5
Mean no. of Fertility 
children at differential1 
diagnosis5
Overall fertility 
differential2
London SSA 0.46 0.18 2.25 0.90 0.79
Other 0.28 0.13 2.01 0.96 0.79
Rest SSA 0.58 0.23 2.22 0.88 0.80
Other 0.45 0.21 2.14 1.00 0.80
For example, for women bom in SSA & resident in London the fertility differential=mean no. of children at diagnosis divided by expected no. 
of children gathered by the general Household Survey =0.46/2.51
2 For example, for women bom in SSA & resident in London the overall fertility differential=(0.18*0.34*0.70) + (0.90*0.34*0.30) + (1.0*0.66). 
It was assumed women who did not want children after their HIV diagnosis (34% of cohort of women) would have the reduced fertility 
differential as estimated in the table according to number of children at time of diagnosis and that women who said HIV had not affected their 
decisions (66% of cohort of women) had a fertility differential of 1.0
3 Data analysed from question 26 of the questionnaire survey
4 Data based on proportion of women with <2 children or 2 or more children interviewed in the questionnaire survey. These results were similar 
to data obtained from new HIV diagnoses (CDSC reports) and reports of HIV infected pregnant women (ICH reports).
5 Mean number of children at diagnosis amongst HIV positive women participating in the questionnaire survey
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7.4.5: Estimate of the number of HIV-positive women who had completed family size 
at the time of their diagnosis
Results from chapter 6 indicated that 17% of African women and 13% of other 
women had completed their family at the time of their HIV diagnosis. These 
proportions were therefore applied to SOPHID data to estimate overall number of 
women aged 15-44 who would not appear in neonatal surveys because they had 
already had their children at the time of their HIV diagnosis. Newly diagnosed HTV 
infection reports received at CDSC were assessed to determine what proportion of 
women had had 2 or more children at time of diagnosis and whether this had changed 
over time. Results showed that between 2000-2002 16% of African women and 11% 
of other women had had 2 or more children and that this had not changed during the 
time period studied, which is in line with our estimates used from the questionnaire 
survey.
7.4.6: Estimate of the number of HIV-positive women not wanting children 
Results from chapter 6 showed that 1.8% of African women and 4.8% of other 
women never wanted children, regardless of their HIV status. These proportions were 
applied to SOPHID data to estimate number of women aged 15-44 who would not 
appear in neonatal surveys. The number of undiagnosed women was estimated using 
the proportions diagnosed presented in Table 7.2.
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7.5: Results: Number of HIV infections in women in the general population
Estimates of numbers of infections amongst women are presented in Table 7.4. More 
detailed results are presented separately in Appendix G including a working example 
of how the data for the model were generated. Ninety-five percent confidence 
intervals are provided for totals which allow for uncertainty regarding the neonatal 
seroprevalence. Uncertainties regarding assumptions made throughout the modeling 
analyses are explored in a sensitivity analysis.
In 2002, an estimated 16,120 (15,790-16,450) women were living with HIV, of whom 
6210 (38%) were unaware of their infection. Numbers of infections have risen 2.5 
fold between 1997 and 2002, and this rise was most marked in diagnosed infections. 
The rise in numbers of infections likely reflect improvements in HTV testing services, 
increased awareness about the benefits of getting tested, continuing migration 
between countries with high HIV prevalence and the UK and the decline in HIV- 
associated deaths since the introduction of more effective therapies.
The age-specific estimated number of infections among women in GB for 2002 are 
shown in Table 7.5. It was assumed the age distribution was the same for diagnosed 
as well as undiagnosed infection. The majority of infections were amongst women 
aged 25-34 years. Few women aged under 20 were infected with HIV, whilst there is 
an increasing prevalence of infected women aged above 45 years . Older women with 
HIV is having an increasing importance over time, as survival in women increases 
with advancements in therapies.
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The model has provided a point estimate of number of infections amongst women in a 
given year using neonatal seroprevalence data. Deaths and HIV-infected women 
emigrating from the UK has not therefore been included in the figures as these women 
would have been unlikely to have had a live birth in that year. Whilst uncertainty 
remains about the level of emigration due to lack of available information, deaths 
among HIV infected women is now small in the era of HAART. The effect of these 
issues is addressed in chapter 8.
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Table 7.4: Overall numbers of infections amongst women in GB*
1997 2000 2001 2002
Diagnosed 2690 6730 7910 9910
London Women born in SSA 920 2690 3250 4250
London Other 860 1320 1690 1690
Rest GB Women born in SSA 230 1460 1510 2180
Rest GB Other 680 1260 1460 1790
Undiagnosed 2890 4720 5510 6210
London Women born in SSA 1560 1680 2010 1940
London Other 560 640 830 860
Rest GB Women born in SSA 600 920 930 1300
Rest GB Other 1170 1490 1740 2110
Total 6580
(6480-6660)
11,460
(11,120-11,800)
13,420
(12,930-13,890)
16,120
(15,790-16,450)
*A11 figures rounded to nearest 10
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Table 7.5: Number of HIV infections amongst women by age category: 2002*
Women born in SSA Women born elsewhere Total
Diagnosed (%) Undiagnosed Diagnosed (%) Undiagnosed
<20 120 (1.9) 50 30 (0.9) 20 220
20-24 710 (11.0) 310 580 (16.7) 430 2030
25-29 2070 (32.2) 920 670 (19.3) 500 4160
30-34 2020 (31.4) 890 1200 (34.4) 890 5000
35-39 880 (13.7) 390 550 (15.8) 410 2230
40-44 90 (1.4) 40 30 (0.9) 20 180
45+ 540 (8.4) 640 420 (12.1) 700 2300
Total 6430 (100) 3240 3480 (100) 2970 16,120
*Figures rounded to the nearest 10.
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7.6: Sensitivity analyses
Sensitivity analyses were undertaken in areas of uncertainty surrounding the model to test 
the robustness of assumptions and to look at the effect of changes on prevalence estimates. 
Three different scenarios were considered:
1. Effect of changes in fertility differential between HTV-positive & HIV-negative 
women
2. Effect of changes in the estimate of proportions of infections diagnosed
3. Effect of changes in migration patterns on HIV prevalence estimates
7.6.1: Effect of changes in the fertility differential between HIV positive and HIV negative 
women
Fertility information used in the model was predominantly gathered as part of the 
questionnaire study, described and analysed in chapter 6 of this thesis. Whilst it was clear 
an HIV diagnosis had had an effect on intentional fertility decisions, assumptions were 
made in order to quantify the fertility differential between HTV-positive and HIV-negative 
women. A third of women stated that an HIV diagnosis had made them not want children 
anymore. Among the women who stated that their HIV diagnosis had had no effect on 
their childbearing intentions, at the time of the survey many HTV-positive women did not 
have a partner, many women were in a discordant relationship and uncertainties remained 
about asylum status. On the other hand it was clear from the questionnaire that recent 
improvements in HIV management had altered women’s desire for children in that they 
now wanted more children which may in turn complicate the interpretation of trends in 
neonatal seroprevalence.
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Three different scenarios were considered to explore uncertainty surrounding fertility 
amongst HIV-positive women. The first scenario (A) assumed that all HTV-positive 
women stop having children once they have had an HIV diagnosis, thereby applying the 
reduced fertility differentials shown in Table 7.3 to all women with an HTV diagnosis. The 
second scenario (B) assumed that an HIV diagnosis would not have any effect on 
subsequent childbearing, and hence all HTV-positive women would have a fertility 
differential of 1.0. The final scenario (C) considered women who had changed their 
fertility decisions in light of improvements in HTV management (14%) whereby these 
women were assumed to revert to having a fertility differential of 1.0.
The neonatal seroprevalence data for 2002 were adjusted assuming the above scenarios, 
and results are presented in Figure 7.3. If it is assumed all HIV-positive women no longer 
have children once an HTV diagnosis has been made (A) and a necessary adjustment is 
made for this, the number of infections estimated in the population would be 23,600. This 
is 47% higher than the 16,120 infections predicted. If however HIV-positive women are 
assumed not to be affected by their HIV status (B) and no adjustment is made to the 
prevalence data, 12,200 women would be estimated to be living with HIV in GB in 2002. 
This is an underestimate of 32% of that predicted by the model. Allowing for changes in 
response to improvements in HIV management (C) made a more modest impact on the 
difference in the estimated number of infections (13,720). This suggests that 
improvements in treatments and interventions in HIV management have probably had 
limited effect on the increasing seroprevalence seen amongst pregnant women since 1997 
and that this rise is more likely to be attributed to changes in migrational patterns.
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An additional factor to consider were women (16%) who stated in the questionnaire 
survey that an HIV diagnosis had made them want children sooner. Whilst these women 
would not have more children overall and therefore would not affect numbers of infections 
in a given year, they may affect trends as they would have their children over a shorter 
time span. This effect was not thought to be great and not therefore included in the 
sensitivity analyses.
Figure 7.3: Effect of changes in the fertility differential between HIV-positive 
and HIV-negative women on numbers of HIV infections
I
2 5 0 0 0  
20000  
1 5 0 0 0  -I
*5
10 000
5 0 0 0
B
S c e n a r io
-----------Number of infections predicted in 2002
7.6.2: Effect o f changes in the proportion o f  infections diagnosed
Estimating the proportion of infections diagnosed in a population is difficult without 
undertaking a population-based serosurvey. In this analysis, the proportion of infections 
diagnosed was assumed to be the same for all women as for women proceeding to birth 
who had already had their infection diagnosed regardless of the current pregnancy. 
However, this approach assumes women who become pregnant are representative of all 
women and women who do not get pregnant are excluded. An accurate estimate of
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proportion of infections diagnosed is important as that is the proportion of HIV-positive 
women to whom a fertility differential is applied to.
We originally assumed 32-52% of infections were diagnosed, dependent on country of 
birth and area of residence, but yearly fluctuations in this estimation were apparent. The 
effect of changes in the proportions of infections diagnosed was explored as part of the 
sensitivity analysis. If one allows in the model for fewer HIV-positive women being 
diagnosed (for example 25%) and thereby a lower proportion of women altering their 
childbearing decisions due to knowledge of their HIV status, the estimated number of 
infections decrease from 16,120 to 13,810 (Figure 7.4). However, if one allows in the 
model for more women being diagnosed (for example 65%) and hence a higher proportion 
of women being affected by the fertility differential, then numbers of infections increase to 
16,880. With improved HIV testing services within the UK and fluctuations in migration 
patterns, changes in the proportion of women diagnosed may alter over time and the model 
developed in this thesis should be adapted accordingly.
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Figure 7.4: Effect of changes in the proportions of infections diagnosed amongst 
HIV-positive women
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7.6.3: Effect o f changes in migration patterns on HIV prevalence estimates 
The majority of newly diagnosed HIV infections in GB are amongst women bom in sub- 
Sahara Africa, reflecting close links between Africa and the UK and the higher HIV 
prevalence rates in African countries. Updated HIV prevalence estimates have recently 
been published for Africa (15), with estimates for the overall adult population ranging 
from 1% in Western Africa to 39% in Southern Africa. The course of the HIV epidemic 
within GB has been and will in the future be dominated by what is happening in Africa.
The largest African community within the UK are women bom in Nigeria, however due to 
the low HIV prevalence rate throughout Western Africa, people originating from Nigeria 
have not featured that widely in the UK HIV epidemic to date. Instead the majority of new 
HIV infections in the UK up until the early 1990’s were associated with Uganda, a country 
with an HIV prevalence rate of 5%. More recently however the majority of new infections 
have been attributed to recent migration from Zimbabwe, a country where HIV prevalence
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is estimated to be much higher at 38%. The rise since 1997 of HTV infections in the UK 
corresponds to the rise in migration patterns of people from Zimbabwe to the UK.
Understanding trends in HIV infection therefore requires an understanding of what is 
happening in Africa and migration patterns and changes in migration patterns between 
Africa and the UK. It will also be important to have knowledge of age structure and 
fertility history amongst women migrating to the UK. Plausibly, a new wave of women 
could arrive who have not had any previous children and who are diagnosed earlier in their 
fertility life. This group of women may then choose not to have any children and never 
appear in British neonatal surveys. Alternatively, if improvements in treatments continue, 
an HTV diagnosis may cease to affect fertility plans and the importance of applying a 
fertility differential to neonatal seroprevalence data will diminish although ethnicity would 
still need to be adjusted for.
The effect on HTV estimates of a high proportion of women from Africa arriving in GB in 
the middle of their childbearing years, having previously had live births outside GB which 
would not have appeared in the British neonatal surveys was explored. It has earlier been 
shown that approximately 70% of women bom in SSA had less than 2 children at time of 
diagnosis. Of these women, 38% of women had had no children at all and therefore could 
potentially have their full childbearing years in GB, and thus would not affect prevalence 
results. Forty five percent of women had had 1 child outside GB at diagnosis, thereby 
reducing their expected number of children (or alternatively live births which would have 
been picked up by neonatal screening) in GB from 2.5 to 1.5 and having a fertility ratio of 
0.6 compared to other women. Finally sixteen percent of women had had 2 children 
outside GB at diagnosis, thereby reducing their expected number of children in GB from
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2.5 to 0.5 and having a fertility ratio compared to other women of 0.2. The overall effect 
on the fertility ratio for women bom in SSA would be 0.69 ((0.45*0.6) + (0.16*0.2) + 
0.38). An additional application of this ratio to seroprevalence data amongst women bom 
in SSA and resident in London would change the estimated number of infections form 
3250 to 4710. This analysis confirms the importance of the inclusion of parity in the final 
model and highlights the necessity of monitoring fertility patterns in women migrating to 
GB and women newly diagnosed with HIV infection.
7.7: Validation of model
The ideal way to validate the model described in this chapter would be to compare the 
HTV estimates amongst women, with female prevalence from a population prevalence 
survey (71- 72). However, population surveys are not available for Great Britain.
A different approach of validating the model is to compare the prevalence estimates with 
the estimated number of diagnosed women from SOPHID, which collects data on numbers 
of HIV infected persons receiving HIV-related care in a given year.
The estimated number of diagnosed infections generated in this thesis was higher than that 
estimated by SOPHID, particularly for women resident in London (Table 7.6). There are 
two possible explanations for the discrepancy. SOPHID data refer to HTV infections 
amongst black Africans whereas the data in this thesis is for women bom in SSA. This 
discrepancy is likely to be minimal as the majority (98.5%) of HTV-positive black African 
women were bom in SSA and few (1%) of HIV-positive women bom in SSA were not of 
black African ethnicity (ref unpublished data, CDSC). The second and more likely 
explanation for the difference is that it has been acknowledged that SOPHID data 
underestimates numbers of diagnosed prevalent infections for women by approximately
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13% due to under-reporting (134). After this underestimate to the SOPHID total has been 
accounted for in this analysis, the total number of diagnosed infections estimated by the 2 
methods were comparable.
Table 7.6: Comparison of number of diagnosed prevalent infections derived 
from SOPHID and the Model for all women in GB: 2002
SOPHID Adjusted Model
____________________________________ SOPHID2
London Bom in SSA1 3730 4210
Other 1330 1500
Rest GB Bom in SSA1 2130 2410
Other 1590 1800
Total_____________________________ 8780__________9920
1 SOPHID data relates to African women
2 Data adjusted for under-reporting and diagnosed HIV-positive persons not accessing 
HIV-related care
Whilst it is relatively easy to validate diagnosed HIV estimates, validating undiagnosed 
estimates is more problematic as less is known about the spread of undiagnosed HIV 
infection in GB. Compared to undiagnosed estimates produced by the direct method, the 
number of infected women produced by our approach was higher (6210 compared to 
4600) (Table 7.7). The direct approach uses neonatal and STD clinic attenders 
seroprevalence rates applied to population data to estimate numbers of infections amongst 
women. The method used in this thesis uses neonatal seroprevalence rates and adjusts 
these rates for a fertility differential between HIV positive women and all women and has 
accounted for women who would not appear in neonatal surveys because they were not at 
risk of pregnancy.
4250
1690
2180
1790
9910
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Table 7.7: Comparison of undiagnosed estimates with HPA Direct estimates for
2002
Direct estimates Model Estimates
Diagnosed Undiagnosed Diagnosed Undiagnosed
Born in SSA 6800 2300 6430 3240
Other 3000 2300 3480 2970
Total 9800 4600 9910 6210
In summary, the 16,120 (15,790-16,450) HTV infections estimated amongst women in 
2002 using the methodology developed in this thesis appears a plausible estimate and can 
be used as an improved approach to the direct method when estimating HIV amongst 
women. Results from sensitivity analyses indicated that the number of infections could be 
as high as 23,000 if the fertility differential used in this thesis was underestimated. In order 
to be valid, estimates need to be repeated on a yearly basis in order to accommodate any 
changes in the HIV epidemic within GB. The adaptability of this method to other 
countries, however, would depend on the availability of HIV surveillance data, population 
data and information regarding fertility amongst the HIV-positive population.
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7.8: Key points
1. A model was developed to quantify and interpret the HIV epidemic amongst 
women in GB. This model provided a point prevalence estimate of HIV amongst 
women, using neonatal seroprevalence and other data sources. It was estimated that 
approximately 16,000 women were living with HIV in GB in 2002. This is a 
significant rise since 1997, when an estimated 6,500 women were living with HIV
2. Adjustment of neonatal seroprevalence data for a fertility differential between 
HTV- positive and HTV-negative women had a substantial effect on the unadjusted 
prevalence. For example, without adjustment an estimated 12,200 persons were 
HIV infected in 2002, increasing to 16,000 once an adjustment factor had been 
applied.
3. The estimates produced by the model were comparable with previous estimates of 
diagnosed infection provided by SOPHID. The number of undiagnosed infections 
estimated by the model was, however, more than that previously estimated using a 
direct approach (6,200 compared with 4,600). This discrepancy is due to improved 
methodology in this thesis.
4. HTV estimates were sensitive to the following factors: proportion of infections 
estimated to be diagnosed (13,810 -  16,880), fertility differential between HIV- 
positive and HIV-negative women (13,000 -  23,000) and changes in migration 
patterns between GB and countries with high HIV prevalence rates.
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Chapter 8: Extrapolation of neonatal seroprevalence data to the general female
population in GB: conclusion and way forward
8.1: Summary of main findings
Neonatal seroprevalence data has been extensively collected throughout GB since the 
early 1990’s (50). Whether or not this data can be used directly to estimate numbers of 
HIV infections among all women depends on fertility being independent of HIV status (7). 
There are a number of reasons why this is unlikely to be the case and whilst any 
associations between fertility and HIV do not invalidate the production of HIV estimates, 
they do indicate that extrapolations of neonatal seroprevalence to all women should be 
cautious. The differences between neonatal and population seroprevalence could be 
relatively small, however the denominators to which seroprevalence rates are applied are 
extremely large, and a small difference in HTV seroprevalence between neonates and the 
general female population could result in a substantial underestimate or overestimate of 
the total numbers infected. It is therefore important to develop an approach of using 
neonatal seroprevalence data which incorporates adjustment factors for differential fertility 
between persons at varying HTV risk.
Whilst information was available prior to this project on HIV levels amongst neonates, 
little was known about reproductive-decision making amongst HIV-positive women in GB 
other than the apparent decline in live births after diagnosis (68,92-94). As this is 
important information required for the extrapolation of neonatal seroprevalence data to the 
general population, this area of research was addressed in detail in a cross-sectional 
questionnaire study which provided a unique opportunity to ask HIV-positive women 
about their desire for children and whether their decisions had been affected by their HIV 
diagnosis. The timing of this study was opportune in relation to recent changes in the
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management of HIV, for example advancements in HIV therapies (152), a reduction in 
vertical transmission rates (34-35) and initiatives to improve HIV diagnosis (46), factors 
which could be expected to influence a woman’s desire for children. Analyses throughout 
this thesis also took advantage of multiple existing data sources in various ways, including 
improved demographic data collected with neonatal seroprevalence results, recently 
published 2001 census of population data and fertility history information collected on 
new diagnosis reports amongst HIV positive women.
The factors identified which would influence the usage of neonatal seroprevalence data in 
estimating numbers of HTV infections amongst all women are shown in Table 8.1. 
Adjustment for these factors produced plausible numbers of HTV infections amongst 
women which were higher than previously estimated in GB with an approach not adjusting 
neonatal data for differential fertility and HIV risk. Individually, each factor described in 
Table 8.1 was shown to have a different effect on the numbers of infections derived and it 
should not therefore be assumed that seroprevalence among neonates will universally 
underestimate or overestimate population seroprevalence. The data here indicate that in 
GB either could occur under plausible conditions. For example, one of the main factors 
associated with differing fertility and HIV risk was whether or not the woman had been 
bom in SSA. Failure to adjust for this factor would lead to an overestimate of about 30% 
in numbers of infections amongst women if using neonatal seroprevalence data. On the 
other hand, survey results revealed that many women irrespective of ethnicity may 
experience a reduction in the number of live births after diagnosis, as has been shown 
previously, leading to an underestimate of infections (68,92-94). Whereas it has not been 
possible in other studies to investigate whether this decline is explained by knowledge of 
HIV status or other factors, in the study presented in this thesis for the one- third of HIV-
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positive women who decide they did not want children after their HIV diagnosis, this was 
most strongly dependent on number of children the woman had already had at time of 
diagnosis. Results from the questionnaire survey highlighted the fact that half the women 
who initially did not want children after their diagnosis went on to change their mind in 
light of improvements in HIV management, thus limiting the overall impact of knowledge 
of HIV status on future fertility decisions. Other analyses demonstrated that many HIV 
positive women have already had their children at time of diagnosis, would never have 
wanted children regardless of their HIV status or had aged out of their childbearing years 
and would therefore not appear in neonatal surveys. These factors were adjusted for in the 
final model.
Table 8.1: Potential biases in using HIV prevalence amongst neonates as an indicator 
of general female population prevalence
Factor likely to cause bias Effect on 
HIV risk
Effect on 
fertility
Probable effect on 
prevalence in all women
Included 
in model
Bom in SSA + + Overestimate Yes
Known HIV-positive status N/A - Underestimate Yes
Urban area of residence + + or-* Probably Overestimate Yes
Older (>=25) women + + Overestimate Yes
<2 children at HIV diagnosis NK + or - Overestimate or 
underestimate
Yes
Married/Co-habit women NK + Overestimate or 
underestimate
No
History of injecting drug use + - Negligible effect No
+ = Increased risk 
- = Decreased risk 
* Depending on country of birth
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Another pattern of results which emerged from the analyses using routine population data 
sources was the more subtle importance of area of residence and age group, factors which 
would probably lead to an overestimate in number of infections if not accounted for when 
extrapolating neonatal seroprevalence data. Both women resident in London and older 
women were shown to have higher HIV infection rates and higher fertility patterns than 
other women. The increased HIV prevalence in London was predominantly attributed to 
the higher concentration of women bora in SSA resident in that area, although HIV 
prevalence rates were still higher in London after adjustment for mother’s country o f birth.
In order to keep the model developed in this thesis as simple as possible, only factors 
considered easily quantifiable were incorporated. Two factors shown to be related to 
fertility and/or HTV risk but not included in the model were history of injecting drug use 
and partnership status. The biases associated with differential fertility amongst drug users 
have not previously been considered. Whilst fertility data were sparse, results indicated 
that IDUs were less likely to have a previous live birth than other women, more likely to 
have had a previous termination and more likely to have had a subsequent pregnancy after 
HIV diagnosis. However, analyses also indicated that drug users constituted a relatively 
small proportion of the British population and their HIV risk was relatively low compared 
to women bora in SSA. Any bias associated with this group in estimating general 
population prevalence would therefore be limited.
Although partnership status was associated with desire for children and changes in desire 
in relation to improvements in HIV management, limited data were available on 
partnership and HIV risk and for this reason partnership was not quantified in the final 
model. Other studies have looked at the effect of partnership status amongst HIV-positive
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women on fertility decisions in detail and have found the relationship to be complex. Sherr 
et al found that partners, when present in clinic, were invariably involved and consulted in 
childbearing decisions (127). Kline et al found that it was the partner’s desire for children 
that represented the determining factor for childbearing and that the respondents own 
desire for children had no direct effect (105). In our study, whilst partnership status played 
an important role in desire for children, partner’s HIV status appeared not to be a 
significant factor. Over a third of women in a partnership were in a discordant relationship 
and in addition a substantial minority (16%) of women were unaware of their partner’s 
HTV status, which could be suggestive of a lack of intimacy and possibly short duration of 
relationship.
Previous studies have found health status of the mother to be an important factor when 
making decisions about childbearing (106), although this was not the case in our survey. 
This was not surprising since most HIV-positive women are now less at risk of an AIDS- 
defining illness due to the availability of treatments than was previously the case. As 
expected, HIV-positive women of sub-Saharan African origin had had more pregnancies 
than other HIV-positive women at time of diagnosis. This finding was concordant with 
earlier analyses in the thesis using routinely available population data sources which 
showed that in GB fertility was higher in women bom in SSA after adjusting for age. Race 
was not, however, a predictor for desire for children after diagnosis, a consistent finding 
from a previous study (125). This suggests that whilst women of African origin have more 
pregnancies than other women, the effect of an HIV diagnosis is similar for all women 
regardless of race.
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Another question of interest throughout this thesis was the interpretation of the increase in 
neonatal HTV seroprevalence which has been recorded in all parts of GB since 1997 (30). 
It was unclear whether this rise corresponded to an increase in HIV in the general female 
population, or whether fertility decisions amongst HIV-infected women had changed due 
to improvements in the management of HTV infection, in which case the rise in prevalence 
could only be a temporary effect. Nearly half of the women who no longer wanted a child 
after their HIV diagnosis changed their mind once they had become aware of the 
improvements made in HIV management, confirming suggestions made by others of a 
relationship between altering fertility decisions and advancements in the natural history of 
HTV (99-100). Whilst women with less than two children were more likely to not want 
children after their HIV diagnosis, they were more likely to have changed their mind about 
wanting more children due to improvements in HTV management. This suggests that 
women who have not completed their family size at time of diagnosis are now more 
hopeful in the light of advancements in HIV therapies.
The overall proportion of women who did not want children after diagnosis but changed 
their mind in response to improvements in HIV management was modest (14% of the total 
cohort of women interviewed). Further analyses also indicated that women who did 
change their minds had not had significantly more pregnancies overall after their HIV 
diagnosis than other women. It was therefore considered unlikely that changes in 
childbearing intentions would have greatly impacted on the doubling of neonatal 
seroprevalence observed between 1997 and 2002 and that other factors such as migrational 
changes between GB and countries of high HIV prevalence were more likely to account 
for this rise.
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Whilst in the survey many women reported to desire children, only 16% of them had had a 
pregnancy subsequent to diagnosis, thereby suggesting a discrepancy between desire and 
achievement. The questionnaire did not go into details about whether or not the woman 
was currently trying to conceive, so whilst she may have said she wants more children, she 
may not have currently been trying to achieve this. Secondly, a high proportion of the 
women included in the study had only been diagnosed within the previous 2 years and had 
therefore not yet been given a reasonable chance to become pregnant. However, it was 
also clear from the qualitative data collected in the survey that barriers were present which 
made childbearing difficult for this group of women. Many women had no partner and 
many of those who did have a partner were in a discordant relationship. A 
disproportionately large segment of those women affected by HIV were from minority 
groups, often financially disadvantaged with uncertainties regarding their asylum status in 
the UK. A study in England investigating the maternity experiences o f asylum seekers 
(regardless of HIV status) found that many of the women in emergency accommodation 
were going hungry, no formula milk was being provided for the babies and little 
information about services and support was being given to them (153). A descriptive study 
of HIV positive African women living in London found that most had experienced very 
poor housing and financial conditions, many had been dependent on the National Asylum 
Support Service and almost half had been diagnosed because of ill health or the suspicions 
of a clinician (154). It is clear from these studies and the survey carried out in this thesis 
that whilst many HIV-positive women desire children, the contemplation of pregnancy is 
very difficult.
Nevertheless, results from separate analyses presented in this thesis using a national data 
source which included all reported diagnosed HIV pregnant women in GB but no
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qualitative information on decision-making did indicate that the proportion of HTV 
positive women with a subsequent live birth after their diagnosis has increased in recent 
years (24). This finding is consistent with observations from other studies in America (99- 
100) and Europe (155). The observed higher likelihood of having a subsequent birth to an 
HTV diagnosis during the era of HAART may be the result of a number of factors. 
Increased survival times for women with HIV as well as delayed progression to AIDS may 
result in greater opportunities to become pregnant. Alternatively, more women may be 
choosing pregnancy because of the lower risk of having a child with HIV infection. The 
proportion of pregnancies amongst women newly diagnosed during antenatal care ending 
in a termination has also declined dramatically from 2000 onwards, again suggesting that 
women diagnosed in the HAART era are increasingly willing to carry pregnancies to term.
In summary, many factors of differing influence were found to affect the validity of using 
neonatal seroprevalence data to estimate numbers of infections amongst the general 
population. The overall effect of these factors was an underestimate in the total numbers of 
infections amongst women. Whether or not the woman had been bom in Africa was shown 
to be a bias associated with extrapolating neonatal seroprevalence data to population data 
and one which was easily adjusted for using population and surveillance data sources. The 
influence of differential fertility between HIV-positive and HIV-negative women on the 
HIV estimates was also considered important, although the bias associated with this may 
have been reduced by the fact that of the third of women who initially did not want a child 
after diagnosis, about half of these women later changed their mind in light of the 
improvements in HIV management.
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8.2: Implications of findings
Overall, the results presented in this thesis suggest that data provided by seroprevalence 
studies amongst newborns in an attempt to estimate HIV prevalence amongst the general 
female population are more likely to have under-, rather than over- estimated the true 
number of HIV infections and that more accurate results could be generated using the 
method of adjustment described in this thesis. Rational decisions about health strategies 
and interventions need to be based on reliable and timely knowledge of the distribution of 
HIV infection, thereby necessitating the need for convincing estimates of HIV and the 
associated demographic, social and economic costs. During the time of this project the 
National Strategy for Health stated as one of its objectives the reduction in the numbers of 
undiagnosed HIV infections in the country (156). Data generated by this project could be 
used to monitor this objective amongst women, especially as estimates of undiagnosed 
infections could be repeated on an annual basis using updated surveillance data. In 
addition, a separate report by the Department of Health ‘Getting ahead of the curve’, 
which detailed a strategy to combat infectious diseases, emphasised the need for 
improving surveillance data in order that it gives a complete picture of the size and nature 
of the threat of infection (157). Again, the methodology developed in this thesis is in line 
with this objective.
Since it has been shown that neonatal seroprevalence is likely to underestimate HIV 
infection amongst women, alternative population groups could be considered , for example 
extension of surveillance programmes to include other groups of women, particularly 
those who do not become pregnant. Hospital patients have been used previously, although 
the absence of risk information with specimens has made interpretation of results 
problematic and these surveys have now been discontinued
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(23, 158). HIV screening results from blood donations have also been suggested as a 
useful tool; however, results would be severely biased due to the difficultly in accessing 
population groups at highest risk of HIV coupled with active discouragement of people 
who perceive themselves to be at risk to donate blood. Therefore, usage of neonatal data 
remains the best approach to estimating HTV amongst women.
Results from this project also demonstrated that women with HIV do not rule out 
childbirth, an important consideration for health care professionals who treat HIV-positive 
women. Our finding that approximately 40% of diagnosed HIV-positive women desired 
children translates into over 3,500 positive women in GB who potentially will have a live 
birth in the next two years or so. In addition, many women with undiagnosed HTV 
infection are becoming pregnant and are increasingly likely to be diagnosed during 
antenatal care (46). HTV-positive women who desire children have numerous service 
needs in addition to the medical care needed for their own infection (105,125,127). To 
help make informed choices, family planning counselling and children of infected parents 
may need social service support (159). The desire for children also has implications for the 
transmission of HIV to partners and newborns. In the questionnaire survey a third of the 
HIV positive women who wanted children and were in a partnership had a partner who 
was HIV-negative or of unknown status. Women who give birth will require follow-up of 
the newborn until maternal antibodies disappear and HIV status can be ascertained (40). 
Whilst guidelines exist for the management of HIV infection in pregnant women (40), 
there are no established guidelines for defining access to fertility care for individuals 
infected with HIV and only a handful of in vitro fertilisation units in GB are prepared to 
treat couples if one or other partner tests positive (160). In the past the primary concern of 
fertility clinics has been the life expectancy of the infected parent, this is less justifiable in
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light of HAART and may now need to be re-considered, especially as the number of HIV- 
positive women is rising rapidly, the majority of women are within child-bearing age and 
without AIDS-related symptoms.
8.3: Limitations of data sources and analyses
Whilst the methodology developed in this thesis has undoubtedly improved HIV estimates 
among women, the results can only be as good as the data sources used and the 
appropriateness of the assumptions made. This section discusses the potential limitations 
of results and suggests areas for which improved information collection would benefit the 
reliability of the estimates.
8.3.1: Availability and Compatibility of information gathered from surveillance systems 
A summary of the demographic information available from each of the routine 
surveillance data sources used in the analyses is shown in Table 8.2. Surveillance data 
always have limitations, for example records where information is missing. Ethnicity, 
country of birth and, in particular parity, was not reported or requested in a number of 
instances and it is difficult to know what effect this unavailability of information had on 
the overall results.
Information was derived from a number of different sources and the scope of analyses 
may have been limited by some issues of incompatibility between availability of ethnicity 
and country of birth information, overlapping but not identical categories (Table 8.2). The 
size of the Black African population in GB in 2002 was nearly 480,000 whilst the number 
of women bom in SSA in GB was over 740,000. This discrepancy exists because many 
Africans were bom in GB and many women bom in SSA were of White or Asian ethnicity 
(census 2001 unpublished data).
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When estimating numbers of HIV infections it is crucial to determine HIV prevalence 
rates by the correct risk factor, to apply these rates to the most appropriate population 
denominator and for definitions of population sub-groups to be consistent across the 
different data sources. If not, the number of infections may be over or under-estimated. 
Currently in GB, women bom in SSA have a relatively high HIV prevalence whereas 
prevalence in the UK-bom black African community is low (55). This data supports other 
evidence which shows the majority o f HIV infection in women in GB is associated with 
time spent in Africa (26). The model developed in this thesis therefore categorised women 
according to their country of birth, a data item collected in all data sources except for the 
SOPHID survey. However, if appreciable changes in the HTV epidemic were to occur as 
the numbers of infections amongst migrants in GB continues to increase, ethnicity may 
become increasingly important. Unfortunately, this is a data item not collected in 
sufficient detail in the neonatal seroprevalence programme. Attempts have been made to 
improve capture of mother's ethnicity information with neonatal samples, although to date 
this has proved problematic with a large number of records having missing information 
(55).
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Table 8.2: Summary of ethnicity, country of birth and parity information available through routine surveillance systems
Survey Country of 
birth data
Ethnicity data Parity data Summary
Unlinked Anonymous 
neonatal seroprevalence 
survey
Collected for 3 
regions in GB
Limited collection of maternal 
ethnicity in 1 region in GB 
between 1997 and 2001, 
affecting 56,000/640,000 
births annually (55). Collection 
of child’s ethnicity in 3 regions 
inGB
Not collected Little demographic data collected outside 
London (29)
In regions which collect country of birth, 6% 
of samples have missing information (29)
SOPHID: Survey of 
Prevalent Diagnosed 
HIV Infections
Not collected Requested for all Not collected Missing ethnicity information on 4% of 
reports (Unpublished data, CDSC)
New HIV Diagnoses Requested for 
all
Requested for all Collected for 
2000-2002
24% of reports have missing information on 
parity, 4% of reports miss country of birth and 
1% of reports miss ethnicity (Unpublished 
data, CDSC)
NSHPC: Reports of 
HIV Infected Pregnant 
Women
Requested for 
all
Requested for all Requested for all Overall 31% of reports have missing 
information on parity, 18% of reports miss 
country of birth and 9% of reports miss 
ethnicity (Unpublished data, ICH)
8.3.2: Estimate of diagnosis rates amongst HIV-infected women 
Results from sensitivity analyses in chapter 7 demonstrated that HIV estimates were 
sensitive to the proportion of infections assumed to be diagnosed. For example, if 
fewer HIV-positive women had been diagnosed than allowed in the model and 
thereby a lower proportion of women would have altered their childbearing decisions 
due to knowledge of their HIV status, the number of infections among all women 
would have been overestimated. The method developed in this thesis assumed that the 
probability of diagnosis in the whole female population was represented by the 
NSHPC data on numbers of diagnoses prior to the pregnancy. There are two reasons 
why this assumption may have under-estimated the true probability of diagnosis 
within the female population. Firstly, analyses from the survey showed that some 
diagnosed HIV-positive women no longer desired children after their diagnosis. 
Secondly, this approach fails to take into account the fact that women who had been 
pregnant in the previous year would have a higher probability of being diagnosed as a 
result of prenatal screening but a lower probability of being pregnant and thus 
reported in the NSHPC for the current year. The numbers of diagnosed infections 
estimated by the model did in fact correlate well with information deduced from other 
surveillance data sources. However, if alternative approaches to estimating the 
proportion of infections diagnosed were needed, the ideal source of information 
would be population-based serosurveys which included women who do not get 
pregnant. Information on whether or not the sample had been taken from a known 
infected person would also need to be collected, making this approach extremely 
difficult.
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8.3.3: Representativeness of newborns included in the neonatal seroprevalence 
surveys
The unlinked anonymous neonatal survey is assumed to be population-based as it 
includes residual samples taken from virtually all neonates in GB who receive routine 
metabolic screening in the first week of life. It is reasonable to assume samples in the 
UA survey are representative of all samples taken from newborns as the objection rate 
for UA surveillance and the number of samples where insufficient residual blood is 
available for HIV testing after routine tests have been completed is extremely low 
(<1%) (23). However, selective under-coverage of babies bom to women of black 
African ethnicity by routine neonatal screening has been suggested. The ratio of 
probability of black African women being included in neonatal screening in South 
East London to the ratio of all other women being included was found to be 0.97 (63). 
This could have implications for the UA surveys since HIV prevalence is higher 
among African women in GB suggesting that seroprevalence surveys may 
underestimate female population prevalence due to an under-representation of women 
at high risk of HIV infection. Further analyses by Hutchinson et al found that despite 
some selective under-representation, the results of the neonatal seroprevalence survey 
identified prevalence among childbearing women with a good degree of accuracy 
(62). These analyses were undertaken in 1996 and it is not certain whether any 
important changes have occurred since this research was undertaken. The recent 
introduction of assigning NHS numbers at birth and the continued enhancement of 
child health systems throughout GB may facilitate more research in this area. Birth 
registration records, which contain information about mother’s country of birth, could 
be linked to neonatal laboratory records using the unique NHS number with a high
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degree of accuracy. This would enable identification of babies who have not 
undergone neonatal screening.
8.3.4: Generalisabilitv of results from HIV positive women included in the cross- 
sectional questionnaire survey to all HIV positive women
The generalisability of results from the questionnaire study to the HIV-positive 
population at large depends on how representative the study cases were of all HIV- 
positive women in GB. A comparison of HIV positive women participating in the 
survey with all diagnosed prevalent HTV infections amongst women in England and 
Wales showed similar age distributions in both groups of women. As child-bearing is 
strongly related to age, this is an important finding when studying fertility decisions. 
However, it is known that a proportion of HIV positive women are not in HIV-related 
care (estimated at 5%) (134) and these women would therefore not have been sampled 
as part of the questionnaire survey. All the women in the study were outpatients and 
thus the views of severely ill women would not have been reflected in this study 
either.
It is also important to ensure that the HIV positive women in the questionnaire survey 
were representative of the population for whom HIV estimates are to be derived. For 
example, pregnant women would not be suitable as a source of fertility data as they 
would exclude infertile women. One concern was that the women participating in the 
questionnaire survey would be biased towards women who have previously been 
pregnant, as they are more likely to have been diagnosed following an HIV test as part 
of their antenatal care. Whilst this may have been the case, results indicated that the 
majority (70%) of women surveyed were not pregnant at the time of their diagnosis
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and would therefore have been diagnosed due to other reasons such as presence of 
HIV-related symptoms.
8.4: Future work
There are many ways analyses in this project could be developed further. This section 
discusses four different approaches: 1) Using results to estimate HIV prevalence 
amongst men, 2) Applying the model to different country settings, 3) Use of neonatal 
seroprevalence data for estimating incidence and 4) Developing the model further to 
predict and interpret changes in HIV prevalence over time.
8.4.1: Estimating HIV prevalence amongst men
The method developed in this project could be extended to estimate numbers of 
infections amongst men in the general population. This would involve generating an 
HIV male/female prevalence ratio and applying this ratio to the estimated number of 
infections amongst females. The current approach in GB (‘Direct method’) assumes 
the prevalence ratio in men is the same as in women (4-5). However, we know most 
heterosexually-acquired infections in GB are amongst Africans, that within Africa the 
prevalence ratio tends to be lower amongst men in the younger age groups and that 
variability in the ratio is dependent on individual country in Africa and severity of the 
HIV epidemic (28,161-162).
Historically, prevalence ratios in the developed world have been derived by using an 
AIDS incidence sex ratio (58). But, with the advent of new antiretroviral therapies 
few people now progress to AIDS, severely limiting the value of this method. The 
ratio of new HIV diagnoses amongst men compared to women has never been 
considered a suitable approach as the likelihood of an HIV diagnosis depends on
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perception of risk and whether or not someone has been offered an HIV test, factors 
which could differ between men and women. An alternative strategy would be to base 
an HTV prevalence ratio on knowledge of migration patterns of HIV-positive persons 
to GB and the HIV prevalence sex ratio in countries from which these persons have 
originated from. This would be the approach recommended based on results generated 
throughout this thesis, although current information on migration in GB is very 
limited.
8.4.2: Application of the model to countries outside GB to generate country-speci fic 
estimates
An additional application of this project could be to use the methodology to generate 
HTV estimates in other countries. The extrapolation from neonatal data to the adult 
population is based on assumptions that may not equally apply to all countries or at all 
times during the course of the epidemic. In GB, HTV prevalence was low and mainly 
restricted to certain risk groups such as migrants from high prevalence countries, 
about half the women were diagnosed, HIV-related treatment was readily available 
and there were low underlying patterns of fertility. The approach developed here 
would be most readily applied to other developed countries for example France with 
similar underlying HIV, migration and fertility patterns, depending on availability of 
neonatal seroprevalence data, fertility information on HIV-positive women and 
population statistics. Neonatal seroprevalence data is collected in France, however the 
usefulness of uding this data to generate estimates amongst all women in the general 
population has not been explored (personal communication, F Hammers).
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In Africa, where the epidemic is more severe and accurate HIV estimates most 
needed, fertility and HTV patterns are different to those seen in GB. The majority of 
HTV-positive women are unaware of their infection, most HIV is heterosexually 
acquired, there are high underlying patterns of fertility among the population and 
HIV-related treatment is not readily available. In the African setting it is likely that 
any fertility differential between HIV-positive and HIV-negative women is 
attributable to biological or social factors rather than conscious decision-making. 
UNAIDS and WHO in collaboration with countries in Africa have already developed 
a six-step method to estimate HIV prevalence amongst adults. These estimates have 
been based on seroprevalence data derived from antenatal clinic attenders and adjust 
for representativeness of pregnant women who attend antenatal clinics, reduced 
fertility of HTV-positive women and under-representation of rural sites in surveillance 
systems (163).
8.4.3: Estimating incidence from neonatal seroprevalence data 
Estimates of HIV incidence (“new infections”) are rare as this data is difficult and 
costly to collect. Longitudinal cohort-based studies are required and these demand 
greater resources and organisation than cross-sectional studies used to obtain HIV 
prevalence data. Laboratory techniques have been developed which can identify blood 
specimens from individuals infected with HIV within the previous 6 months (164) and 
although costly these techniques can be extended to dried blood spots collected from 
neonates (165). However, this approach is only fully validated for testing specimens 
from HIV-infected individuals with subtype B (166), and previous studies in GB have 
shown that nearly 80% of HIV-positive pregnant women are a non-B subtype, 
reflecting the acquisition of HIV throughout Africa (167). This limitation is
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unfortunate because estimates of incidence rates can provide information on recent 
levels and patterns of infection. In contrast, prevalence data frequently reflects levels 
of infections over a period of many years, providing information which is already out 
of date when it is collected.
Previous studies in France and Africa have considered whether useful estimates o f the 
incidence of infection can be derived from the readily available data on HIV 
prevalence (168-170). Incidence was estimated modelling age-specific prevalence 
data, accounting for mortality effects but not migration. The authors concluded the 
methods were useful in monitoring HTV infection and could be applied to data 
collected in other countries such as GB.
8.4.4: Predicting the course of the HIV epidemic over time
Whilst the model developed in this thesis provides a point prevalence estimate by 
year, the course of the HIV epidemic over time and the resulting estimates of 
incidence and mortality could not be evaluated. There are several factors which may 
affect the course or the description of the course of the HIV epidemic including:
1) The unknown duration of the effect of HAART in delaying death.
2) A change in the incidence of new infections in GB. Within GB the majority of new 
infections are now mainly confined to men who have sex with men, whilst 
transmission occurring within the indigenous heterosexual population is extremely 
small and stable (18). Most new HTV diagnoses among heterosexually infected 
individuals in GB are of long-standing infections acquired in Africa rather than
228
incident cases. Late diagnosis amongst Africans attending services in GB has been 
reported (149) and many of those diagnosed late have arrived in the country recently 
(26). However, this situation could change if the numbers of migrants continues to 
rise and the frequency of travel to countries with high HTV prevalence continues to 
increase.
3) A change in the movement of HIV infected people from Africa to GB. Major 
uncertainties remain over the future course of an epidemic dominated by infection 
probably acquired overseas. Knowledge of migration patterns of HIV-infected 
persons is crucial if the effect of this factor on HIV estimates in GB are to be 
interpreted with any certainty.
4) Increasing importance of non-African groups on the HIV epidemic in GB. Within 
Britain the size of population sub-groups bom abroad and HIV risk of different 
groups is a changing dynamic. The majority of all women, regardless of HIV status, 
in this thesis were classified as Rest (ie. bom outside SSA), a low HIV-risk category 
which includes an inhomogeneous group of women with a mixture of ethnicities and 
countries of birth. However the continuing influx of refugees and asylum seekers in 
GB could lead to a spread of HTV infection in groups from other areas outside of 
SSA, for example Eastern Europe (13), a region where HIV prevalence rates are 
rising sharply. The impact of the epidemic from countries such as Eastern Europe on 
migrant populations in GB should therefore be monitored closely, especially as the 
sexual mixing patterns amongst ‘new’ migrants may be different from behaviour 
patterns amongst more established migrants.
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5) The effect of a policy of dispersal of new migrants to different parts of GB may 
affect the description of the course of the epidemic (13). The national policy of 
dispersal of refugees and asylum seekers could lead to a geographical spread of HIV 
throughout the country, with subsequent rises in neonatal seroprevalence outside 
London.
8) The proportion of HIV infections diagnosed amongst women may change, for 
example as a result of the promotion of HIV testing as recommended by the National 
Strategy for Sexual Health and HTV (156). Intended campaigns to enhance levels of 
diagnosis among women may lead to an apparent fall in the Relative Inclusion Ratio 
and thus the observed neonatal seroprevalence would decline even though there was 
no change in prevalence.
Work leading on from this thesis could be developed to monitor the course of the HIV 
epidemic taking the above factors into consideration. This would involve the 
development of a Markov Chain-based model which would analyze the changes of an 
individual through categories related to progression of HIV infection (171). Such a 
model would assume that an HTV-positive individual would start in an unrecognized 
state and gradually progress to a recognized state either due to HIV testing or 
development of HIV-related symptoms. Over time, HIV-positive women considered 
to be at risk of pregnancy will irreversibly progress to the stage of no longer being at 
risk of pregnancy. A proportion of new infections will occur each year, and a 
proportion of infections will pass to AIDS and possibly death. The changes in 
numbers of HIV infections in GB due to in-migration and out-migration would also 
be an important component of the model. Figure 8.1 illustrates the structure of such a
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model, which would need to be repeated for the 4 subgroups of women used in 
chapter 7; 1) Women bom in SSA and resident in London, 2) Women bom elsewhere 
and resident in London, 3) Women bom in SSA and resident outside London, 4) 
Women bom elsewhere and resident outside London.
The parameters estimated from the model developed in chapter 7 would create the 
starting point for this further work and would be defined as follows:
DRl=No. of diagnosed women with <2 children who are at risk of pregnancy 
DR2=No. of diagnosed women with >=2 children who are at risk of pregnancy 
D>45=No. of diagnosed women older than 45 yrs who are not at risk of pregnancy 
DNR 15-44= No. of diagnosed women aged 15-44 who are not at risk of pregnancy 
UR1= No. of undiagnosed women with <2 children who are at risk of pregnancy 
UR2=No. of undiagnosed women with >=2 children who are at risk of pregnancy 
U>45=No. of undiagnosed women older than 45 yrs who are not at risk of pregnancy 
UNR 15-44= No. of undiagnosed women aged 15-44 who are not at risk of pregnancy
In addition to these estimates, the following information would be required:
Numbers of new HIV infections in a given year 
Number of HIV-related deaths in a given year 
Number of non HIV-related deaths in a given year
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Figure 8.1: Structure of a model which could be used to monitor the course of the HIV epidemic in GB over time
A
No. of undiagnosed HIV 
positive women at risk 
of pregnancy
No. of undiagnosed 
HIV positive women 
not at risk of 
pregnancy
r
No. of diagnosed HIV 
positive women not at 
risk of pregnancy
No. of diagnosed 
HIV positive 
women at risk of 
pregnancy
► New infections / immigration
Death / emigration
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The next stage would be the development of an “Allowed Transition Matrix”. This is 
a matrix based on knowledge of the course of HIV infection and the likelihood of 
moving from one stage of infection to another. Table 8.3 gives an example of this 
matrix, where 1 indicates an allowed transition. For example, in a given year a 
diagnosed woman with <2 children (DR1) can either stay in that state or move to 
diagnosed with >~2 children (DR2), diagnosed >=45 years (DNR>45) or leave due to 
migration out of the UK or death. Once a woman is HIV infected she cannot move 
back to an uninfected state and once a woman is diagnosed she cannot move back to 
an undiagnosed state.
Table 8.3: Allowed transitions matrix
DNR: UNR:
Link matrix 
Recent
HIV- DR1 DR2 D>45 15-44 UR1 UR2 U>45 1!
arrival 1 1 1 1 1 1 1 1 1
HIV- 1 1 1 1 1 1 1 1 1
DRI 0 1 1 1 0 0 0 0 0
DR2 0 0 1 1 0 0 0 0 0
DNR>45 0 0 0 1 0 0 0 0 0
DNR:15-44 0 0 0 1 1 0 0 0 0
UR1 0 1 0 1 1 1 0 1 0
UR2 0 0 1 1 1 0 1 1 0
UNR>45 0 0 0 1 0 0 0 1 0
UNR:15-44 0 0 0 1 1 0 0 1 1
Estimates of the probabilities of transition across different HIV-related states in the 
model would then be defined. Much of the information required for this model is 
uncertain, thereby making sensitivity analyses crucial. Examples of how initial values 
required to estimate the transition probabilities could be generated are as follows:
Death/out
migration
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Firstly, the movement of women in a given year between different HIV-related 
diagnosed states according to number of children and age (for example DR1 to DR2) 
may be based on data gathered on HIV-infected pregnant women reported to the 
NSHPC, analyses from the cross-sectional questionnaire survey showing proportions 
of women who never wanted or already had children at diagnosis and the age 
distribution of prevalent HIV infections diagnosed from SOPHID. Movement of 
women between undiagnosed states could be assumed to be either the same as in the 
corresponding diagnosed state or the same as HIV-uninfected women given that 
women who are unaware of their HTV status are less likely to change their 
childbearing plans because of their HTV infection.
Secondly, the transition of HIV from an undiagnosed to diagnosed state (for example 
UR1 to DR1) would need to be quantified. The majority of new HIV infections 
initially remain undiagnosed as testing is not undertaken on a regular basis and HIV- 
related symptoms only develop later in the course of infection. For the purposes of 
this model, it would be reasonable to assume that 10% of new infections will be 
diagnosed per year and that this is the same across all HIV states.
Thirdly, an estimate of numbers of new infections per year is needed (for example 
HIV negative to UR1). In women bom in the UK incidence would be expected to be 
extremely low. However, in women bom in Africa, the majority of new infections 
will equate to recently arrived HIV infected persons coming into the country who 
were infected elsewhere. This data could be estimated using reports of newly 
diagnosed HIV infections received at CDSC which contain information on year of 
arrival in the UK and fertility history.
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Lastly, the risk of death could be derived from estimates of time of HIV diagnosis to 
death at different ages. These have already been derived in cohorts of HIV infected 
individuals in Europe, North America and Australia (152). Prior to widespread use of 
antiretroviral therapies, median survival rates were 12.5 years for persons aged 15-24 
and 7.9 years for persons aged 45 and over. Since the use of therapies, death rates due 
to AIDS have fallen by 64%. It may be assumed that an HIV-infected woman with 
undiagnosed infection would have a death rate equivalent to that pre-HAART whilst a 
diagnosed HIV-infected woman would have a death rate equivalent to that since 
HAART has been made widely available.
Preliminary work which has used 2001 data to predict the course of the epidemic in 
2002, and then compared the predicted values for 2002 with observed values for 
2002, suggests that the model described has a reasonable fit. However, areas of 
uncertainty need to be addressed in order to refine the methodology. Whilst we are 
well informed about fertility patterns in different groups of women in GB, much less 
is known about migration patterns of HIV-positive persons in and out of the country 
and the effect of these patterns on the HIV epidemic in GB. The model depends on 
knowledge of HIV prevalence amongst migrants, according to age and sex. However, 
this data is not available and neither is it known how long migrants stay in the 
country. It is probably not reasonable to assume that the HIV prevalence in migrant 
populations is the same as that in the home country, as surveillance data indicate that 
whilst women resident in Zimbabwe have an HIV prevalence of about 30%, women 
bom in Zimbabwe who have had a livebirth in GB have a prevalence much lower at 
10%. Further development of this model depends on improved information on
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migration patterns, especially as any changes in HIV prevalence in countries within 
Africa are likely to be the major factor driving the course of the epidemic in GB.
8.5: Conclusions
An approach for improving HIV estimates among women in GB has been developed 
which can easily be updated on an annual basis using the adjustment factors derived 
in this project. This approach could be implemented using the routinely available data 
sources and the results of this thesis have been presented to both the HPA and ICH for 
consideration. Publication of findings will also be important. A primary aim of 
collecting sentinel unlinked anonymous prevalence data has been to monitor trends in 
HIV prevalence in the source population (2). The method developed here shows how 
this can be done, allowing for fertility and demographic changes in the population 
over time. The project demonstrates not only the importance of knowing fertility 
patterns amongst HTV-positive women, but also the requirement for more detailed 
demographic data on the British population. A large increase in numbers of HIV 
infections amongst women was shown to have occurred between 1997 and 2002 and 
this trend is likely to be attributed to migrational changes between the UK and 
countries of high HIV prevalence. However, the actual contribution of migration to 
numbers of infections is difficult to gauge in the absence of more detailed data on 
migrational patterns. Work furthering on from this thesis would be more complex 
modelling (which will experience difficulties in predicting migration) to improve our 
understanding of factors which are likely to drive the HIV epidemic in GB in the 
future.
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C lnk  name:
'N ^ / In s titu te  o f  C h ild  H ea lth
Questionnaire number:
Health Protection Agency
Study to understand the effect of HIV 
on pregnancy decisions
Thank you for giving up your time and agreeing to be part of this survey. This study is 
anonymous and none of the information provided will be communicated to anyone else. If 
the study has raised any concerns or questions you would like to discuss, please speak to 
your doctor or health advisor.
Study Address:
HTV & Fertility Study
Centre for Paediatric Epidemiology & Biostatistics
Institute of Child Health
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SECTION 1; Questions 1-7 ask about you
1. W hat is your year of birth?
2. Where do you currently live?
London D
Elsewhere in England & Wales □
Scotland D
Other □   ► Please specify.
3. Were you born in the UK? Yes □  No □  If NO, Which country were you bom? ------
What year did you arrive in the UK?
4. What is your partnership status?
Single □  Widowed D
Married D Cohabiting (living with partner) D
Divorced/separated D Non-cohabiting partner D
(Regular partner but not living with them)
5. Which ethnic group would you describe yourself as belonging to?
White □  Black African □
Black Caribbean □  Black Other □
Asian □  Other □
6. If you have a partner, what is their ethnic group?
White □  Black African □  Not Applicable □
Black Caribbean □  Black Other □
Asian □  Other □
7. Have you ever injected drugs?
Yes □  ------- ► If YES, have you injected in the last year? Yes □  No □
No □  *
SECTION 2: Questions 8-14 ask about vour HIV status
8. Please tell us the month and year of your first positive HTV test--------(mth) (year)
9. Is your partner also HTV positive? (tick one box only)
Yes □  No □  Not applicable □
Not tested □  Don’t know D
10. How would you describe your current HTV symptoms? (tick one box only)
No symptoms □  Mild/moderate symptoms □  Severe symptoms □
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11. Do you know your current CD4 count? Yes □  No □
If yes, in which category does it fall? <200 D 200-349 D 350-699 D >=700 D
12. Has your CD4 count changed significantly in the last 6 months?
No □
Yes D If yes, how has it changed? It has increased D It has decreased D
13. Which describes your HTV therapy? (tick one box only)
Never on treatment □  Started treatment within past 3 months □
On treatment for more than 3 months D Treated in the past but currently off treatment D
14. If on treatment, does your regime include:
1 drug D 2 drugs D 3 drugs D 4 drugs D 5+ drugs D Not Applicable D
SECTION 3
We would now like to ask you some questions about pregnancies you have already had.
15. Are you or have you ever been pregnant? Yes □  No □  (if NO please go to Section 4)
16. Are you currently pregnant? Yes □ No D
17. Do you have, or have you had, any children? Yes □  (how many? ) No □
If yes, please give year of birth for each child in the boxes below:
18. If you have had children, are or were any of your chfldren HIV positive?
Yes □  No □  Awaiting outcome □  Don’t know □  Not Applicable D
19. Have you ever taken therapy during pregnancy to reduce the risk of having an infected child?
Yes □  No □
20. Have you ever had a pregnancy which has ended in any of the following:
Number Year(s)
(if none write V)
a) Miscarriage ________  ________  ________  ________  ________
b) Stillbirth [ | ________  ________  ________  ________
c) Termination
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21. If you have ever had a termination of pregnancy (abortion), was the reason connected in any 
way to your HIV infection?
Yes □  No □  Not applicable □
22. Were you pregnant at the time your HlV was diagnosed? YesG NoG 
If YES, what was the outcome of that pregnancy?
Live birth (baby born alive) G Still birth (baby died at delivery) G Miscarriage Q Termination G
SECTION 4
We are very interested in knowing about how many (more) children you would like to have, and 
whether this has changed because o f your HIV status
23. 'Would you like any (more) children?
Yes G No Q Don’t know G I already have desired number of children Q
24. Have you ever had a time, lasting 6 months or longer, when you and your partner were trying 
for a pregnancy but it did not happen?
Yes Q No G Not Applicable G
25. Have you (or your partner) ever sought medical help about fertility?
Yes G  ► If YES, are you currently receiving treatment? YesG NoG
No G
26. Having had your HTV diagnosed did you change your mind about wanting (more) children?
I wanted children sooner G I decided I didn’t want children anymore G
I had already had my children G My HTV diagnosis had no effect G
I never wanted children anyway Q Other...........................................................  Q
27. Are you aware that treatments (‘Combination therapy9) for your HIV have improved recently 
and have made some people stay well? Yes □  No □
If YES, have these treatments made you feel better & changed your mind about wanting (more) children?
Yes they have made me feel better & want (more) children G
Always wanted (more) children anyway Q
No they haven’t made me feel better & want (more) children G
Never wanted (more) children anyway G
Other........................................................................................  G
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28. Are you aware that measures can be taken to help women reduce their chance of having a baby 
with HIV? Yes □  No □
If YES, have these measures have made you want (more) children?
Yes they have made me want (more) children □
No they haven’t made me want (more) children □
Always wanted (more) children anyway □
Never wanted (more) children anyway □
Other......................................................................  □
29. Please provide the date you completed this questionnaire ......../ ............. / .................
30. Please provide any additional information about factors affecting your fertility decisions, for 
example your partner’s feelings, immigration status, financial situation etc
Thank you very much for completing this questionnaire. Please put it in the envelope provided, seal 
it and either post it or hand it to the doctor/nurse/health advisor who asked you to participate.
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S f  ^ Institute o f  Child Health rr  ... «  . .. .v  J Health Protection Agency
Study to understand the effect of 
HIV on pregnancy decisions
YOU ARE BEING INVITED TO TAKE PART IN A RESEARCH STUDY. 
PLEASE READ THIS INFORMATION SHEET BEFORE STARTING
THE QUESTIONNAIRE
THIS STUDY IS STRICTLY CONFIDENTIAL
The aim of the study: A study among women is being carried out to understand how 
HTV affects pregnancy decisions.
Why is the study being done? We are keen to understand as much as we can about 
reasons for wanting children. You may be aware that there have been improvements in 
treatments that delay HTV disease and also improvements in measures to reduce the risk 
of a woman passing the virus to her child. We would like to know whether this has 
changed pregnancy decisions.
How is the study being done? All women attending clinic are being asked if they would 
like to take part in the study. If you agree, you will be asked to complete a questionnaire. 
It is important to stress that the study is completely confidential. We do not need your 
name or address and will collect nothing that identifies you. The questionnaire may be 
completed at clinic whilst you are waiting for your appointment or at home at a time 
convenient to you. If you take the questionnaire home a reply-paid envelope will be 
provided for returning the questionnaire.
The nurse or researcher involved with the study will be available if you would like to 
discuss any issues the study has raised.
Do I have to take part in this study? No. If you decide, now or at a later stage, that you 
do not wish to take part in this project, that is entirely your right, and will not in any way 
affect your care. If you have any complaints about the way in which this research project 
has been, or is being conducted, please, in the first instance, discuss them with the 
researcher.
Details of how to contact the Researcher: The researcher for this project is Susan Cliffe 
who can be contacted either by telephone on , or by post: Centre for 
Paediatric Epidemiology & Biostatistics, Institute of Child Health,  
Finally, we would like to thank you for considering to take part in this survey.
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Appendix B3: Consent form used in survey of fertility decisions amongst HIV
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STUDY TO UNDERSTAND THE EFFECT OF HIV 
ON PREGNANCY DECISIONS
Consent Form for PARTICIPANTS
NOTES FOR PARTICIPANTS
1. You have been asked to take part in some research. The person organising that 
study must explain the project to you before you agree to take part
2. Please ask the researcher or clinic nurse/doctor any questions you like about 
this project, before you decide whether to join in
3. If you decide, now or at any other time, that you do not wish to be involved in 
the research project, just tell us and we will stop the research. If you are a 
patient your treatment will carry on as normal
4. You will be given an information sheet which describes the research. This 
information is for you to keep and refer to at any time. Please read it 
carefully.
CONSENT
I ...................................................................................agree that the research project
named above has been explained to me to my satisfaction, and I agree to take part in 
this study. I have read both the notes written above and the information sheet about 
the project, and understand what the research study involves.
SIGNED PRINTED DATE
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Appendix E: National Study of HIV in Pregnancy questionnaire
CONFIDENTIAL
Tick boxes, complete, ring, or delete es week FI 133
Hospital . .  .Newham................  Your ref (eg woman's hospital number, local code or soundex)..................
Woman’s date of birth /  /  Previous livebirths............  stillbirths...........miscs/terms
Ethnic origin P"] White Q  Black African Q  Black Caribbean Q  Black other
“  [J O r k  _| | Indian Subcontinent f | Oriental [ | Other or mixed, specify
Country of birth...................................................................................... □ □ □ □
PREGNANCY LMP /  /
| | Continuing to term EDD
| | Spontaneous abortion or Q ]  termination on at   weeks gestation
If spontaneous abortion or termination, any congenital abnormality? P ]  No Q ]  Yes Please specify overleaf
Were antenatal booking bloods taken at this asaternity nnit? Q  No Q  Yes
PROBABLE SOURCE OF INFECTION
| \ From high prevalence country, specify...................................................  Date arrived UK/RoI  /_
| | Injecting drug use Q ]  Transfusion recipient Q ]  Other, specify........................................
| | Infected partner, specify his likely risk factor ...........................................................................................
HIV STATUS IDENTIFIED
| | During this pregnancy: voluntary antenatal testing / other setting, specify .............................
| \ Known prior to this pregnancy: tested at GUM Clinic / GP / Drug Clinic / other .....................
Date of first positive test   If HIV-2 only, please tick here | |
HIV RELATED CLINICAL STATUS A DRUG TREATMENT DURING PREGNANCY
j | Asymptomatic Q  Symptomatic, not AIDS Q ]  AIDS diagnosis Date of AIDS onset /  /
Details .................................................................................................................................................................................
Was this wonuui on drug treatment when she became pregnant? Q  No Q ]  Yes Started /  /
I f  Yes, specify drugfs)  Continuing? Q  No Q  Yes
................................................................................................................................  Date stopped
Drag treatment changed or started daring pregnancy? Q  Not applicable. Pregnancy not continuing to term 
| 1 No | | Not yet decided Drug treatment declined | | Yes, changed or started, details below:
Drug(s)................................................................................................................................. Date started or
.........................................................................................................................................  due to start / /
RECENT TEST RESULTS
Viral load copies/ml (  loglO) test.........................................  Date /  /
T-cell subsets | | not done, or give most recent results below (specify units | 110^ /1 | |l()6/l [/mm^])
CD4______ % no._________  CDS % no._________  Total lymphocytes no.__________  ___ / /
Form completed by: Name_______________________________________  Date
Position__________________Telephone_________________ Email__________________________
PLEASE ADD ANY ADDITIONAL INFORMATION OR COMMENTS OVERLEAF.
Appendix F: Full results tables for analyses undertaken in chapter 6
Table F .l: Odds and adjusted odds for wanting (more) children
Maternal factor Total
(N)
Desire children 
N (%)
OR 95% Cl P
value
Adjusted
OR1
95% Cl P
value
Ethnicity (n=450) Non-African 126 45 (35.7%) 1.00 - - 1.00 - -
African 324 140 (43.2%) 1.37 0.89-2.09 0.15 1.39 0.77-2.49 0.27
Residence (n=450) Non-London 166 65 (39.2%) 1.00 - - 1.00 - -
London 324 120 (42.3%) 1.14 0.77-1.68 0.52 0.65 0.35-1.19 0.16
Born in UK (n-450) No 355 158 (44.5%) 1.00 - - - - -
Yes 95 27 (28.4%) 0.50 0.30-0.81 <0.001 - - -
Years in UK (ns 310) <=5 years 175 75 (42.9%) 1.00 - - 1.00
5+ years 135 63 (46.7%) 1.17 0.74-1.83 0.50 1.41 0.77-2.59 0.27
In a partnership (n=450) No 217 71 (32.7%) 1.00 - - 1.00 - -
Yes 233 114(48.9%) 1.96 1.34-2.89 0.001 1.97 1.16-3.34 0.013
Age at diagnosis (n=415) <=29 211 91 (43.1%) 1.00 - - 1.00 - -
>29 239 94 (39.3%) 0.85 0.59-1.25 0.41 1.04 0.58-1.88 0.89
Years since diagnosis (n-433) <=5 years 286 124 (43.4%) 1.00 - - 1.00 - -
5+ years 147 55 (37.4%) 0.78 0.52-1.17 0.24 0.71 0.35-1.44 0.34
Partner HIV status (n=196)2 Negative 88 44 (50.0%) 1.00 - - - - -
Positive 108 52 (48.1%) 0.93 0.53-1.63 0.80 - - -
History of IDU (n=445) No 410 169 (41.2%) 1.00 - - 1.00 - -
Yes 35 13(37.1%) 0.84 0.41-1.72 0.64 1.67 0.36-7.76 0.51
Current HIV symptoms None 234 95 (40.6%) 1.00 - - - - -
(n=433) Mild/Mod. 173 74 (42.8%) 1.09 0.73-1.63 0.66 - - -
Severe 26 8 (30.8%) 0.65 0.27-1.55 0.33 - - -
CD4 count (n=345) <350 194 78 (40.2%) 1.00 - - - - -
>=350 151 63 (41.7%) 1.06 0.69-1.64 0.78 - - -
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Table F .l: Odds and adjusted odds for wanting (more) children (contd)
Maternal factor Total
(N)
Desire children 
N (%)
OR 95% Cl P
value
Adjusted
OR1
95% Cl P
value
HIV-related therapy (n=445) No 141 69 (48.9%) 1.00 - - 1.00 - -
Yes 304 115(37.8%) 0.63 0.42-0.95 0.027 0.88 0.50-1.55 0.66
No. of children (n=450) <2 254 127 (50.0%) 1.00 - - 1.00
>=2 196 58 (29.6%) 0.42 0.28-0.62 <0.001 0.28 0.15-0.51 <0.001
Has had a positive child(n-271) No 210 69 (32.9%) 1.00 - - - - -
Yes 61 23 (37.7%) 1.24 0.68-2.24 0.48 - - -
Ever had a misc. or TOP (n=450) No 269 99 (36.8%) 1.00 - - 1.00
Yes 181 86 (47.5%) 1.55 1.06-2.28 0.024 1.10 0.65-1.88 0.72
Pregnant at diagnosis (n=450) No 320 130 (40.6%) 1.00 - - - - -
Yes 130 55 (42.3%) 1.07 0.71-1.62 0.74 - - -
Trying for a pregnancy (n=336) No 263 92 (34.9%) 1.00 - - 1.00 - -
Yes 73 53 (72.6%) 4.92 2.77-8.74 <0.001 3.46 1.68-7.13 <0.001
Adjusted for ethnicity, residence, years in UK, partnership status, age at diagnosis, years since HIV diagnosis, HIV-related therapy, history of 
injecting drug use, number of previous children, previous miscarriage or termination of pregnancy, trying for a pregnancy >6 months. These 
were the factors found to be associated with child-bearing in univariate analyses.Whether or not the woman had been bom in the UK was not 
included in the adjusted analysis as this variable was closely correlated to years in the UK.
2 37 cases were not known or not tested and therefore not included in the analysis
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Table F.2: Odds and Adjusted odds for not wanting children after an HIV diagnosis1
Maternal factor Total
(n)
Not want 
children N (%)
OR 95% Cl P
value
Adjusted
OR2
95% Cl P
value
Ethnicity (n=356) Non-African 90 41 (45.6%) 1.00 - - 1.00 - -
African 266 114(42.9%) 0.90 0.55-1.45 0.66 2.01 0.78-5.13 0.15
Residence (n-356) Non-London 123 57 (46.3%) 1.00 - - 1.00 - -
London 233 98 (42.1%) 0.84 0.54-1.30 0.44 0.83 0.40-1.74 0.63
Born in UK (n=356) No 286 120 (41.9%) 1.00 - - - - -
Yes 70 35 (50.0%) 1.38 0.82-2.34 0.23 - - -
Years in UK (n=320) <=5 years 182 85 (46.7%) 1.00 - - 1.00 - -
5+ years 138 57 (41.3%) 1.26 0.71-2.21 0.43 1.29 0.64-2.60 0.48
In a partnership (n=356) No 178 82(46.1%) 1.00 - - 1.00 - -
Yes 178 73 (41.0%) 0.81 0.54-1.24 0.34 0.83 0.44-1.56 0.56
Age at diagnosis (n=356) <=29 157 82 (52.2%) 1.00 - - 1.00 - -
>29 199 73 (36.7%) 0.53 0.35-0.81 0.003 0.93 0.47-1.85 0.84
Years since diagnosis (n-341) <=5 years 224 88 (39.3%) 1.00 - - 1.00 - -
5+ years 117 62 (53.0%) 1.74 1.11-2.74 0.016 1.75 0.76-3.99 0.19
Partner HIV status (n=153) Negative 69 29 (42.0%) 1.00 - - - - -
Positive 84 38 (45.2%) 1.14 0.60-2.17 0.69 - - -
History of IDU (n=352) No 329 140 (42.6%) 1.00 - - 1.00 - -
Yes 23 13 (56.5%) 1.76 0.75-4.12 0.20 1.73 0.26-11.77 0.57
Current HIV symptoms None 185 77(41.6%) 1.00 - - - - -
(n=341) Mild/Mod. 132 64 (48.5%) 1.32 0.84-2.07 0.23 - - -
Severe 24 10(41.7%) 1.00 0.42-2.37 0.99 - - -
CD4 count (n=277) <350 158 67 (42.2%) 1.00 - - - - -
>=350 119 51 (42.9%) 1.02 0.63-1.65 0.94 - - -
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Table F.2: Odds and Adjusted odds for not wanting children after an HIV diagnosis1 (contd)
Maternal factor Total
(“)
Not want 
children N (%)
OR 95% Cl P
value
Adjusted
OR2
95% Cl P
value
HIV-related therapy (n=351) No 102 48(47.1%) 1.00 - - 1.00 - -
Yes 249 105 (42.2%) 0.82 0.52-1.30 0.40 0.65 0.33-1.29 0.22
No. of children at diagnosis (n=356) <2 187 98 (52.4%) 1.00 - - 1.00 - -
>=2 169 57(33.7%) 0.46 0.30-0.71 <0.001 1.46 0.70-3.01 0.31
Has had a positive child(n=222) No 175 72 (41.1%) 1.00 - - - - -
Yes 47 17 (36.2%) 0.81 0.42-1.58 0.54 - - -
Ever had a misc. or TOP (n=356) No 213 88 (41.3%) 1.00 - - 1.00 - -
Yes 143 67 (46.9%) 1.25 0.82-1.92 0.30 1.11 0.59-2.09 0.75
Pregnant at diagnosis (n=356) No 250 103 (41.2%) 1.00 - - - - -
Yes 106 52 (49.1%) 1.37 0.87-2.17 0.17 - - -
Trying for a pregnancy (n=356) No 302 133 (44.0%) 1.00 - - 1.00 - -
Yes 54 22 (40.7%) 0.87 0.49-1.57 0.65 0.61 0.27-1.36 0.23
1 Comparison of women who did not want children anymore after their diagnosis with women who said HIV had had no effect on their 
childbearing intentions
2Adjusted for ethnicity, residence, years in UK, partnership status, age at diagnosis, years since HIV diagnosis, HIV-related therapy, history of 
injecting drug use, number of previous children, previous miscarriage or termination of pregnancy, trying for a pregnancy >6 months. These 
were the factors found to be associated with child-bearing in univariate analyses. Whether or not the woman had been bom in the UK was not 
included in the adjusted analysis as this variable was closely correlated to years in the UK.
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Table F.3: Odds and Adjusted odds for changing mind about having children after improvements in HIV-related treatments
Maternal factor Total
(n)
Want children
N (%)
OR 95% Cl P
value
Adjusted
OR1
95% Cl P
value
Ethnicity (n=144) Non-African 39 15(38.5%) 1.00 - - 1.00 - -
African 105 34 (32.4%) 0.63 0.26-1.53 0.31 1.25 0.19-7.85 0.81
Residence (n=144) Non-London 51 12 (23.5%) 1.00 - - 1.00 - -
London 93 37 (39.8%) 2.06 0.88-4.79 0.095 1.21 0.31-4.75 0.78
Born in UK (n=144) No 111 39 (35.1%) 1.00 - - - - -
Yes 33 10(30.3%) 1.15 0.43-3.06 0.77 - - -
Years in UK (n=135) <=5 years 81 28 (34.6%) 1.00 - - 1.00 - -
5+ years 54 18(33.3%) 1.39 0.57-3.38 0.47 0.90 0.26-3.10 0.87
In a partnership (n=144) No 76 16(21.1%) 1.00 - - 1.00 - -
Yes 68 33 (48.5%) 2.48 1.11-5.50 0.026 8.24 1.87-36.13 0.005
Age at diagnosis (n=144) <=29 74 27 (36.5%) 1.00 - - 1.00 - -
>29 70 22 (31.4%) 0.68 0.31-1.47 0.33 0.94 0.26-3.46 0.93
Years since diagnosis (n-140) <=5 years 81 26 (32.1%) 1.00 - - 1.00 - -
5+ years 59 22 (37.3%) 1.40 0.63-3.09 0.41 1.15 0.25-5.30 0.85
Partner HIV status (n=63) Negative 26 13 (50.0%) 1.00 - - - - -
Positive 37 18 (48.6%) 0.96 0.32-2.91 0.94 - - -
History of IDU (0=140) No 129 45 (34.9%) 1.00 - - 1.00 - -
Yes 13 3 (23.1%) 0.83 0.18-3.93 0.82 0.27 0.01-9.54 0.47
Current HIV symptoms None 70 31 (44.3%) 1.00 - - - - -
(n=140) Mild/Mod. 60 18 (30.0%) 0.69 0.30-1.57 0.38 - - -
Severe 10 0 (0%) - - - - - -
CD4 count (n = lll) <350 63 22 (34.9%) 1.00 - - - - -
>=350 48 13(27.1%) 0.89 0.36-2.20 0.80 - - -
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Table F.3: Odds and Adjusted odds for changing mind about having children after improvements in HIV-related treatments (contd)
Maternal factor Total
(n)
Want children
N (%)
OR 95% Cl P
value
Adjusted
OR1
95% Cl P
value
HIV-related therapy (n=142) No 41 12 (29.3%) 1.00 - - 1.00 - -
Yes 101 37 (36.6%) 2.02 0.86-4.75 0.11 6.67 1.44-30.80 0.015
No. of children at diagnosis(n=144) <2 87 35 (40.2%) 1.00 - - 1.00 - -
>=2 57 14 (24.6%) 0.56 0.25-1.26 0.16 0.15 0.03-0.65 0.011
Has had a positive child(n=86) No 69 18(26.1%) 1.00 - - - - -
Yes 17 6 (35.3%) 1.61 0.45-5.77 0.46 - - -
Ever had a misc. or TOP (n-144) No 80 28 (35.0%) 1.00 - - 1.00 - -
Yes 64 21 (32.8%) 0.90 0.41-1.96 0.79 0.68 0.21-2.18 0.51
Pregnant at diagnosis (0=144) No 95 34 (35.8%) 1.00 - - - - -
Yes 49 15 (30.6%) 0.77 0.34-1.75 0.54 - - -
Trying for a pregnancy (n=144) No 123 39(31.7%) 1.00 - - 1.00 - -
Yes 21 10 (47.6%) 2.09 0.70-6.27 0.19 2.38 0.52-10.79 0.26
Adjusted for ethnicity, residence, years in UK, partnership status, age at diagnosis, years since HIV diagnosis, HIV-related therapy, history of 
injecting drug use, number of previous children, previous miscarriage or termination of pregnancy, trying for a pregnancy >6 months. Whether 
or not the woman had been bom in the UK was not included in the adjusted analysis as this variable was closely correlated to years in the UK.
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Table F.4: Odds and adjusted odds for changing mind about having children after improvements in interventions which reduce MTCT
Maternal factor Total
(n)
Want children 
N (%)
OR 95% Cl P
value
Adjusted
OR1
95% Cl P
value
Ethnicity (n=129) Non-African 38 18 (47.4%) 1.00 - - 1.00 - -
African 91 36 (39.6%) 0.63 0.27-1.47 0.29 1.70 0.28-10.37 0.57
Residence (n-129) Non-London 47 15(31.9%) 1.00 - - 1.00 - -
London 82 39 (47.6%) 2.24 1.00-4.99 0.048 1.77 0.42-7.44 0.44
Born in UK (n=129) No 97 38 (39.2%) 1.00 - - - - -
Yes 32 16 (50.0%) 1.85 0.75-4.56 0.18 - - -
Years in UK (n=122) <=5 years 74 34 (45.9%) 1.00 - - 1.00 - -
5+ years 48 17 (35.4%) 2.36 0.93-5.99 0.07 1.84 0.54-6.25 0.33
In a partnership (n=129) No 62 18 (29.0%) 1.00 - - 1.00 - -
Yes 67 36(53.7%) 2.15 0.99-4.69 0.053 5.34 1.29-22.21 0.021
Age at diagnosis (n=129) <=29 68 33 (48.5%) 1.00 - - 1.00 - -
>29 61 21 (34.4%) 0.64 0.30-1.37 0.25 1.20 0.33-4.38 0.78
Years since diagnosis (n=126) <=5 years 70 27 (38.6%) 1.00 - - 1.00 - -
5+ years 56 26 (46.4%) 1.54 0.71-3.35 0.28 1.28 0.28-5.81 0.75
Partner HIV status (n=62) Negative 27 16(59.3%) 1.00 - - - - -
Positive 35 18(51.4%) 0.60 0.21-1.79 0.36 - - -
History of IDU (n=127) No 115 48 (41.7%) 1.00 - - 1.00 - -
Yes 12 5 (41.7%) 1.27 0.32-5.04 0.73 0.49 0.01-19.63 0.70
Current HIV symptoms None 61 31 (50.8%) 1.00 - - - - -
(n=127) Mild/Moderate 57 22 (38.6%) 0.92 0.41-2.05 0.84 - - -
Severe 9 1 (U.1%) 0.14 0.02-1.24 0.077 - - -
CD4 count (n=101) <350 55 23 (41.8%) 1.00 - - - - -
>=350 46 16(34.8%) 0.90 0.38-2.15 0.82 - - -
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Table F.4: Odds and adjusted odds for changing mind about having children after improvements in interventions which reduce MTCT 
(contd)
Maternal factor Total
(n)
Want children
N (%)
OR 95% Cl P
value
Adjusted
OR1
95% Cl P
value
HIV-related therapy (n=127) No 38 17 (44.7%) 1.00 - - 1.00 - -
Yes 89 37(41.6%) 1.15 0.51-2.59 0.73 3.81 0.86-16.98 0.079
No. of children at diagnosis(n=129) <2 80 41 (51.3%) 1.00 - - 1.00 - -
>=2 49 13 (26.5%) 0.37 0.16-0.84 0.017 0.15 0.03-0.64 0.010
Has had a positive child(n=76) No 61 20 (32.8%) 1.00 - - - - -
Yes 15 5 (33.3%) 1.14 0.32-4.10 0.84 - - -
Ever had a misc. or TOP (n=129) No 71 27 (38.0%) 1.00 - - 1.00 - -
Yes 58 27 (46.6%) 1.45 0.68-3.11 0.34 1.09 0.32-3.67 0.14
Pregnant at diagnosis (n-129) No 82 36 (43.9%) 1.00 - - - - -
Yes 47 18(38.3%) 0.73 0.33-1.59 0.43 - - -
Trying for a pregnancy (n=129) No 108 44 (40.7%) 1.00 - - 1.00 - -
Yes 21 10 (47.6%) 1.52 0.53-4.36 0.43 1.25 0.26-5.90 0.78
Adjusted for ethnicity, residence, years in UK, partnership status, age at diagnosis, years since HIV diagnosis, HIV-related therapy, history of 
injecting drug use, number of previous children, previous miscarriage or termination of pregnancy, trying for a pregnancy >6 months. Whether 
or not the woman had been bom in the UK was not included in the adjusted analysis as this variable was closely correlated to years in the UK.
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Table F.5: Odds and Adjusted odds for having had a pregnancy after HIV diagnosis2
Maternal factor Total
(n)
Had pregnancy
N (%)
OR 95% Cl P
value
Adjusted
OR1
95% Cl P
value
Ethnicity (n=312) Non-African 105 24 (22.9%) 1.00 - - 1.00 - -
African 207 47 (22.7%) 0.99 0.57-1.74 0.98 3.93 1.21-12.80 0.023
Residence (n-312) Non-London 100 24 (24.0%) 1.00 - - 1.00 - -
London 212 47 (22.2%) 0.90 0.51-1.58 0.72 1.21 0.41-3.58 0.73
Born in UK (n=312) No 231 51 (22.1%) 1.00 - - - - -
Yes 81 20 (24.7%) 1.16 0.64-2.09 0.63 - - -
Years in UK (n=205) <=5 years 89 18 (20.2%) 1.00 - - 1.00 - -
5+ years 116 30 (25.9%) 1.38 0.71-2.67 0.35 0.95 0.40-2.28 0.91
In a partnership (n=312) No 150 27(18.0%) 1.00 - - 1.00 - -
Yes 162 44 (27.2%) 1.69 0.99-2.92 0.06 2.29 1.05-5.01 0.036
Age at diagnosis (n=312) <=29 162 52 (32.1%) 1.00 - - 1.00 - -
>29 150 19 (12.7%) 0.31 0.17-0.55 <0.001 0.54 0.23-1.28 0.16
Years since diagnosis (n=295) <=5 years 148 18(12.2%) 1.00 - - 1.00 - -
5+ years 147 53 (36.1%) 4.07 2.24-7.39 <0.001 4.94 1.91-12.79 0.001
Partner HIV status (n=144) Negative 66 19 (28.8%) 1.00 - - - - -
Positive 78 22 (28.2%) 0.97 0.47-2.01 0.94 - - -
History of IDU (n=310) No 277 61 (22.0%) 1.00 - - 1.00 - -
Yes 33 10(30.3%) 1.54 0.70-3.40 0.29 1.55 0.25-9.67 0.64
Current HIV symptoms None 159 40 (25.2%) 1.00 - - - - -
(n=303) Mild/Mod. 123 25 (20.3%) 0.75 0.43-1.33 0.34 - - -
Severe 21 3 (14.3%) 0.49 0.14-1.77 0.28 - - -
CD4 count (n=239) <350 122 25 (20.5%) 1.00 - - - - -
>=350 117 25 (21.4%) 1.05 0.57-1.96 0.87 - - -
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Table F.5: Odds and Adjusted odds for having had a pregnancy after HIV diagnosis2 (contd)
Maternal factor Total
(«)
Had pregnancy
N (%)
OR 95% Cl P
value
Adjusted
OR1
95% Cl P
value
HIV-related therapy (n=308) No 88 23 (26.1%) 1.00 - - 1.00 - -
Yes 220 46 (20.9%) 0.75 0.42-1.33 0.32 0.76 0.33-1.77 0.53
No. of children at d iagnosis ln^n ) <2 221 58 (26.2%) 1.00 - - 1.00 - -
>=2 91 13(14.3%) 0.47 0.24-0.91 0.024 0.48 0.18-1.31 0.15
Has had a positive child(n=202) No 154 49 (31.8%) 1.00 - - - - -
Yes 48 16(33.3%) 1.07 0.54-2.13 0.84 - - -
Ever had a misc. or TOP (n=312) No 180 38(21.1%) 1.00 - - 1.00 - -
Yes 132 33 (25.0%) 1.25 0.73-2.12 0.42 0.69 0.31-1.53 0.36
Pregnant at diagnosis (n=312) No 227 45 (19.8%) 1.00 - - - - -
Yes 85 26 (30.6%) 1.78 1.01-3.14 0.05 - - -
Trying for a pregnancy (n=312) No 257 57 (22.2%) 1.00 - - 1.00 - -
Yes 55 14(25.5%) 1.20 0.61-2.35 0.60 0.60 0.23-1.60 0.31
Adjusted for ethnicity, residence, years in UK, partnership status, age at diagnosis, years since HIV diagnosis, HIV-related therapy, history of 
injecting drug use, number of previous children, previous miscarriage of termination or pregnancy, trying for a pregnancy >6 months. Whether 
or not the woman had been bom in the UK was not included in the adjusted analysis as this variable was closely correlated to years in the UK.
2 Analysis restricted to women who had been diagnosed with HIV for at least 2 years
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Appendix G: Full result tables for analyses undertaken in chapter 7 
Table G.l: Numbers of infections in women at risk of pregnancy in Great Britain
1997 2000 2001 2002
Diagnosed London Women born in SSA <2 children 580 1820 2100 2770
Diagnosed London Women born in SSA >=2 children 100 320 380 480
Diagnosed London Other <2 children 610 930 1210 1170
Diagnosed London Other >=2 children 80 120 160 160
Diagnosed Rest GB Women born in SSA <2 children 140 1060 990 1360
Diagnosed Rest GB Women born in SSA >=2 children 30 220 210 290
Diagnosed Rest GB Other <2 children 420 780 900 1140
Diagnosed Rest GB Other >=2 children 70 140 170 210
Undiagnosed London Women born in SSA <2 children 910 990 1140 1000
Undiagnosed London Women born in SSA >=2 children 390 420 490 430
Undiagnosed London Other <2 children 290 320 420 400
Undiagnosed London Other >=2 children 130 140 180 180
Undiagnosed Rest GB Women born in SSA <2 children 350 580 540 740
Undiagnosed Rest GB Women born in SSA >=2 children 150 250 230 320
Undiagnosed Rest GB Other <2 children 560 730 840 1060
Undiagnosed Rest GB Other >=2 children 240 310 360 460
Total 5050 9130 10,320 12,170
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able G.2: Table: Numbers of infections in women not at risk of pregnancy in Great Britain
1997 2000 2001 2002
>iagnosed London Women born in SSA >=45 40 160 260 370
)iagnosed London Other >=45 60 120 160 200
Hagnosed Rest Women born in SSA >=45 20 60 110 170
Diagnosed Rest Other >=45 90 170 200 220
Undiagnosed London Women born in SSA >=45 180 220 340 440
Undiagnosed London Other >=45 90 140 180 230
Undiagnosed Rest Women born in SSA >=45 80 70 130 200
Undiagnosed Rest Other >=45 280 360 430 470
Diagnosed London Women born in SSA Completed family 180 350 460 570
Diagnosed London Other Completed family 80 110 120 120
Diagnosed Rest Women born in SSA Completed family 30 110 180 330
Diagnosed Rest Other Completed family 80 120 130 160
Diagnosed London Women born in SSA Didn’t want children 20 40 50 60
Diagnosed London Other Didn’t want children 30 40 40 40
Diagnosed Rest Women born in SSA Didn’t want children 10 10 20 30
Diagnosed Rest Other Didn’t want children 20 50 60 60
Undiagnosed London Women born in SSA Didn’t want children 80 50 40 70
Undiagnosed London Other Didn’t want children 50 40 50 50
Undiagnosed Rest Women born in SSA Didn’t want children 20 10 30 40
Undiagnosed Rest Other Didn’t want children 90 100 110 120
Total 1530 2330 3100 3950
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Figure G.l: Working example of how HIV estimates for Table 7.4 were 
generated.: Women bora in SSA and resident in London: 2002
The following example shows how data in Table 7.4 were generated, using women 
bom in SSA and resident in London (2002) as the specific example. Diagnosed and 
undiagnosed estimates were generated for the 2 components of the model separately 
and finally summed together.
The number of women at risk of pregnancy (component 1) was estimated according to 
Figure G.l (as explained on pages 177-179). The overall neonatal seroprevalence (as 
estimated from table 7.1) was adjusted according to whether or not the woman's 
infection was diagnosed, the proportion of women who did not want a child after their 
HIV diagnosis, the number of children the woman had had at time of diagnosis and a 
fertility differential (Figure G.l). Each prevalence was then applied to the total 
population of women bom in SSA and resident in London to derive the total number 
of HIV infections. The number of infections estimated was 4680, of which 3250 were 
diagnosed and 1430 undiagnosed.
The number of women not at risk o f becoming pregnant (component 2) was estimated 
by the sum o f parameters A-E (Table G.3). More details were provided on page 179- 
181.
Table G.3: Number of women not at risk of being pregnant
Parameter Source of data Sum of 
infections
A No. of diagnosed 
women>45
SOPHID data 370
B No. of undiagnosed 
women>45
Estimated using 
SOPHID data and 
proportions of infections 
undiagnosed (table 7.2)
440
C No. of women who had 
completed family at time 
of diagnosis
Questionnaire data 
Which showed 17% of 
women had completed 
family at diagnosis. This 
proportion applied to 
SOPHID women 15-44
570
D No. of diagnosed women 
who never wanted 
children regardless of 
HIV
Questionnaire data 
Which showed 1.8% of 
women never wanted 
children. This proportion 
applied to SOPHID 
women 15-44
60
E No. of undiagnosed 
women who never wanted 
children regardless of 
HIV
Estimated using 
parameter D and 
proportion of infections 
undiagnosed (Table 7.2)
70
Total 1510
The number of infections for component 2 was estimated at 1510, of which 1000 were 
diagnosed and 510 undiagnosed. Therefore combining the data from the 2 
components it was estimated there were a total of 6190 infections (4250 
diagnosed and 1940 undiagnosed). These data were presented in Table 7.4.
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Figure G .l: Flow diagram for estimating number of women at risk of becoming pregnant (Component 1)
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1 neonatal seroprevalence derived from unlinked anonymous surveys (Ref Table 7.1)2 Fertility amongst HIV positive women depends on whether the infection 
was diagnosed or undiagnosed. This data was obtained from Table 7.2 3 A reduced fertility differential was applied to women who stated in the questionnaire 
survey that they did not want children anymore after their HIV diagnosis (ref table 6.4)4 A fertility differential was estimated separately for women who had <2 
children and women who had >-2 children at time of diagnosis. The proportions of women in these two categories was estimated using questionnaire data and 
validated using routine reports of HIV infection amongst women which collect parity data. 5 The estimated fertility differential (Table 7.3)6 Prevalence rate 
applied to total population of women bom in SSA and resident in London(n= 128,670) to generate numbers of infections
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